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Abstract 
This thesis examines the evolution of HIV-1 subtype C multiple linked multi-class 
antiretroviral resistance mutations in the viral protease (PR) and reverse transcriptase 
(RT) genes of vertically infected children. Emergence of PI resistance on the 
backdrop of pre-existing non-nucleoside reverse transcriptase inhibitor (NNRTI) 
resistance could compromise long-term treatment options in such children. We 
characterised multi-class drug resistance using single genome sequencing (SGS) in 
children with viraemia while receiving PI-based ART. We applied SGS of HIV-1 
protease (PR) and reverse transcriptase (RT) to longitudinal samples from a cohort of 
the Children with HIV Early Antiretroviral Therapy (CHER) trial with viral loads 
>1000c/ml after 40 weeks of early ART. Bulk sequencing revealed NVP-selected 
resistance in 50% of these children while SGS revealed NVP-selected resistance in 
70%. Two children had baseline NRTI and PI mutations, suggesting previous 
maternal ART. Linked multi-class drug resistance following PI-based ART was 
detected by SGS in 2/10 children. In one child, the majority species contained M184V 
in RT linked to L10F, M46I/L, I54V and V82A in PR and a triple-class drug resistant 
variant with these mutations linked to the NNRTI mutation V108I. In the second 
child, the majority species contained M184V and V82A linked within viral genomes. 
I correlated nucleotide variation of PR-RT with the number of single genomes 
obtained at each time point and ART status and used maximum likelihood trees, 
recombination analysis, positive selection analysis and co-evolution analysis to 
describe the evolution of PR-RT of the viral populations. Six children who received 
early ART for 40/96 weeks only or received continuous ART for the duration of the 
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CHER trial had clusters of identical sequences from baseline and week 40 of ART. 
These sequences did not harbour known drug resistance mutations. Therefore one 
could hypothesize viral replication from a persisting viral reservoir that was 
established from infection that occurred prior to the initiation of ART. The rooted ML 
trees of 2 children who developed drug resistance during ART had clusters of 
identical sequences harbouring common drug resistance mutations from multiple time 
points which is characteristic of the selection of drug resistant viral populations that 
cause virological failure during ART. When drug resistant viral populations 
developed during treatment failure, M184V single mutated viruses were selected from 
multiple wildtype viral populations but only one population became the major 
contributor to drug resistant viraemia in both children. Triple-class drug resistant 
sequences that had common DRMs (M184V, V108I in RT and M46I in PR) did not 
cluster together. I found no evidence of recombination or coevolving sites in PR-RT 
for any of these children. 
I used a luciferase based single replication cycle assay to examine drug susceptibility 
and replication capacity (RC) conferred by multi-class drug resistant PR-RT from the 
2 children who developed such drug resistant variants. I tested the susceptibility of 
pseudoviruses to the components of early ART (AZT, 3TC and LPV), the components 
of second-line therapy for these children (Abacavir (ABC), Didanosine (ddI), 
Efavirenz (EFV) and (NVP), the PIs Nelfinavir (NFV) and Saquinavir (SQV), which 
are also approved for use in children and Darunavir (DRV), which has been identified 
as a PI option needed in paediatric co-formulation. Pseudoviruses with known PI 
resistance conferring mutations showed reduced susceptibility to all PIs except DRV. 
Those with known NNRTI resistance conferring mutations showed reduced 
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susceptibility to EFV and NVP. M184V mutated pseudoviruses conferred high-level 
resistance to 3TC. In one child, a combination or one of the RT mutations V35T, 
E36D, T39R, S48T, T165I, K173A, D177E, T200A, Q207D, R211K, V245Q, 
E248N, D250N, A272P, K277R, E291D, I293V, T296N may be associated with high-
level ABC and ddI resistance when genetically linked with M184V. 
Population sequence analysis was used to characterize the viral gag genes that 
encoded matrix, capsid, nucleocapsid, p6, and spacer peptides 1 and 2 along with PR-
RT as a single amplicon. I determined the presence of compensatory PI-resistance 
mutations in gag, drug resistance mutations in PR and RT and other amino acid 
changes that occurred during ART. To determining the polymorphic nature of these 
sites, I compared them to a position-specific scoring matrix for gag that was derived 
from HIV-1 subtype C sequences from children from Sub-Saharan Africa. P453L in 
the p1/p6 cleavage site of Gag emerged in the viral population of one child during PI-
based ART. It was the only amino acid change in Gag that emerged among all 
children in the study cohort that has been characterised as a compensatory mutation 
that is selected by and enhances PI-resistance. 
This project is the first to identify multi-class drug resistance mutations in PR and RT 
that were linked on the same genome as well as characterise their development during 
early PI-based ART in children. Triple class drug resistant viruses detected in the 
minority species of the viral population of one child demonstrated significant levels of 
resistance to LPV, SQV, NFV, 3TC and NVP, and established that such variants 
could compromise future ART regimes if they became the dominant species of the 
viral population. I note that the small convenience sample (n = 10) chosen for this 
project limited the power of this study so that findings could not be generalized. 
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Chapter 1 Introduction 
1.1 HIV etiology and diversity 
In 1982 the Centre for Disease Control and Prevention was the first to define 
Acquired Immune Deficiency Syndrome (AIDS) [1] as a disease predictive of 
defective cell-mediated immunity without a known cause for disease susceptibility. 
Kaposi’s sarcoma, Penumocystis carinii pneumonia and other opportunistic 
infections were predictive of this cellular immunodeficiency [1]. A year later the 
causative agent of AIDS, Human Immune Deficiency Virus (HIV), was isolated at 
the Institute de Pasteur [2] and then the National Cancer Institute [3] and identified 
as a distinct retrovirus from the family of Human T-cell Leukemia viruses (HTLV). 
HIV became known by two names, Human T-cell Lymphotropic virus type 3 
(HTLV-III) and Lymphadenopathy associated virus (LAV). In 1986 a subcommittee 
of the International Committee on the Taxonomy of viruses suggested the name HIV 
for this newly described etiological agent of AIDS and characterized it as a member 
of the Lentiviridae family of retroviruses, which could infect a range of species 
including cats, horses, equine species and primates [4].  
The relatedness of HIV genomic sequences determined the origin of HIV as a 
zoonosis of Simian Immunodeficiency Viruses (SIV) from primates to humans [5]. 
Zoonoses were previously observed with viruses like HTLV-1 and smallpox [5]. The 
HIV epidemic was divided into two types: HIV-1 and HIV-2. In 1999 a strain of SIV 
retrieved from the Pan troglodytes troglodytes subspecies of chimpanzees found in 
Cameroon was reported as the origin of at least three independent introductions of 
SIVcpz and was determined as the primary reservoir for HIV-1 [6].  
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There are four known strains of HIV-1 of which the main strain, group M, leads the 
worldwide epidemic [7]. The “non-M, non-O strain” called group N is rare and has 
not been detected outside of Cameroon [8]. The outlier group O is also most 
frequently detected in Cameroon as 2% of all HIV infections [9]. Group P was 
identified in 2009 from a Cameroonian woman living in France and this strain was 
determined to be more closely related to gorilla SIV (SIVgor) than SIVcpz [10].  
The evolutionary flexibility of HIV has allowed different strains to be established 
around the world. Single strains of HIV can populate particular geographic locations 
so that a population is established with time. Sequence analyses of viruses from these 
populations demonstrate greater sequence similarities within them, compared to 
those from other geographic locations. Given the effect of these founder infections, 
HIV-1 group M is sub-divided into subtypes designated A-D, F-H, J, K (no E and no 
I) and circulating recombinant forms, (CRFs). CRFs are derived from 
recombinations of genomes from two or more Group M subtypes. Subtype A and its 
recombinant forms dominate the epidemic in Central and South Asia and subtype B 
dominates the epidemic in the Americas, Europe and Australia [11]. Subtype C and 
its related CRFs are the most prevalent worldwide, making up >50% of global 
infections [11]. This is mainly due to the pandemic levels of subtype C in highly 
HIV-1 positive populous countries in Southern Africa [12], South America [13] and 
China [14, 15]. The geographical distribution of HIV-1 subtypes worldwide is shown 
in Figure 1.1 
Similar to HIV-1, HIV-2 was also determined as a zoonosis. The primary reservoir 
was identified as a SIV prevalent in a subgroup of West African sooty mangabeys 
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called Cercocebus atys (SIVsm) [6, 16]. Eight subtypes of HIV-2 have been 
identified. These are groups A through H, of which groups A and B constitute the 
HIV-2 epidemic. Groups A and B are primarily endemic in West Africa. Group A 
has a prevalence rate >1% in Cape Verde Islands, Côte d'Ivoire, The Gambia, Ghana, 
Guinea-Bissau, Mali, Senegal, Mauritania, Nigeria, and Sierra Leone as well as 
Angola, Mozambique [17] [18] and reported in Brazil, India, Europe and the United 
States of America at a much lower prevalence [18]. Group B has been confined to 
West Africa and reported mainly in Côte d'Ivoire and Ghana [17]. Groups C through 
H have been identified in six people from West Africa as single independent 
transmission events from SIVsm in Liberia [19], Sierra Leone [19, 20] and Côte 
d'Ivoire [21, 22]. Group A was estimated as 1940 16 years and group B as 1945 
14 years [23].
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Figure 1.1 Geographical distribution of HIV-1 subtypes. The pie charts depict the proportion of 
each subtype or CRF in each geographical region from 2004 to 2007 and are colour-coded according 
to the legend on the left side of the figure. The HIV-1 subtype distributions found around the world 
and within Central African countries are shown in the insets of the main figure. This figure was taken 
from Hemelaar et al [24] and was originally reproduced and adapted with permission from [11]. 
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1.1.1 HIV epidemic 
1.1.1.1 The adult HIV epidemic 
As of 2011 the number of people living with HIV worldwide was estimated at 34.0 
million and 58% of adults who required ART received it. Sub-Saharan Africa bears 
the highest burden of HIV infections with 69% (23.5 million) of the global estimate 
living with HIV and as ART coverage improved, 55% of adults who needed ART 
received it in 2011 [25]. Improvements in HIV prevention strategies have also seen 
the number of new infections in this region decrease from 2.4 million in 2001 to 1.8 
million in 2011 and the improved accessibility to antiretroviral therapy (ART) has 
seen the number of people living with HIV increase from 20.9 million to 23.5 million 
during the same time [25]. 
1.1.1.2 The paediatric HIV epidemic 
The first reports of AIDS in children were in 1985 and the disease was described as 
rapidly progressing with high mortality rates for HIV infected children [26]. Between 
2009 and 2013, there was a 43% reduction in the number of new infections in 
children and between 2011 and 2013, the global estimate of children living with HIV 
dropped from 3.4 million to 3.2 million [27-29]. Similar to the adult epidemic, sub-
Saharan Africa bears the highest burden (91%) of children living with HIV. A large 
gap also exists between paediatric and adult treatment coverage in this region with 
only 24% of children who needed ART receiving it [25]. 
 18 
1.1.2 Prevention of mother-to-child transmission of HIV 
Within the last 15 years there have been continuous improvements to prophylactic 
strategies for the prevention of mother-to-child transmission (PMTCT) of HIV-1 
(Table 1). In resource-rich countries, where these strategies were sufficiently 
implemented, MTCT decreased to ≤ 2% [30]. Without prophylaxis, the MTCT for 
children <15 years of age was estimated as 12% - 45% [31, 32]. Without 
breastfeeding this rate improved to 15 - 30% compared to 30 - 45% with 
breastfeeding [32]. It is estimated that 35% of MTCT occurs during pregnancy, 65% 
as perinatal infections and 7% - 22% from breastfeeding [33, 34]. In 2001 the United 
Nations committed to reducing paediatric HIV infections by 50% by 2010 and 
focused heavily on the scale-up of country PMTCT programmes [35].  
Single-dose NVP (sdNVP) as MTCT prophylaxis in infants (2mg per kg orally 
within 72 hours of birth) has been shown to reduce vertical transmission rates by 
36% compared to the absence of PMTCT regimes [36]. When sdNVP is used in 
combination with maternal administration of single dose NVP (200 mg orally at 
onset of labour), MTCT rates are reduced even further [37, 38]. Single-dose NVP has 
been the most common PMTCT regimen used in resource-limited settings and has 
been a WHO recommendations since 2001 [39]. It is not the most effective 
prophylaxis regime, however its operational effectiveness for PMTCT, especially in 
resource-poor settings makes it a preferred treatment option [40]. As of 2010 the 
WHO no longer recommended sdNVP for PMTCT because longer-term NVP use 
was determined as more effective for this purpose, especially with prolonged 
breastfeeding [41-43] (Table 1). The WHO now recommends daily doses of NVP 
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from birth and until 1 week after the end of the breastfeeding period or for 4-6 weeks 
if breastfeeding ends before the first 6 weeks of life [44-46] (Table 1). 
The WHO reported PMTCT therapy coverage as drastically increased from 9% in 
2004 to 48% in 2010. With increased access to paediatric treatment service, there has 
been a 29% decrease in AIDS-related deaths in children between 2005 and 2011 [27, 
45, 47]. From 2009 to 2011, PMTCT interventions prevented ~ 409 000 vertical 
transmissions of HIV in low- and middle-income countries [27, 47] and there was a 
24% reduction in the number of new infections between 2009 and 2011 [46].
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Recommendation 
name 
Year of WHO 
recommendation 
Recommendation Key Trial / Study  
Mother Child 
Option B+ 2013 Triple ART throughout pregnancy and 
then for life, despite clinical status or 
CD4 count 
Same as Option A HPTN052 [48] 
Option B 2010  Triple ART throughout pregnancy 
and 7 days post breastfeeding. 
 Triple therapy continued for life if 
CD4 count ≤ 500 cells/mm3 
Same as Option A SWEN [41] 
Shapiro et al [49] 
Option A 2006  AZT from week 28 of gestation 
 sdNVP at onset of labour  
 7 days of postnatal AZT/3TC 
 BF: sdNVP from birth and 
then for 6 weeks 
 No BF: once-daily NVP or 
twice-daily AZT from birth 
for 4-6 weeks 
Mashi [50] 
ANRS1201/1202 
DITRAME PLUS [51] 
 
 2004  AZT from week 28 of gestation 
 sdNVP at onset of labour 
sdNVP at birth HIVNET 012 [38] 
 2001 sdNVP at the onset of labour sdNVP at birth HIVNET 012 [38] 
 Before 2001 AZT from week 14 or 36 of gestation 6 weeks of postnatal AZT 
(optional) 
ACTG 076 [52, 53] 
Table 1. Timeline of WHO recommendations for PMTCT of HIV-1. BF = breast-feeding.
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1.1.3 Course of HIV-1 infection 
90% of worldwide HIV infections are a result of oral, rectal, or vaginal mucosa 
exposures during sexual intercourse [54-57]. It can also be transmitted by inoculation 
with contaminated blood or blood products, for example needle sharing during 
intravenous drug use and needle stick injuries, blood transfusions [58] and vertical 
transmission routes in infants from mother-to-child, i.e. in utero, during delivery and 
through breast milk [32, 33, 59]. 
1.1.3.1 Course of HIV-1 infection in adults 
In adults the course of infection in typical HIV-1 progressors, can be divided into 3 
phases: 1) primary infection 2) clinical latency and 3) AIDS [60]. During primary 
infection the viral load can be as high as 108 HIV-1 RNA copies / millilitre of plasma 
(copies/ml)  and coincide with a decline in CD4+ T lymphocyte counts (CD4 
counts). This is followed by a reduction in viraemia, thought to be a result of the 
development of a cytotoxic CD8+ T lymphocyte (CTL) immune response to the 
infection. Clinical latency follows and can last for up to 10 years. During this time 
there is a steady loss of CD4+ T cells that correlates with the viral load. During this 
time, these cells continue to be infected, eradicated and regenerated. During AIDS 
the CD4 count declines rapidly and in tandem with an increase in viral load. It is at 
this stage that patients succumb to opportunistic infections associated with late stage 
disease. The course of HIV-1 infection in normal progressors is shown in Figure 1.2. 
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1.1.3.2 Course of HIV-1 infection in infants 
The course of HIV infection in infants can have two profiles [61-65]: the first profile 
follows the same course described for normal adult HIV-1 progressors (Figure 1.2) 
where HIV progresses to AIDS between 8 and 10 years after initial infection. The 
second profile is characterized by a more rapid progression to AIDS with increased 
risks of opportunistic infections and mortality. In vertically infected infants, rapid 
progression to AIDS is usually characterized by a positive HIV DNA polymerase 
chain reaction test within 4κ hours of delivery and ≤30% CD4+ T-cells out of total 
lymphocytes within the first week of life and may be a sign of in utero transmission 
of HIV (early HIV infection) [66]. Increasing viral loads with decreasing CD4+ 
lymphocyte counts is associated with increased risks in mortality in all HIV-1 
infected children [67]. 
There are several factors that help to predict rapid progression to AIDS in infants, 
but it is important to note that none of these factors can fully predict this. A 
prospective study published in 1996 [68] determined that risk for developing 
AIDS, defined as Centers for Disease Control and Prevention classification Category 
C by 12 months old in vertically infected children were: 1)liver and spleen 
enlargement or adenopathies in infected newborns, 2) <30% CD4+ cells at birth, also 
seen in other paediatric cohorts [62, 69] and 3) positive HIV antigen testing at birth. 
The authors determined that these parameters “were strongly interrelated and could 
reflect active disease onset in utero in some cases of early, severe HIV-1 disease in 
childhood” [68]. 
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Furthermore, Dickover et al [70, 71], Kuhn et al [72] and Rich et al [73] showed 
that vertical infections of HIV-1 that occurred in utero are associated with rapid 
progression to AIDS in these children. In addition, Chen et al [74] showed that 
the presence of the MHC class I allele HLA-A∗2301 has also been associated with 
rapid progression to AIDS and death by 2 years of age for vertically infected 
children. Two studies [69, 75] have also found that maternal AZT treatment was 
associated with rapid disease progression in vertically infected children, an effect 
which is yet to be understood.
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Figure 1.2 Course of HIV-1 infection. The graph shows the typical course of infection in HIV-
1 normal progressors. Rates and values of CD4+ T-lymphocyte loss and virus load increases vary 
between patients. This figure was taken from Coffin et al [60]. 
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1.1.3.3 Treatment of HIV in children 
Without ART, 50% of HIV-infected children did not live past 2 years of age and 
those who survived face a severely reduced quality of life associated with AIDS-
related disease and failure to thrive; 80% of these children die by age 5 [76]. In 2004 
Luzuriaga et al [77] showed that children who received ART within the first 12 
weeks of life had a better virological outcome (viral load <400 copies/ml) by week 
48 of ART compared to children who received ART after the first 3 months of life. 
In 2007, preliminary results of the Children on Early Antiretrovirals (CHER) trial 
showed that child mortality and disease progression in HIV-1 positive children 
improved by ~75% when PI-based ART was started within the first 12 weeks of life 
[78] compared to previous treatment guidelines to start ART when 
immunosuppression was detected [79, 80]. These results influenced the World 
Health Organization (WHO) to change its treatment guidelines for HIV-infected 
infants so that in April 2008, first initiation of ART was strongly recommended for 
in children <1 year old immediately after a positive HIV diagnosis, despite their state 
of health [81]. 
Antiretroviral formulations for young children are dependent on the age and weight 
of the child and may also require multiple dosing since under-dosing carries the risk 
of the development of drug resistance, particularly in resource-poor settings [82]. 
Since most children with HIV infections live in resource-poor settings, they also 
have the highest risk of developing drug resistance [82]. A meta-analysis by Sigaloff 
et al [83] quantified the prevalence of drug resistance in this context for children who 
failed first-line ART at 90% (95% CI 88–93): 80% harboured NRTI resistant viruses, 
88% harboured NNRTI resistance and 54% harboured PI resistance. They also 
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concluded that shortages of appropriate antiretroviral co-formulations or incorrect 
dosage calculations were the major sources of under-dosing [83] (the majority of the 
studies in their meta-analysis were published after 2007 when WHO paediatric 
treatment guidelines were changed to recommend early initiation of first-line ART 
for infants and children [81]). 
The recommended drug dosages for children are intended to achieve comparable 
concentrations to those seen in adults with a good virological response to ART, and 
work continues to determine optimal dosages for infants and children; drug toxicity 
also limits the antiretroviral options that can be used in children [28, 79, 81, 83-86]. 
Of the 28 antiretrovirals currently approved for use in HIV treatment and care, only 5 
are recommended for use in children of any age and they belong to only 3 of the 6 
drug classes available. Even less are approved for use in infants because of drug 
toxicity, poor virological response or insufficient data to support their use (Table 2).
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Drug Class Antiretroviral (Abbreviation) 
Liquid 
formulation 
(Y/N)* 
Age group dosing 
Nucleos(t)ide 
reverse 
transcriptase 
inhibitors 
(NRTIs) 
Zidovudine (AZT) Y All age groups 
Lamivudine (3TC) Y All age groups 
Stavudine (d4T) Y All age groups 
Didanosine (ddI) Y ≥2 weeks old 
Abacavir (ABC) Y >3 months old 
Emtricitabine (FTC) Y ≥3 months old 
Tenofovir (TDF) N >12 years old (only with Hepatitis B coinfection) 
Non-nucleoside 
reverse 
transcriptase 
inhibitors 
(NNRTIs) 
Nevirapine (NVP) Y All age groups 
Efavirenz (EFV) Y >3 years old and >10kg 
Etravirine (ETR) N ≥6 years old 
Protease 
inhibitors (PIs) 
Ritonavir (RTV)** Y All age groups 
Lopinavir/Ritonavir 
(LPV/r) Y ≥2 weeks old 
Nelfinavir (NFV) N >2 years old 
Saquinavir (SQV) N ≥16 years old and >25kg 
Atazanavir 
(ATV)*** N 
100mg capsules 
discontinued in the last 
year, therefore dosing 
recommendations are 
being re-evalutated 
Darunavir 
(DRV)*** N 
>3 years old and 10kg 
(efficacy and co-
formulation evaluations 
have not been conducted) 
Integrase Strand 
Transfer 
Inhibitors 
Dolutegravir*** N ≥16 years old 
Raltegravir*** Y >4 weeks old and >3kg 
Table 2. Antiretrovirals recommended in children according to FDA and WHO 
guidelines. *Y/N=Yes/No. **RTV is usually used as a pharmacokinetic enhancer in 
dual PI regimens. *** Important notes or newly approved for use in children. This 
table is an adaptation of the 2013 WHO report on Antiretrovirals in Paediatric 
patients: Focus on Young Children [87] and Annex E of the 2009 report on 
Antiretroviral Therapy got HIV Infection in Infants and Children: Towards Universal 
Access [28].
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1.1.4 Drug resistance in children 
HIV positive children require long-term use of ART from childhood to adolescence 
to adulthood, therefore they especially require first-line therapy to be highly effective 
and durable by minimizing the emergence of drug resistance and drug toxicity. 
Similar to adults, drug resistance in children is associated with poor adherence and 
suboptimal treatment regimes. Children may be more prone to developing drug 
resistance because they are kept on failing ART regimes for a longer time compared 
to adults and the risk of developing drug resistance increases when the same ART 
regime is continued with a detectable viral load. Reasons for continuing a failing 
therapy regime in children include limited treatment options, dependence on carers 
and deficient paediatric ART formulations [82]. 
In 2011, Sigaloff et al [83] reported that first-line therapy failure in the developing 
world was associated with at least one detectable drug resistance mutation in 90% of 
HIV positive children. Before the overwhelming success of PMTCT programmes in 
the developed world, children were two times more likely to fail triple therapy than 
adults and this risk increased with the duration of therapy into adolescence. 
In low- and middle-income countries, PMTCT programmes and regimes have a 
significant impact on drug resistance in vertically infected children when the 
intervention is unsuccessful. Drug resistance may be a result of mother-to-child 
transmission of drug resistant viruses or peripartum selection of drug resistant 
viruses in the child by maternal antiretrovirals or PMTCT interventions in the child. 
In 2007, Arrive et al [88] reported 52.6% of children who were exposed to 
prophylactic single-dose NVP developed detectable NNRTI resistance and Y181C 
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was most frequently detected. In 2010, Palumbo et al [89] showed that a PI-based 
first line treatment regime was more appropriate for vertically infected children who 
received prophylactic NVP because NNRTI resistance selected by this intervention 
was predictive of virological failure on NVP-based first-line regimes in children. As 
a result, all global paediatric guidelines were amended to recommend PI-based 
therapy in children with prior NVP exposure or for those who have a high risk of 
developing NNRTI resistance. Furthermore, the 2012 Nevirapine Resistance 
(NEVEREST) study [90] determined that a higher risk of virological failure was still 
associated with NNRTI-based ART despite initial suppression of the viral load using 
a PI-based regime and children with detectable baseline NNRTI resistance were also 
more likely to fail NVP-based ART by 3 years of age. 
NVP-based first-line therapy is still recommended for children without prior NNRTI 
exposure, but this recommendation remains debatable and the literature reports 
contrasting views on this topic. Many studies have reported an increased risk of 
NNRTI-based therapy failure in children <3 years old despite no evidence of prior 
NNRTI exposure [91-94], but other studies report no differences in treatment 
outcomes between NNRTI and PI-based regimes in such children [95]. 
Perinatally infected children enter adolescence with increased risks of treatment 
failure because of the development of multiclass drug resistance because of 
antiretroviral exposure from failed MTCT prophylaxis at birth and sub-optimal 
combination antiretroviral therapy throughout childhood. There is also limited range 
and formulations of drugs approved for paediatric use and drug toxicity. In Europe 
and North America, studies showed that perinatally infected adolescents were 
 30 
exposed to five [96] to eight [97] antiretroviral regimes by the time they were 
transferred to adult care and one particular European study found that 20% of 
children <16 years old were failing cART with triple class drug resistance after 8 
years of therapy [98]. Perinatally infected children in the developing world face even 
higher risks of developing multi-class drug resistance because treatment failure is not 
detected rapidly enough to prevent the accumulation of drug resistance mutations. 
Some studies report that a small proportion of the research cohort had virological 
failure during first line therapy in the absence of known drug resistance mutations. 
For example Hamers et al [99] found 29.6% (n=166) of patients from 6 countries in 
Sub-Saharan Africa fit this criteria, Odaibo et al [100] also found 30% (n=46) of 
patients from a Nigerian cohort found the same and Murphy et al [101] also found 
13.5% (n=141) of patients from a South African cohort were also failing first line 
therapy without detecting drug resistance mutations. 
1.1.4.1 HIV-1 subtype and ARV susceptibility 
The susceptibility of HIV-1 subtype B and drug resistance-conferring mutations in 
this subtype is well studied, however differences in ARV susceptibility of the other 
subtypes compared to subtype B is still to be defined. Genetic variation among HIV-
1 subtypes has the potential to yield distinct drug resistance mutation profiles under 
the selection pressure of antiretrovirals. A testament to this is that popular HIV-1 
drug resistance databases like the HIV drug resistance database run by Standford 
University [102] include drug resistance mutation frequencies for non-subtype B pol 
sequences, but mutations are defined as differences compared to a consensus B 
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reference sequence. There is an 8%-10% difference in genetic variation among HIV-
1 subtypes [103].  
Discussion continues about the effect of natural amino acid background of HIV-1 
subtypes on the magnitude of ARV susceptibility conferred by mutations that are 
already known to confer antiretroviral drug resistance and predispositions to the 
development of drug resistance [104, 105]. For example NVP or EFV is more likely 
to select V106M in HIV-1 RT in subtype C viruses, whereas V106A is more 
commonly selected in subtype B. This is because of a silent polymorphism in the 
codon, commonly seen in subtype C that requires 1 nucleotide change to become a 
resistance conferring mutation (GTG→ATG) [106, 107]. Subtype B generally 
requires 2 nucleotide changes for the same mutation to develop (GTA→ATG). 
Another example is the D30N mutations in HIV-1 PR. When this mutation is 
selected by NFV in subtype B, it confers resistance to this PI by making the flap 
region of protease more flexible in the PI-enzyme complex [108, 109]. However the 
same effect is achieved in subtype C proteases when D30N and N83T are both 
selected in the enzyme [108, 109]. 
1.1.4.2 The CHER trial 
The CHER trial began in 2005 and its aim was to determine if there was an optimal 
time to start ART in vertically infected children. The research team hypothesized that 
early ART administered until the 1st or 2nd birthday of the child may delay disease 
progression and delay the need for long-term, continuous ART [110]. Prior to the 
CHER trial, there were no comparative studies to inform ART guidelines for such 
children, and infants had poor disease outcomes and high mortality rates [76]. The 
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inclusion criteria for the CHER trial were (1) <12 weeks old (2) a positive DNA PCR 
test (3) ART naïve with the exception of PMTCT NVP (4) CD4% > 25%. 377 
participants were enrolled in the study based on this criteria [78]. Participants were 
randomly assigned to one of three treatment arms: Arm 1 was deferred ART [84], 
Arm 2 was early ART until week 40; Arm 3 was early ART until week 96.  
The primary endpoint of the study was death or virological failure (viral load >1,000 
copies/ml) during early ART [78]. The secondary endpoints of the study [78, 110, 
111] were a cumulative risk of disease progression that led to hospitalisation, the 
occurrence of Grade 3 or 4 adverse events as defined by the United States National 
Institute of Allergy and Infectious Diseases [112] and the development of drug 
resistance. Children were followed-up for a minimum of 3.5 years. Preliminary 
results revealed that starting ART before 12 weeks of age (Arms 2 & 3) reduced 
infant mortality rates by 76% compared to deferred therapy (Arm 1). Early ART was 
also associated with a 75% improvement in disease progression compared to 
deferred therapy. The frequency of breastfeeding in each Arm of the Study was 20% 
[110]. 
1.1.5 Significance of drug resistance in the minority sub-populations  
Several studies have shown that the drug resistant minority variants in the viral 
population that are not detected by the standard population based genotyping 
techniques can be revealed with more sensitive approaches [113-116]. The clinical 
implications of these minority species that develop in the viral populations of HIV-1 
infected patients continue to be discussed. They have been detected in women and 
mothers [117-120] and children [119-121] who were treated with sdNVP for 
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PMTCT, acute seroconverters [122], patients receiving early therapy [123], those in 
structured treatment interruption programmes [124] and patients experiencing 
virological failure [116, 123, 125-128]. Some studies have shown that drug resistant 
minority species can develop into the major viral population during first-line therapy 
[127], during salvage therapy [116, 129-131] and in, treatment-experienced patients 
[127, 132]. A 2011 systematic review and pooled analysis by Li et al [127] found 
that the detection of minority resistance before starting ART was associated with a 
2.5- to 3- fold risk of virological failure during first-line ART and this increased risk 
of virological failure was associated with NNRTI resistance. More recently, Cozzi-
Lepri et al [133] found that minority RTI resistance that was detected before starting 
first-line RTI based ART was associated with >2-fold risk of virological failure 
during first-line ART. However the low-level drug resistance mutations detected at 
baseline were not always the same mutations detected with virological failure during 
therapy, a finding that is not uncommon in the literature and continues to be a topic 
of discussion for researchers. Also unlike Li et al’s findings, Cozzi-Lepri et al found 
that the risk of virological failure increased when there was a higher mutation load, 
i.e. a higher number of pre-existing minority drug resistance variants in the viral 
population: Patients with 400 to 1000 minority drug-resistant HIV-1 variant 
copies/ml plasma had an intermediate risk of virological failure on first therapy 
whereas those with >1000 minority drug-resistant HIV-1 variant copies/ml plasma 
had a high risk.  
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1.1.6 Approaches for measuring population diversity 
Commercial and ‘home-brew’ population-based sequencing tends to characterise the 
dominant viral species in the plasma sample. The sensitivity of these assays has been 
reported as ≥20%, which does not reflect the true diversity of the viral population 
and does not always provide complete information on the genetic linkage of drug 
resistance mutations (DRMs) on the same genome [134]. Multiple methods have 
been developed to characterize the viral population, each with its limitations. There 
are highly sensitive point mutation assays such as the oligonucleotide ligation assay, 
parallel allele-specific sequencing and allele-specific real-time PCR. Next generation 
sequencing (NGS) is also a highly sensitive approach with many of the advantages of 
the previously mentioned approaches and is also often used for whole genome 
reconstruction. The sensitivity range of these methods to measure HIV-1 population 
diversity has been reported at 0.1-1% [113, 135, 136]. Some clinical limitations of 
these methods are that point mutation assays can be limited by insensitivity of 
primers for their templates and analyzing thousands of sequences to confirm a rare 
variant [113]. NGS has a very high throughput of sequences, requiring specialist 
bioinformatics expertise to be executed as well as to manage the data and analyse 
and interpret results. Read lengths are also shorter in the case of 454™, Illumina®, 
and Ion Torrent™ platforms [137] compared to Sanger sequencing, limiting the 
power to determine the evolution of genetically linked drug resistance mutations 
[135]. In the future, longer read lengths with this technology will no doubt become 
available. 
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Another approach is single genome sequencing (SGS), where viral RNA is reverse 
transcribed and the complimentary DNA (cDNA) product is diluted so that one 
cDNA molecule is used for PCR amplification. This was followed by sequencing of 
a defined region of the viral genome. This is a highly sensitive method as long as a 
sufficient number of single genomes are analysed [138, 139] and the starting 
concentration of cDNA for the dilution series is sufficient to minimize re-sampling 
of the same viral genome [134, 138, 139]. Another approach is to clone the products 
of one-step reverse transcription-polymerase chain reaction amplification (RT-PCR) 
of a region of interest in the viral genome and then randomly select clones for 
sequencing. This may underestimate the diversity of the viral population because of 
poorly reactive RT-PCR primers for their templates. This approach also has a higher 
risk of producing artefactual mutations because of PCR-mediated recombination 
between viral templates, but nonetheless has been shown to be equally effective at 
measuring population diversity compared to SGS [114]. For this project, SGS was 
used because of the reduced risk of producing artefactual mutations compared to 
cloning. SGS was also chosen over NGS techniques because it could detect genetic 
linkage along longer sequence.  
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1.2 HIV-1 structure and replication 
1.2.1 The HIV-1 genome 
The HIV-1 genome is roughly 9.7kb (Figure 1.3A) and exists as diploid, linear, 
positive sense single-stranded RNA within the virion and double-stranded proviral 
DNA after it is reverse transcribed in an infected cell. The HIV-1 genome encodes 
the structural (gag and env) and enzymatic (pol) proteins as well as proteins which 
regulate transcription and transport of viral RNA. The structural elements encoded 
by gag are the viral matrix (MA/p17), capsid (CA/p24), nucleocapsid (NC/p7) and 
p6 and the viral envelope is encoded by env, detailed in Section 1.4.3.2. The 
enzymatic proteins encoded by pol are the viral protease (prot/PR) detailed in 
Section 1.2.4 and 1.2.4.1, reverse transcriptase (p51/RT, RNAse H (p15) detailed in 
Section 1.2.3 and 1.2.3.1 and integrase (INT/p31) detailed in Section 1.2.5 and 
1.2.5.1. The regulatory proteins are: transactivator of transcription (Tat), regulation 
of expression of virion proteins (Rev), negative regulatory factor (Nef), viral 
infectivity factor (Vif), viral protein unique to HIV (Vpu) and viral protein R (Vpr). 
1.2.2 HIV-1 virion 
HIV is a lentivirus, which is a genus of the Retroviridae family. Lentiviruses are 
roughly 80-130 nanometers in size, enveloped and their genetic material is single 
stranded RNA (ssRNA) encased in an icosahedral capsid [140]. The HIV-1 virion 
(Figure 1.3B) is approximately 110 nanometers. Its outer envelope consists of a lipid 
bilayer derived from host cells as well as the viral envelope glycoproteins. Within the 
envelope is a ‘matrix’ shell made up of viral matrix proteins, which are anchored to 
the envelope by N-terminal myristoyl groups [141]. Matrix encapsulates the viral 
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capsid that encased the genetic material of the virus. Gag, Pol and Env proteins are 
initially translated within precursor polyproteins. The Gag precursor Pr55Gag (55kDa) 
is cleaved by the viral protease to produce mature MA, CA, NC and p6 [142]. The 
GagPol precursor Pr160Gag-Pol (160kDa) is also processed by the viral protease to 
produce the mature Gag proteins and the pol encoded enzymes PR, RT, RNAse H 
and IN [142]. The Env precursor gp160 (160kDa) is processed by host cell proteases 
into the mature transmembrane glycoprotein gp41 and the surface glycoprotein 
gp120 [143]. The ends of the viral RNA have terminal direct repeats (R-regions). 
Downstream of the 5’ R-region is the U5 region (5’ unique regulator sequence) and 
upstream of the 3’R region is the U3 region (3’ unique regulatory sequence). On both 
end of proviral DNA are long terminal repeats (LTRs) containing U3-R-U5 
sequences [144] (Figure 1.4). 
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Figure 1.3 (A) Organization of the HIV-1 genome/gene map (~9.7kb). The nucleotide position 
numbering is relative to HXB2CG (accession number K03455). Rectangles represent open reading 
frames. Shaded rectangles represent the spliced exons of tat and rev. Numbers in the upper left corner 
of each rectangle indicate the start of each gene. Numbers in the lower right corner of each rectangle 
indicate the last position of the stop codon. The start of pol is from the first “T” of the stem loop 
TTTTTTTAG sequence for ribosomal slippage for the -1 frameshift for Gag-Pol polyprotein 
translation [145]. (B) Organisation of the mature HIV-1 virion [146]. 
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1.2.3 HIV-1 replication cycle 
There are two phases of the HIV replication cycle (Figure 1.8): (1) early and (2) late. 
The early phase includes binding of the virus to the cell surface receptors, fusion of 
the viral and cell envelopes, viral entry, reverse transcription of the viral genome and 
integration of the viral genome into host cell DNA. The late phase of the cycle 
includes regulated expression of integrated provirus, budding and maturation of the 
virion. 
1.2.3.1 Early phase 
1.2.3.1.1 Binding, fusion and entry of HIV into the host cell 
During the HIV budding process, gp120-gp41 complexes are initially expressed at 
the surface of infected cells and incorporated into the virus envelope to be displayed 
on its surface as viral spikes. The HIV envelope spike consists of three gp120 and 
gp41 subunits in combination to form a trimer of heterodimers that mediate binding 
and entry of the virus into the host cell [147]. Viral entry into a host cell first 
involves the interaction of gp120 with the CD4 receptor [148]. This induces a 
conformational change in gp120 through the variable loops so that the co-receptor 
binding site is formed and exposed [149]. Subsequently the chemokine receptor, 
CCR5 [150] or CXCR4 [151], is bound and induces a conformational change in the 
N-terminus of gp41 so that the viral and cellular membranes fuse, enabling the viral 
capsid to enter the cytoplasm of the cell [149]. The viral core then goes through the 
process of uncoating and the initiation of reverse transcription of the viral RNA 
genome. 
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1.2.3.1.2 Reverse transcription 
Once the content of the HIV-1 virion enters the cytoplasm of a newly infected cell, 
the stage is set for the initiation of reverse transcription. The early steps that lead to 
reverse transcription are still not completely understood, however transcription 
occurs shortly after infection because viral DNA can be detected within hours of 
infection. The main process of converting single stranded RNA (ssRNA) from the 
virion to linear double stranded DNA (dsDNA) is executed primarily by the 
enzymatic activities of RT. These are DNA polymerization from the viral genomic 
RNA and RNAse H activity that degrades processed RNA from an RNA-DNA 
complex. The steps of this process are as follows [60] (Figure 1.5): 
A. Host cell transfer RNA (tRNA), tRNA3Lys, acts as the primer for the synthesis 
of the minus DNA strand of HIV-1. The 3’ end of the tRNA3Lys is base paired 
to its complementary sequence in the primer binding site (pbs) in the viral 
RNA sequence, which is roughly 1κ0 nucleotides from the 5’ end of the 
sequence.   
B. Reverse transcription ensues from the 3’OH group of tRNA3Lys to produce the 
“minus strand strong stop DNA” that encompasses the 5’ end of the viral 
RNA, containing the R and U5 regions of the 5’LTR (100 to 150 
nucleotides). RNAse H degrades the template RNA from the DNA-RNA 
complex.  
C. The R-region of the “minus strand strong stop DNA” base pairs with its 
complementary sequence in the R-region of the 3’ end of viral RNA (minus-
strand transfer), which can occur within the same RNA strand being 
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processed or at the 3’ R-region of the other packaged RNA of the diploid 
genome. Minus strand DNA continues to be generated up to the 5’pbs while 
RNAse H degrades template viral RNA as DNA synthesis proceeds. However 
within the RNA sequence of HIV-1 are two polypurine tracts that are 
resistant to RNAse H degradation, one at the 3’ end of the RNA (3’ppt) and 
the other in the middle of the genome, called the central ppt (cppt). 
D. The 3’ppt and cppt that are not degraded by RNAse H and function as 
primers for the initiation of the synthesis of plus strand DNA. Generation of 
the plus strand DNA starts at the 3’ppt using the minus single-stranded DNA 
as the template for plus strand DNA synthesis, including the 3’pbs which is 
complementary to the 3′ end of the minus strand DNA. 
E.  RNAse H removes the tRNA3Lys to expose the minus strand pbs which binds 
to its complimentary sequence in the 3’ end of the plus strand DNA (plus 
strand DNA transfer) to form a transient circular DNA and DNA synthesis 
continues to proceeds to the end of both templates, completing the generation 
of both DNA strands.  
F. Plus-strand DNA synthesis ceases at the end of the minus-strand or when RT 
reaches the cppt, which results in linear dsDNA with a central plus strand 
overlap of DNA (~99 nucleotides) known as the central DNA flap. The 
completed proviral dsDNA contains long terminal repeats at both ends. This 
flap allows the viral dsDNA to be incorporated into a pre-integration complex 
(PIC) that facilitates nuclear import of the viral dsDNA. During the 
integration process, host cell enzymes remove the flaps and repair the gaps in 
the newly synthesized dsDNA.
 42 
 
Figure 1.4 The process of reverse transcription of the HIV-1 RNA genome. Figure taken from 
Coffin et al [60]. 
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1.2.3.1.3 Integration 
Integration of viral dsDNA occurs in 3 steps [152]μ 1) 3’ processing, 2) strand 
transfer and 3) gap repair. 3’ processing occurs in the cytoplasm. Integrase cleaves 
G-T at the 3’ end of a conserved CAGT motif on each strand of the viral dsDNA. 
This results in hydroxyl group overhangs at either ends of the 3’ and 5’ LTRs. A pre-
integration complex (PIC) proposed to contain the processed viral dsDNA, IN, RT, 
MA and Vpr is imported into the nucleus. A host cell transcriptional co-activator 
called LEDGF/p75 tethers the PIC to the host cell genomic DNA so that the viral 
dsDNA is targeted to the host genome [153]. Strand transfer occurs where the two 
ends of viral DNA are inserted in the host genome at sites that are 5 nucleotides 
apart. The gaps created in the genome are then repaired by host DNA repair 
enzymes, removing unpaired viral nucleotides at 5’ end of each viral DNA strand, 
replacing the five bases in gaps created during strand transfer and ligating the viral 
dsDNA in to the host genome. 
1.2.3.2 Late phase 
1.2.3.2.1 The action of protease 
The Gag and Pol precursor polypeptides, Pr55Gag and Pr160Gag-Pol are the natural 
substrates of HIV-1 protease [154]. They are cleaved to produce p2, p6 and the 
structural elements of the virus: MA, CA, NC, the viral enzymes PR, RT, RNAse H, 
IN and a pol transframe protein (Figure 1.7). The binding cleft of protease can 
accommodate 6 to 7 amino acids from its substrate with 3 to 4 amino acids on either 
side of the scissile bond being cleaved [155].  
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Gag and Pol proteins are encoded by overlapping reading frames. The gag reading 
frame has its own ‘start’ (AUG) and ‘stop” (TAA) codons and pol processing is a 
result of a -1 frame shift during translation [156]. The ribosomal slippage site where 
this frameshift occurs is a stem structure at the C-terminus of the sequence that 
encodes NC, which stalls the ribosome during translation [156]. Protease autocleaves 
itself from Pr160Gag-Pol at the cellular plasma membrane or just after viral budding 
[157, 158]. The mechanism by which this process is thought to occur is by 
dimerization of immature protease within its precursor in cis, which creates a 
partially active catalytic site that cleaves the N-terminus of protease out of its 
precursor, releasing a fully functional active site with an extended C-terminus [157, 
158].
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Pr55gag polyprotein cleavage 
sites: 
Pr160gag-pol polyprotein 
cleavage sites: 
Nef protein cleavage 
sites: 
   
1. MA/CA 6. NC/TFP 12. Nef 
2. CA/p2 7. TFP/p6pol  
3. p2/NC 8. p6pol/PR  
4. NC/p1 9. PR/RTp51  
5. p1/p6gag 10. RT/RTp66  
 11. RTp66/INT  
Figure 1.5 Proteins cleaved from the Gag-Pol 
precursor polypeptide are encoded by HIV-1 gag, pol and 
nef genes (grey) into their precursor polypeptides (green). 
The structural proteins (yellow) are formed by cleavage of 
the Pr55gag polyprotein into matrix (MA, p17), capsid (CA, 
p24), nucleocapsid (NC, p7), p2, p1, p6gag. The viral 
enzymes (pink) are formed by cleavage of a second 
polyprotein, Pr160gag-pol. Although Pr160gag-pol also 
contains p17, p24 and p2, its C-terminal cleavage products 
are NC, a transframe protein (TFP), p6pol, protease (PR), 
reverse transcriptase (RTp51), RT-RNase H (RTp66) and 
integrase (IN). Nef (orange) is not encoded by pol but is also 
cleaved from its precursor protein by the viral PR (Figure 
taken from de Oliveira et al [159]). 
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1.2.3.2.2 Reverse transcriptase 
The reverse transcriptase enzyme (RT) is a product of the cleavage of Pr160Gag-Pol by 
viral protease. Mature HIV-1 RT is a heterodimer with two subunits: p66 (560 amino 
acids) and p51 440 amino acids) (Figure 1.4). p51 is a product of protease cleavage 
of p66. The enzymatic domains of RT, polymerase and RNAse H, are found in p66. 
p51 has identical subunits to p66 at its N-terminus, but does not have the RNAse H 
domain or enzymatic activity; instead, it has a structural role [60].  
The crystal structure of RT has been resolved in several states as bound and unbound 
to its ligand, revealing the right-handed fingers, palm, thumb and connection 
domains of the polymerase site [160, 161]. The ‘palm’ of p66 contains the 
polymerase active site with a nucleic acid binding cleft that exposes three catalytic 
aspartate residues at amino acid positions 110, 185 and 186. Mutagenesis of any of 
these residues renders the catalytic site inactive. The suggested mechanism of action 
of RT is: association of the ssRNA template with the catalytic site of RT. The fingers 
of the motif closed down around the primer-template and deoxyribonucleotide 
triphosphates (dNTPs) before the formation of a 3’to 5’ phosphodiester bond is 
formed. Once the bond is formed, the DNA chain lengthens and the finger 
subdomain relaxes, releasing the pyrophosphate and allowing the next dNTP to be 
incorporated. The palm and thumb subdomains clamp down on the DNA and the 3’-
hydroxyl group (OH) of the primer site in the correct conformation relative to the 
amino acid residues in the active site of p66 so that the primer-template chain 
extends for roughly 18 nucleotides between the active sites of the RT and RNAse H 
domains.
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Figure 1.6 The sub-domains of HIV-1 RT. Both subunits, p51 and p66, are shown. The 
polymerase domains are named based on analogy to a human right hand and color coded: fingers 
(blue), palm (red), thumb (green), connection (yellow). The RNase H domain in the p66 subunit, is 
shown in light brown. This figure was taken from Coffin et al [60]. 
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1.2.3.2.3 Integrase 
HIV-1 integrase is an enzymatic element of the virion and is responsible for 
integrating viral DNA into the host genome. It has three domains: (1) an N-terminal 
domain with a His2Cys2 motif that chelates zinc, (2) a core domain with a catalytic 
DDE motif which is necessary for enzymatic activity and (3) the C-terminal domain 
that has an SH3-like fold that non-specifically binds DNA [152]. 
1.2.3.2.4 Protease 
HIV-1 protease is an aspartyl-mediated protease with the active site spread across 
three amino acids Asp25-Thr26-Gly27 [155, 162-164]. It is 99 amino acids long and 
contains two identical subunits [163]. A beta-hairpin or “flap” extends from each 
monomer over the substrate binding cleft [163, 164] and the flexibility of the flap is 
thought to be essential for enzyme activity by positioning the substrate in the active 
site [155, 162, 163]. When PIs bind to active site, these flaps protect it from the 
external environment. Aspartate mediated proteolysis involves the activation of a 
water molecule between the two Asp25 residues of the homodimer by removing a 
proton from it so that H2O- can attack the carbonyl group of the substrate scissile 
bond which leads to protonation and cleavage of the scissile amide in the substrate 
[155]. The structure of the viral protease is shown in Figure 1.6.
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Figure 1.7 Structure of HIV-1 Protease. Colours indicate distinct regions. Red = Flaps: residues 
43–58; yellow = flap tips: residues 49–52; pink = flap elbows: residues 37–42; blue = -strandmotif 
forming the dimer interface: residues 1–4 and 96–99; green = residues 59–75; orange = residues 10–
23. Figure adapted from Hornak et al [155].
 
 
– – –
– –
– –
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1.3 HIV-1 Antiretrovirals 
To date there are 6 HIV-1 antiretroviral drug classes which consist of 24 drugs that 
have been approved for the treatment of HIV-1 infection by the U.S. Food and Drug 
Administration (FDA) [165].  Drug classes are based on their point of 
action/molecular mechanism and resistance profiles. The classes are as follows: (1) 
nucleoside-analog reverse transcriptase inhibitors (NRTIs), (2) non–nucleoside 
reverse transcriptase inhibitors (NNRTIs), (3) integrase inhibitors (INIs or InSTIs) 
(4) protease inhibitors (PIs), (5) fusion inhibitors, and (6) coreceptor antagonists 
[166]. A schematic of the HIV-1 replication cycle and the point of inhibition/action 
of each FDA-approved drug/drug class is shown in Figure 1.8. 
1.3.1 Targets and mechanisms of action of HIV-1 antiretrovirals 
The first step in the HIV-1 replication cycle, (binding, fusion and entry of HIV into 
the host cell), is the target for antiretroviral agents: attachment inhibitors, chemokine 
receptor antagonists, and fusion inhibitors. Fusion of the HIV-1 envelope with the 
host cell membrane is followed by entry of the viral core into the cytoplasm of the 
host cell and then uncoating of the viral core. Even though the uncoating process is 
not fully understood, it protects the viral RNA genome whilst permitting access to 
dNTPs for reverse transcription by the viral RT enzyme and proviral DNA synthesis 
[167].  
RT was the first viral enzyme to be exploited for antiretroviral drug discovery and it 
is the target of the NRTIs as analogues of native nucleoside substrates. NNRTIs, 
bind to an allosteric site 10 angstroms (Å) away from the polymerase’s active site, 
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distorting it so that dNTPs cannot easily access the RT active site [160, 168]. There 
are 12 FDA-approved RTI drugs within these two classes that account for roughly 
half of all approved ARVs. Although the NRTIs and NNRTIs target different sites 
and have different mechanisms of action, they both inhibit the same process: DNA 
polymerization activity of the RT enzyme that inhibits the production of full-length 
viral DNA. Integrase inhibitors are a relatively newer class of ARV that have been 
FDA-approved for treatment of HIV infection. They inhibit strand transfer and block 
integration of the HIV-1 DNA into the cellular DNA. 
The PIs block cleavage/proteolysis of the viral polyprotein precursors, a step 
required for the production of infectious HIV-1 virions. They are the most potent of 
the approved drug classes and serve as competitive inhibitors to the natural substrate 
of protease. They also need to be the co-administered with a “boosting” agent to 
inhibit their metabolism through the cytochrome P450-3A4 (CYP3A4) pathway in 
the liver [169] in order to enhance drug levels. Therefore, PI-based ART includes 
RTV as a pharmacokinetic enhancer/booster for the active PI in the drug regime 
[170]. Figure 1.8 shows the drug targets for the ARV classes described above in the 
context of the life cycle of HIV-1 in a host cell.
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Figure 1.8 The HIV-1 
life cycle and current or 
potential targets for 
antiretroviral drugs (ARV) 
[166]. (A) Schematic of the 
HIV-1 life cycle in a 
susceptible CD4+ cell. (B) 
Time frame for ARV action 
during a single-cycle HIV-1 
replication assay. (C) 
Preclinical, abandoned 
(normal text), or FDA-
approved (bold and italic text) 
inhibitors in relation to 
specificity of action and drug 
target. The NNRTI, 
Rilpivirine (not in bold) and the integrase inhibitor: Dolutegravir (not included in this figure), are also FDA approved. 
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1.4 Antiretroviral resistance 
1.4.1 Mechanisms of HIV-1 genetic diversity 
Genetic diversity of the viral population is key to the selection of drug resistant viral 
populations in the correct ARV environment. An HIV infected patient generates 
between 109 and 1010 virions daily [171, 172] [173]. RNA viral loads of 105 to107 
copies/ml have been associated with primary infection within one week of patients 
showing clinical symptoms of infection and represent a mere 102 to 104 infectious 
units of HIV [174-177]. The main sources of genetic diversity in an HIV population 
are (1) the lack of an error-repair mechanism in the viral RT which results in a high 
mutation rate between 1.4 x 10-5 and 3 x 10-5 nucleotide substitutions per site per 
generation) and gives rise to every possible point mutation, every day in an infected 
patient [178, 179], (2) recombination between two RNA strands of the diploid viral 
genome where each strand encodes different genetic information, and (3) selective 
pressures induced by antiretrovirals used for treatment or from host immunity. 
The main source of mutations in the HIV genome are thought to arise during reverse 
transcription of viral RNA to DNA by RT because of its lack of exonucleolytic 
proofreading activity. Other processes in the replication cycle of HIV that can 
introduce mutations in the viral genome are when integrated proviral DNA is copied 
by host cell DNA-dependent DNA polymerase when an HIV infected cell replicates 
and when viral RNA is transcribed from proviral DNA by host cell DNA-dependent 
RNA polymerase, however their contributions are much less significant because the 
cellular polymerases have proof-reading activity. Host cellular factors can also 
influence the generation of mutations, such as APOBEC3G (A3G), which causes G-
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to-A mutations in the minus strand of viral DNA via deamination of cytidine [180]. 
Cellular DNA repair enzymes are also thought to cause mutations in the viral DNA. 
1.4.2 Reverse transcriptase inhibitor resistance 
There are two known mechanisms by which NRTI resistance is conferred. The first 
mechanism is steric hindrance of analogues from being incorporated into the 
growing DNA chain [168]: the replacement of methionine (M) at position 184 in RT 
with valine (V) or isoleucine (I), (annotated as M184V/I), is an example of a 
mutation that causes steric hindrance of NRTIs like 3TC. Position 184 of RT is 
within a highly conserved motif in the active site of reverse transcriptase [161]. 
When 3TC tries to be incorporated into the viral DNA chain being generated by an 
M184V/I mutated RT, the ozathiolane ring of the drug clashes with the -branch 
of184V/I so that it cannot be incorporated into the growing DNA chain [181]. V at 
this position confers cross-resistance to 3TC, abacavir (ABC) and emtricitabine 
(FTC) and I at this position confers cross- resistance to 3TC and FTC [182]. 
The second mechanism by which NRTI resistance is conferred is the removal of 
thymidine analogues from a terminated DNA chain by pyrophosphorolysis [168]: RT 
that has thymidine analogue mutations (TAMs) can still allow thymidine analogues 
like zidovudine (AZT) or d4T (stavudine) to be correctly incorporated into the viral 
DNA chain. They can be removed by pyrophosphorolysis from the terminated DNA 
chain [168] and an accumulation of TAMs further enhances this hydrolysis and 
release of the drug from the terminated DNA chain [183]. 
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NVP and EFV resistance results from mutations in the NNRTI binding pocket of RT, 
which causes a conformational change that no longer allow the drug to fit in the 
pocket [160]. RTI resistance mutations in RT are shown in Figure 1.9A and B.
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(A) 
 
(B) 
 
Figure 1.9 Resistance mutations in RT associated with reduced susceptibilities to the RTIs. (A) 
DRMs that confer resistance to NRTIs and (B) DRMs that confer resistance to NNRTIs. Figures were 
taken from the International AIDS Society Update on Drug Resistance Mutations 2013 [182]. 
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1.4.3 Protease inhibitor resistance 
1.4.3.1 Drug resistance mutations in protease 
Mutations in the viral protease that alter the conformation of the active site and its 
interactions with the enzyme’s substrate cause resistance to PIs [168]. PI resistance 
mutations are categorized as major and minor and the majority are single point 
mutations [168]. Major and minor mutations have been described in the vicinity of 
protease’s active site as well as outside of the active site. Mutations near the active 
site are usually major mutations that directly affect the PIs affinity for protease. 
Mutations outside of the active site are usually minor or silent but influence the 
stability of the homodimer and the flexibility of the active site.  
Major mutations single-handedly cause detectable reductions in susceptibility to one 
or more PIs. Minor mutations alone usually have a silent phenotype, but in 
combination with major PI mutations, they enhance PI resistance conferred by the 
major PI mutations [184, 185] and/or enhance replication capacity of mutated viruses 
[164, 186]. For example, V82A in PR confers 2- to 4- fold reductions in LPV 
susceptibility however as minor mutations accumulate in PR, resistance to LPV 
increases and cross-resistance to other PIs occur [187]. Major and minor PI 
resistance mutations in PR are shown in Figure 1.10.
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Figure 1.10 Resistance mutations in PR associated with reduced susceptibilities to the PIs. 
Figure were taken from the International AIDS Society Update on Drug Resistance Mutations 2013 
[182]. In bold are major PI resistance mutations which are able to confer reduced susceptibility to PIs 
one their own. Minor PI mutations are not in bold and are phenotypically silent when present in the 
absence of a major PI. Minor PI resistance mutations enhance the resistance phenotype of major PI 
mutations. 
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1.4.3.2 HIV-1 subtype, antiretroviral resistance and treatment failure 
Until 2015, there was no clear demonstration of HIV-1 subtype playing an important 
role in treatment outcomes and researchers have been divided about its significance 
in this context: [188-195]. Therefore subtype has not been a consideration for clinical 
care [103, 191]. In January 2015, Kantor et al [190] were the first to associate HIV-1 
subtype to virological failure during ART. They found that patients infected with 
subtype C viruses “were more likely to fail ART, and to fail earlier than those 
infected with subtype B viruses”. Virological failure was defined as consecutive viral 
loads ≥1000 copies/ml ≥14 weeks after randomization to 1 of 3 treatment arms and 
viral loads were taken at baseline and then every 8 weeks. The treatment arms were 
NNRTI or PI based. For the purpose of this project, what is known about subtype C 
in this context will now be introduced, but it is noted that specific drug resistance 
mutations have been associated with other HIV-1 subtypes.  
The prevalence of NRTI and NNRTI resistance mutations seem to be higher in HIV-
1 subtype C [196, 197]. The NNRTI resistance mutation V106M has been associated 
as most frequently emerged in HIV-1 subtype C and confers cross-resistance to other 
NNRTIs, compared to V106A [106]. One study found that Etravirine (ETR) 
preferentially selected E138K as the first mutation in RT for subtypes B, C and 
CRF02_AG [198]. Another study found that Y181C in RT was the first mutation 
selected by ETR in subtype C viruses [199]. The TAM K65R has been shown to 
occur more frequently in subtype C in treatment naïve patients failing TDF-
containing ART regimes [200, 201]. Under the selection pressure of PIs, the 
polymorphism of Methionine at position 89 in PR is thought to preferentially lead to 
the emergence of threonine at this position [202], which confers high level resistance 
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to LPV, ATV and NFV [102]. The importance of subtype to mutations in Gag 
cleavage sites [154] and the viral matrix [154, 203], which are known to be involved 
in PI susceptibility, are still not well defined. However it is thought that 
polymorphisms in these regions of Gag may be more frequent in non-B subtypes 
[191]. 
1.4.3.3 Contribution of Gag to protease inhibitor resistance 
Accessory mutations have been described in the cleavage sites of the viral protease’s 
substrates, the gag and pol precursor polypeptides. The majority of these mutations 
improve the fitness of mutant virus and a few can confer resistance to PIs [154, 204, 
205]. Cleavage site mutations in the gag and pol precursor polypeptides tend to 
increase the accessibility of the cleavage site for the active site of protease. An 
exception is the A431V mutation in NC/p1 (of the SP2) cleavage site, which showed 
to enhance the PI resistance of virus which contain a major mutation in protease 
[154, 206]. 
In 1996, Doyon et al [207] analysed the sequence of viruses that were sequentially 
passaged in the presence of PIs until they displayed up to a 1,500 fold increase in 
resistance compared to the wildtype. They developed mutations in the CA/p2/NC 
and NC/p1/p6 cleavage sites of the gag and pol precursor polypeptides after the 
appearance of major mutations in the viral protease. These cleavage site mutations 
were Q430R and A431V in the NC/p1 cleavage site and L449F in the p1/p6 cleavage 
site. When these mutations were reversed by mutagenesis, viral growth experienced 
a dramatic reduction or was completely abolished, but they did not decrease the 
ability of the PIs to inhibit the protease’s activity. Dam et al [206] went on to show 
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that A431V augmented PI resistance when associated with V82A; a major PI 
resistance mutations in protease. 
In 2009, Dam et al [206] showed that a patient protease that had V82A in PR in had 
21.4-, 16.9- and 15.9-fold increases in resistance to SQV, LPV and ATV. When 
A431V in the NC/p1 cleavage site was coupled with V82A in protease, the fold 
change in IC50s increased to >66 for SQV, 56.2 for LPV and 51.1 for ATV. 
Verheyen et al [208] also observed compensatory mutations A431V, K436R and 
I437V of NC/p1 cleavage site as well as L449F/V, P452S and P453L/A in the p1/p6 
cleavage site. In 2011, Parry et al [203, 204] identified a triad of mutations (R76K, 
Y79F and T81A) in matrix that confer intermediate PI resistance (5-10 fold 
decreased PI susceptibility) in the absence of known resistance conferring mutations 
in protease.
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1.5 Thesis rational 
The overall aim of this thesis was to describe the longitudinal development of drug 
resistance in the viral population of HIV-1 infected children who failed early PI-
based ART during the CHER study. In particular, I theorized (1) the development of 
drug resistance mutations in PR and RT that were linked on the same genome, (2) the 
persistence of NNRTI resistance during PI-based ART and (3) drug resistant 
minority species contributing to future ART outcomes by eventually becoming the 
dominant species under the correct conditions. 
Prevention of mother-to-child transmission (PMTCT) has led to significant 
reductions in vertical transmission [209]. However, children infected with HIV-1 
despite this intervention have high levels of non-nucleoside reverse transcriptase 
inhibitor (NNRTI) resistance [88]. This has led to World Health Organisation 
recommendations to use protease inhibitor-based (PI-based) triple therapy in such 
children [45]. Furthermore, the CHER study reported >70% improvement in 
mortality rates and disease progression in vertically infected children who received 
early ART [78, 111] compared to those initiating ART according to previous 
recommendations [44]. Eshleman et al [119] reported that in the absence of ART in 
children who were HIV infected despite prophylaxis, NNRTI resistance fades from 
the majority species with time. However, especially in the context of immediate 
triple therapy, the potential emergence of PI drug resistance on the back of pre-
existing NNRTI resistance would signal major implications for longer term 
antiretroviral efficacy.  
 63 
The CHER trial was an open-label randomised controlled trial in South Africa [78, 
111]. The participants in this trial were randomized to receive deferred or early PI-
based ART [40 or 96 weeks of zidovudine (AZT), lamivudine (3TC) and Kaletra® 
(LPV/r) (Table 3) started within the first 12 weeks of life)] [111]. AZT was replaced 
with stavudine (d4T) if there were clinical signs of AZT intolerance. Further details 
of the CHER study can be reviewed in section 1.1.4.1, page 29. 
My research cohort was derived from the CHER study; after median follow-up of 4.8 
years, 12% (27/230) of the children from the immediate therapy groups had a viral 
load >1,000 copies/ml [111]. I randomly selected 10/27 children who had a viral load 
>1000 copies/ml at week 40 of early ART. Table 4 compares the children in my 
SGA study (VL>1000 at 40wk time point) with the children in the CHER study who 
had virological failure within a year. One can see that the patients in my study were 
representative but it was not appropriate to compare the 10 children from the project 
cohort to the other 17 children because the latter group had virological failures at a 
median age of 80 months and had been treated for a median of 96 weeks. 
Parents provided informed consent for specimens to be collected from the CHER 
study participants, which were collected and stored as part of the CHER trial. Plasma 
remaining after viral load testing was used for my analyses and therefore subject to 
availability.  
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 Therapy status  
Early ART No ART Re-started ART  
Study ID Duration (weeks) Comments 
143646 0 – 273   - 
141586 0 – 96 97-164  - 
130166 0 – 40   d4T, 3TC, LPV/r from Week 40 – 313 
131326 0 – 316   - 
153716* 0 – 44   - 
138506 0 – 40   - 
146666* 0 – 99   RTV-superboost from week 96 – 106 of early ART 
147636 0 – 96 97 - 164  RTV-superboost from week 48 – 65 of early ART 
141806 0 – 96 97 - 164 165-272 - 
134102 0 – 96 97 - 164 165 - 298 RTV-superboost from Weeks 88 – 96 of early ART 
Table 3. Antiretroviral history for each child participating in this study. Early ART was started within 1 week of birth for each child and 
consisted of AZT, 3TC and LPV/r. Three children received additional RTV to achieve mg:mg parity with LPV (RTV-superboost) and 1 child 
had AZT substituted for stavudine (d4T) at week 40 of ART as indicated in the comments section. “*” Indicated those children who died by the 
end of the CHER trial from non-AIDS related causes.
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Variable Children in CHER with 
virological failure within a 
year (n=7) 
Children included in 
single genome study 
(n=10) 
Median age (IQR) at 
treatment failure in weeks 
46.3 (46.1-52.0) 54.6 (54.1-56.6) 
CD4% 33.9 (29.5-40.7) 31.8 (30.8-33.7) 
CD4 Count 2084 (1455-2829) 2460.5 (1215-2695) 
Log10 HIV RNA 4.6 (4.2-5.9) 5.5 (4.8-5.9) 
Median (IQR) length of 
time on treatment in weeks 
41 (40-48) 48 (40-48) 
CDC Stage   
CDC Stage B Disease (%) 0 (0) 0 (0) 
Severe CDC Stage B 
Disease (%) 
0 (0) 0 (0) 
Table 4. Comparison of the children in my SGA study (VL>1000 at 40wk time 
point) with the children in the CHER study who had virological failure within a year.
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This is project is the first to use SGS to characterise antiretroviral resistance in 
children on early PI-based ART as first line therapy. I used SGS to measure the 
longitudinal diversity PR-RT within the viral populations of each child in my study 
cohort (n=10). This technique allowed us to identify drug resistance mutation in PR 
and RT as well as reveal the presence of viral genomes with linked drug resistance 
mutations. I used phylogenetic techniques to further characterise the evolution of the 
viral population and I described the drug susceptibility and replication capacities 
conferred by patient PR-RT with multiple DRMS linked on the same genomes that 
conferred reduced susceptibility to multiple drug classes. I also explored the 
population dynamics and timing of compensatory mutations that emerge in gag 
compared to their associated protease inhibitor resistance conferring mutations in PR, 
to determine if mutations in gag were predictive of mutations in PR.
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Chapter 2 General Materials and Methods 
2.1 Clinical samples 
Two anonymised, patient derived RNA samples from confirmed HIV-1 subtype C 
infected persons provided by the Virology Laboratory, University College London 
Hospitals NHS Foundation Trust. These were used for the design and optimization of 
complementary DNA (cDNA) synthesis and all polymerase chain reactions (PCRs). 
They were called TS4 and TS5 and had previously determined viral loads of 
2,400,000 c/ml and 2,253,700 c/ml, respectively. 
Plasma samples from ten children failing immediate PI-based triple therapy from the 
CHER study were used for this project. The sampling time points from these children 
included at least a baseline sample and a sample taken after 40 weeks of early ART. 
The sampling time points obtained for each child are listed in Table 5. 
  
68 
68 
Study ID Plasma sampling time points (weeks of immediate therapy) 
baseline 12 40 72 96 164 224 298 
143646 Y - Y - - - - - 
141586 Y - Y - - - - - 
130166 Y - Y - - - - - 
138506 Y - Y - - - - - 
141806 Y Y Y Y Y Y Y - 
131326 Y - Y - - - - - 
147636 Y - Y - Y Y - - 
134102 Y - Y - Y Y Y Y 
153716 Y - Y - - - - - 
146666 Y - Y - - - - - 
Table 5. Time points from which plasma samples were obtained for ten children 
failing immediate therapy in the CHER study. “Y” indicates that plasma was obtained 
and “-” indicates that no plasma was obtained. 
2.2 Molecular biology techniques 
2.2.1 Viral RNA extraction  
HIV-1 viral RNA was extracted from plasma samples using the QIAamp viral RNA 
mini kit (Qiagen, Valencia, CA): Purification of Viral RNA (Spin Protocol). To 
inactivate RNAses and lyse virions to release the viral RNA, 140ȝL of plasma was 
added to Buffer AVL with 5.6ug of carrier RNA (in AVL buffer) to a total volume of 
600ul (carrier RNA protects viral RNA from degradation and increases the yield of 
RNA by improving binding to the membrane of the spin column). This mixture was 
incubated at room temperature for 10 minutes. Viral RNA was ethanol-bound to the 
membrane of the spin column and sequentially washed with Buffers AW1 and AW2. 
Finally the purified RNA was eluted in 40ul to 80ul of Buffer AVE. The extracted 
RNA was either used immediately in cDNA synthesis or stored at - later 
use.  
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The concentration range of RNA required for optimum HIV-1 cDNA synthesis 
followed by single genome amplification was theoretically determined as 20,000 
RNA molecules [114]. Therefore 1,000 to 4,000 copies of RNA per microliter (ul) of 
AVE buffer were eluted into a total volume of 40ul to 80ul. Below is an example of 
how I calculated the volume of plasma required for RNA extraction in order to 
achieve 20,000 RNA molecules for cDNA synthesis: 
At baseline, Study ID 134102 had a viral load of 535,000 copies / ml 
This is equal to 535 copies of RNA / ul of plasma  
I used the formula: (Concentration 1) (Volume 1) = (Concentration 2) (Volume 2) 
Therefore:  
(535 copies RNA / ul) (Volume 1) = (4000 copies RNA /ul) (40 ul of eluate) 
Therefore Volume 1 = (4000)(40) / (535) = 299.1ul plasma used for RNA extraction. 
Then I used 5 ul of this eluate, which should contain 20,000 RNA molecules, for the 
cDNA synthesis reaction. 
When there was insufficient sample volume coupled with viral loads that were too 
low to extract the optimal quantity of RNA molecules, the entire sample volume was 
used to extract the maximum number of RNA molecules in 40ul of eluate. In order to 
protect plasma samples from contamination with plasmid DNA and the environment 
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from infectious virus particles, HIV-1 viral RNA extractions were carried out in a 
Class II Biosafety Cabinet within areas designated for clinical samples only. 
2.2.2 Oligonucleotide primer design 
Oligonucleotide primers for cDNA syntheses, PCR amplifications and Sanger 
sequencing were empirically designed by aligning South African HIV-1 subtypes C 
sequences from the Los Alamos HIV Sequence database in DNA Dynamo Sequence 
Analysis Software (BLUETRACTOR SOFTWARE LTD). With the exception of the 
pantropic oligonucleotides HIVOut1, HIVOut2, HIVRes1, HIVRes2, which were 
provided by the Virology Laboratory, University College London Hospitals NHS 
Foundation Trust and 5’GagOut, which was designed by Parry et al [203]. The 
empirically designed primer sequence were based on conserved regions upstream and 
downstream of the genes of interest for PCR amplification. Particular attention was 
paid to the 3’ end of the primers that were designed to anneal to highly conserved 
regions and preferentially ending in one or more G or C nucleotides with melting 
temperatures (Tm) between 45oC and 68oC. The Tm for each primer was calculated by 
the New England Biolabs Tm Calculator, which can be found at 
https://www.neb.com/tools-and-resources/interactive-tools/tm-calculator, because it 
was the most suitable for Phusion DNA polymerases and primers >13 nucleotides in 
length. Sequencing primers were designed with the same criteria and 200-300 
nucleotides apart in forward and reverse orientations in order to provide overlapping 
sequencing reads. The details of each oligonucleotide primer are described in their 
relevant sections. 
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2.2.3 cDNA synthesis 
First strand cDNA synthesis from extracted RNA was carried out using SuperScript 
III (Invitrogen Life Technologies, Carlsbad, CA) and RNAse H (2U/ȝl) treated 
(Invitrogen Life Technologies, Carlsbad, CA). Briefly, viral RNA was denatured at 
65°C for 5 minutes with 0.08uM of a pol specific reverse primer and 1mM of dNTP. 
The denaturated and primed RNA sample was immediately incubated at 4°C and 
mixed with the reverse transcription mastermix containing 0.001M Dithiothreitol, 0.4 
unit/ul RNAse Out and 1 unit of SuperScript III. cDNA was synthesized at 50°C for 
60 minutes and then all enzymes were denatured at 85°C for 5 minutes. Template 
viral RNA in RNA-cDNA complexes was dissociated by RNAse H treatment at 37oC 
for 20 minutes. Newly synthesized cDNA was either used immediately for PCR 
amplification reactions or stored at -80oC for later use.  
cDNA synthesis of genes encoded by pol and gag (upstream of pol) required a gene 
specific primer. Two such primers were usedμ HIVOut2 (5’- 
AGTCTTTCCCCATATTACTATGCTTTC -3’) and OPCRS (5’- 
ATACCTGCCCACCAACAGG -3’) whose design was based on a consensus 
sequence of a conserved region of pol created by aligning 100 South African HIV-1 
subtype C pol sequences that were imported from the Los Alamos HIV sequence 
database: geography search interface [210]. 
OPCRS was complementary to a sequence at the end of the pol gene: nucleotide 
positions 4615 to 4633 by HXB2 numbering which allowed the 5’LTR, full-length 
gag and pol to be reverse transcribed. HIVOut2 was complimentary to a sequence at 
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the end of the RT subunit in pol: nucleotide positions 3681 to 3707 so that the 
5’LTR, full-length gag and the RT subunit of pol could be reverse transcribed (Figure 
2.1). 
The cDNA synthesis and PCR protocols were validated with test sample TS5. The 
TS5 RNA inputs used to test the sensitivity of the reverse transcription protocol 
ranged from 20,000 RNA molecules to 350 RNA molecules. TS5 was used to test the 
sensitivity of these assays because it was stored at -80oC for 10 years and freeze-
thawed twice before use, which was comparable to the age and storage conditions of 
the project samples and the PCR conditions used were those recommended by the 
manufacturer for the high fidelity Phusion Flex Hot Start DNA polymerase (New 
England Biolabs Limited): DNA denaturation at 94 oC, 35 amplification cycles and a 
final extension at 72 oC for 10 minutes. For bulk PCR amplifications, 1ȝl of the neat 
cDNA synthesis reaction (≤3λ2 cDNA molecules/ul if 20,000 RNA molecules were 
reverse transcribed) was subjected to first-round PCR in a final reaction volume of 
25ȝl. 
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Figure 2.1 Oligonucleotide primers HIVOut2 and OPCRS used for reverse transcription. Their complementary sequences in pol are indicated by nucleotide position in 
HXB2 (Accession number K03455). This figure was created in the DNADynamo Features map for HXB2. 
 
Figure 2.2 Oligonucleotide primers used for PR-RT PCR amplification. HIVOut1/HIVOut2 primer pair was used for the first round of PCR and HIVRes1/HIVRes2 
was used for the second round of PCR. Their complementary sequences are indicated by nucleotide position in HXB2 (Accession number K03455). This was created in the 
DNADynamo Features map for HXB2. Primers are not annotated to scale.
3681 3707
4615 4633
1824 1847
2015 2038
3681 3707
3555 3583
PR RT RNAse H INT
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Different concentrations of TS5 RNA were used to validate the sensitivity of the 
cDNA synthesis protocol using the HIVOut2 primer and the PCR amplification of 
PR-RT. A nested PCR approach was used with first round PCR primers HIVOut2 and 
HIVOut1 5’- AATGATGACAGCATGYCAGGGAGT -3’ at an annealing 
temperature (Ta) of 60oC followed by a second round of PCR amplification using 
HIVRes1 5’- GGAAAAAGGGCTGTTGGAAATGTG -3’ and HIVRes2 5’- 
GGCTCTTGATAAATTTGATATGTCCATTG -3’ with a Ta of 58oC (Figure 2.2).  
PCR amplification of Gag-PR-RT using a nested PCR approach was also done with 
TS5 using first round PCR primers HIVOut2 and GagFOut 5’- 
ATTGTGTGACTCTGGTAACTAGAGATCCCT -3’ at an annealing temperature 
(Ta) of 56oC followed by a second round of PCR amplification using IGCF1-1 5’- 
TTGACTAGCGGCGGCCGCAAGGAGAGAGAT -3’ and HIVRes2 with a Ta of 
60oC (Figure 2.3). 
PCR amplification of gag-pol using a nested PCR approach was also done with TS5 
using first round PCR primers OPCRS and 5’GagOut 5’- 
GTGTGGAAAATCTCTAGCAG -3’ at an annealing temperature (Ta) of 61oC 
followed by a second round of PCR amplification using IGCF1-1 5 and IPCR1 5’- 
CCATARCCCGGGACCACACTCTACTTGTCCATG-3’ with a Ta of 51oC (Figure 
2.4).
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Figure 2.3 Oligonucleotide primers used for Gag-PR-RT PCR amplification. GagFOut/HIVOut2 primer pair was used for the first round of PCR and IGCF1-
1/HIVRes2 was used for the second round of PCR. Their complementary sequences are indicated by nucleotide position in HXB2 (Accession number K03455). This figure 
was created in the DNADynamo Features map for HXB2. Primers are not annotated to scale. 
 
Figure 2.4 Oligonucleotide primers used for gag-pol PCR amplification. 5’GagOut/OPCRS primer pair was used for the first round of PCR and IGCF1-1/IPCR1 was 
used for the second round of PCR. Their complementary sequences are indicated by nucleotide position in HXB2 (Accession number K03455). This figure was created in the 
DNADynamo Features map for HXB2. Primers are not annotated to scale.
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All PCR and cDNA synthesis reactions were carried on the G-Storm GS4 Q4 Quad 
Block Thermal Cycler by Labtech International Ltd. PCR products were visualized by 
agarose gel electrophoresis that was either manually prepared as 1% agarose 
supplemented with 0.4mg/ml ethidium Bromide, 1% agarose supplemented with 
0.0001% GelRed or using the Invitrogen E-Gel® 96 High-Throughput DNA 
Electrophoresis System by Life Technologies for products of the predicted sizes: PR-
RT ≈ 1.7 kilobases (kb); Gag-PR ≈ 1.8kb; Gag-PR-RT ≈ 2.4 to 2.8 kb; gag-pol ≈ 3.7 
to 4 kb. 
To reduce the risks of reaction contaminations, separate plasmid and amplicon-free 
areas were used to make-up the RT and PCR mastermixes, to add RNA to the RT 
reactions, to carry out cDNA serial dilutions and to add cDNA to PCR mastermixes. 
These areas were cleaned with DNAse Away (Roche) and UV irradiated for thirty 
minutes prior to use. 
2.2.4 Endpoint dilution PCR 
Single genome analysis (SGA) of PR-RT was carried out to determine genetic 
linkages of drug resistance conferring mutations in full-length protease (PR) and the 
reverse transcriptase subunit (RT) of the RT/RNAse H heterodimer encoded by pol as 
well as the evolution of these mutations in the viral population from baseline. The 
sampling time points used for PR-RT SGA are those stated in Table 5. 
SGA required endpoint dilution of cDNA followed by PCR amplification of PR-RT 
so that 33% or less of PCR reactions yielded an amplification product. According to 
the Poisson distribution, the cDNA dilution that yielded PCR products in no more 
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than 33% of wells contained one amplifiable HIV-1 cDNA template per positive 
PCR more than 80% of the time [114, 134, 138, 139, 211]. 
The diluent used for cDNA dilutions was 5mM Tris-HCl. Endpoint dilutions were 
determined from nine replicate reactions for PR-RT, starting with a 1 in 3 dilution of 
cDNA which was serially diluted 3-fold to a maximum of 1 in 6561. Particular 
attention was paid to the distribution of cDNA molecules along the dilution series in 
order to maintain the reliability of each dilution. This meant that all dilutions in the 
series were thoroughly mixed to evenly distribute the cDNA. After mixing the cDNA 
thoroughly, a clean pipette tip was subsequently used to aliquot into the next dilution 
in the series so that cDNA on the outside of the tip was not transferred into the next 
dilution in the series. Each aliquot was taken from the surface of the cDNA mixture to 
avoid transfer of extra cDNA molecules that may adhere to the outside of the pipette 
tip. A PCR reagent mastermix was made for the number of PCR reactions plus two 
more reaction volumes. One reaction volume (24ul) was set aside as the negative PCR 
control and the balance was used for PR-RT amplification from viral cDNA. 10ul of 
each cDNA dilution in the series was aliquoted into the PCR mastermix, thoroughly 
mixed and ten 25ul PCR reactions (cDNA + mastermix) were re-aliquoted into ten 
consecutive wells in a 96-well PCR reaction plate (StarLab Limited, product number 
E1403-0100) and sealed with an adhesive foil (StarLab Limited) for subsequent PR-
RT PCR amplification using the mentioned PCR conditions.  
The target endpoint dilution was a yield 22-33% positivity of PR-RT amplification. If 
this was not achieved from the dilution series, then the Poissonian distribution was 
applied to the results of the titration to determine the cDNA dilution at which this 
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positivity was likely to be achieved. Below is a worked example of this calculation 
for cDNA from the baseline sample of study ID 138506. 
Poisson distribution [211]: F (k; Ȝ) = ((Ȝk) (e-Ȝ))/k! 
Ȝ1 is calculated from a cDNA dilution of 1 in 486 which produced five out of nine 
(5/λ) negative PCR reactions. Ȝ2 is calculated from the dilution at which to expect 7/9 
(88%) negative PCR reactions so that there is greater than an 80% chance that 
positive reactions are derived from singular HIV-1 genomes. The putative dilution to 
expect 2/9 (22%) positive reactions (if –ln(0.88) is used) is calculated with the 
formula:  
((Ȝ1 / Ȝ2) (fold dilution from which Ȝ1 was calculated)). 
Ȝ1  = -ln (5/9) = 0.587786665 
Ȝ2  = -ln(0.88)  = 0.127833372 
Therefore: 
(Ȝ1 / Ȝ2)(486)  = (0.587786665/0.127833372) (486) = 2235 
Therefore cDNA derived from the baseline sample of 138506 should be diluted 2235-
fold for a 22% positive yield of PR-RT amplicons. 
Once the endpoint dilution was determined, PR-RT PCR mastermix was made for 192 
PR-RT reactions (176 PR-RT amplifications from endpoint dilutes cDNA and 16 
PCR negative controls) and aliquoted into two 96-well plates for subsequent PR-RT 
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PCR amplifications and visualization with the Invitrogen E-Gel® 96 High-
Throughput DNA Electrophoresis System by Life Technologies.  
2.2.5 Sanger sequencing 
The nucleotide sequences derived from bulk and single genome amplifications were 
determined by Sanger sequencing provided by Beckman Coulter Genomics 
Incorporated. A 25ul PCR reaction yielded ~500ng of non-purified amplicons, 
therefore a 1 in 5 dilution of non-purified PCR product (~90 to 100ng/ul PR-RT 
amplicons) and 5uM of each sequencing primer were provided for sequencing. The 
sequencing primers used for each gene of interest are listed in Table 6. 
2.2.6 Sequence analysis and multiple sequence alignments 
Sequencing reads (contigs) generated from each sequencing primer were imported 
into DNA Dynamo Sequence Analysis Software (BLUETRACTOR SOFTWARE 
LTD). The chromatograms for each contig were scrutinized for poor quality data, 
usually at the 5’ and 3’ end of each read, which were removed and mixed bases were 
defined and called as mixtures that occurred in more than one contig and were more 
than 25% of the dominant peak. For single genome sequence analysis, sequences with 
mixed bases were disregarded and not used for further analysis because they were not 
derived from single viral genomes. Any sequences containing premature stop codons 
were also omitted from the analysis. 
Multiple sequence alignments (MSAs) of contiguous nucleotide sequences were also 
created in DNA Dynamo Sequence Analysis Software with default settings and the 
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sequences were manually determined to be in the correct reading frame by 
translating them to amino acid sequences.  
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Gene Primer name Sequence Nucleotide 
position 
Forward/
Reverse 
gag IGCF1-1 TTGACTAGCGGCGGCCGCA
AGGAGAGAGAT 
762-791 Forward 
 S1 CATTATCAGAAGGAGCCAC
C 
1310-1329 Forward 
 S2 TCTATCCCATTCTGCAGC 1414-1431 Reverse 
 S3 CACATTTCCAACAGCCCTT
TTTCC 
2015-2038 Reverse 
pol HIVRes1 GGAAAAAGGGCTGTTGGA
AATGTG 
1895-1918 Forward 
 S4 GTTAAACAATGGCCATTGA
CAGAAGA 
2610-2635 Forward 
 S5 TCCTAATTGAACYTCCCAR
AARTCYTGAGTTC 
2797-2828 Reverse 
 S6 TGGAAAGGATCACCAGCA
ATATTCCA 
3006-3031 Forward 
 S7 AAGCACTAACAGAAGTAAT
ACCACTAACTG 
3409-3438 Forward 
 HIVRes2 GGCTCTTGATAAATTTGAT
ATGTCCATTG 
3555-3583 Reverse 
 HIVOut2 AGTCTTTCCCCATATTACTA
TGCTTTC 
3681-3707 Reverse 
 S8 GGAAAAGCAGGATATGTTA
CTG 
3906-3927 Forward 
 S9 CCATARCCCGGGACCACAC
TCTACTTGTCCATG 
4380-4412 Reverse 
Table 6. Sequencing primers used for Sanger sequencing. The nucleotide 
position of the complimentary sequence to each primer is indicated as well as the 
direction of the sequencing read.
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2.2.7 Subtype and drug resistance determinations 
PR and RT nucleotide sequences were submitted to the Genotyping Resistance 
Interpretation Algorithm hosted by Stanford University’s HIV Drug Resistance 
Database [102]. PR-RT sequences were also submitted to REGA HIV-1 subtyping 
tool at http://dbpartners.stanford.edu:8080/RegaSubtyping/stanford-hiv/typingtool/ for 
subtype determination. 
To identify compensatory mutations in gag that are associated with drug resistance 
conferring mutations in the viral protease. Table 7 lists these mutations. Patient 
derived gag sequences were translated to their amino acid sequence in DNADynamo 
and then screened against the mutations in Gag from Table 7. 
Unit of Gag Mutation 
Associated with PI 
resistance 
Associated with PI 
exposure 
Matrix 76K, 79F, 81A occurring 
simultaneously 
12K, 62R, 75R, 112E 
Matrix/Capsid CS 128I/T/A/deletion 132F 
Capsid  200I, 219Q/P 
SP1  360V, 362I, 
363M/F/C/N/Y, 368C/N , 
369H, 370A/M/deletion, 
371deletion, 373P/Q/T, 
374P/S, 375N/S, 376V, 
381S 
Nucleocapsid  389T, 390A/D, 401T/V, 
409K 
SP2 431V, 436E/R, 437T/V, 
449F/P/V, 452S/K, 
453A/L/T 
428G, 430R, 451T/G/R 
p6  437N, 468K, 474L, 484G, 
487S, 497L 
Table 7. Mutations in Gag associated with PI resistance and/or PI exposure. 
This table was adapted from Fun et al 2012 [154].
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2.2.8 DNA quantification 
DNA was quantified using the NanoDrop 1000 Spectrophotometer by Thermo 
Scientific Ltd. DNA was quantified from 1ul volumes of plasmid DNA or purified 
PCR product DNA according to the manufacturer’s instructions. The ratio of 
absorbance at 260 nm was used to assess the purity of DNA in each sample. A ratio of 
~1.κ was accepted as “pure” for DNA.  
2.2.9 Addition of restriction endonuclease sites to amplicons by PCR 
To facilitate cloning of PCR products into the gag-pol expression vectors p8MJ4-
HSC, nested PCR primers containing unique restriction enzyme sites were used to 
introduce these sites at the 3’ and 5’ ends of the PCR products so that they flank the 
genes of interest for cloning. The nested PCR primers designed for the addition of 
these restriction enzyme sites contained the relevant restriction endonuclease site-
specific sequence but did not alter the amino acid coding of the fragment. These PCR 
reactions were also carried out with Phusion Flex Hot Start DNA polymerase (New 
England Biolabs Limited) and according to the manufacturer’s instructions and the 
same PCR platform outlined in the previous section.  
PR-RT amplicons were generated with the first-round PCR primers 5’GagOut and 
HIVOut2 (Ta = 56oC for 30 seconds) followed by a second-round of amplification 
with the primers GagApaF1 and RTRevHpa1 (Ta = 60oC for 30 seconds). GagApaF1 
introduced an Apa I site directly upstream of the translational Start of the PR 
encoding gene and RTRevHpa1 introduced an Hpa I site flanking the last codon of 
RT (Figure 2.5). 
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2.2.10 Cloning into p8MJ4-HSC 
PR-RT and gag-pol were purified from their PCR reaction mixtures using the Illustra 
GFX PCR DNA and Gel Band Purification Kit protocol for the isolation and 
concentration of DNA fragments from PCR mixtures (GE Healthcare Life Sciences) 
after being generated by PCR amplification so that they were flanked by their 
respective restriction endonuclease sites as described in the previous section. 
2.2.11 Plasmid preparation 
2.2.11.1 Apa 1/ Hpa 1 double digestion of p8MJ4-HSC 
The gag-pol expression vector p8MJ4-HSC (Figure 2.6) was created by Mbisa et al 
[212] to accommodate RT domain-swapping. It was derived from the gag-pol 
expression plasmid vector p8.9NSX+ [203] with an HIV-1 C-type gag-pol sequence 
that was modified by introducing three restriction enzyme sites including a unique 
Hpa I flanking RT amino acids 288/289 and included a natural and unique Apa 1 site 
in the p6 region of gag (Figure 2.6). 
Wildtype PR-RT was released from p8MJ4-HSC by double digestion with Hpa 1 
(New England Biolabs) and Apa 1 (New England Biolabs). Both enzymes were 100% 
active in CutSmart Buffer (New England Biolabs). One microgram of p8MJ4-HSC 
was first digested with 2.5 units of Hpa I and 1X CutSmart Buffer (New England 
Biolabs Limited) in a 10ul total reaction volume for 1.5 hours at 37oC. The singly 
digested plasmid was purified from the enzymatic reaction using the illustra GFX 
PCR DNA and Gel Band Purification Kit protocol for the isolation and concentration 
of DNA fragments from restriction enzyme digests. The purified, singly digested 
plasmid was eluted in 20ul of Buffer C. A 20ul Apa I digestion mastermix was made 
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with 20 units of Apa I and 4X CutSmart Buffer (New England Biolabs Limited) 
was added to the 20ul eluate containing the singly digested plasmid. The new 40ul 
reaction was mixed gently and thoroughly by pipetting and then divided into two 20ul 
reactions and Apa I was subsequently allowed to digest the amplicon at 25oC for 30 
minutes. The ~1.4kb PR-RT fragment released from the plasmid was distinguished by 
gel electrophoresis and the vector backbone (~10.7kb) was extracted using the illustra 
GFX PCR DNA and Gel Band Purification Kit protocol for the isolation and 
concentration of DNA fragments from DNA-containing agarose gel bands and eluted 
in 20ul of Buffer C. The Hpa 1/ Apa 1 double digested p8MJ4-HSC backbone was 
used for cloning patient derived PR-RT sequences.
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Figure 2.5 The unique restriction sites Apa I and HpaI present in the p8MJ4-HSC gag-pol region that were used for cloning 
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Figure 2.6 Schematic of the p8MJ4-HSC gag-pol expression vector and the unique restriction 
sites, ApaI and HpaI, present in its gag-pol region that were used for cloning. This vector expresses the 
HIV-1 gag-pol gene under the Cytomegalovirus (CMV) promoter. The plasmid vector also contains a 
Simian Vacuolating Virus 40 (SV40) origin of replication (Ori) which allows replication of the plasmid 
in mammalian cells that expres the large T antigen such as 293T cells. It also contains an ampicillin 
resistance gene (amp-r) for bacterial selection
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2.2.11.2 Cloning PR-RT into p8MJ4-HSC 
350ng of PR-RT amplicons were digested with 2.5 units of Hpa I and 1X CutSmart 
Buffer (New England Biolabs Limited) in a 10ul total reaction volume for 1.5 hours at 
37oC. The singly digested amplicon was purified from the enzymatic reaction and 
eluted in 20ul of Buffer C. A 20ul Apa I digestion mastermix was made with 20 units 
of Apa I and 4X CutSmart Buffer (New England Biolabs Limited) and added to the 
20ul eluate containing the singly digested amplicon. The new 40ul reaction was 
mixed gently and thoroughly by pipetting and then divided into two 20ul reactions 
and Apa I was subsequently allowed to digest the amplicon at 25oC for 30 minutes 
and then the double digested PR-RT fragment was purified form the enzymatic 
reaction.  
Apa I/Hpa I double digested PR-RT was ligated into the p8MJ4-HSC double digested 
backbone (with the same enzymes) in a V:I ratio of 1:7 using 7ng of p8MJ4-HSC 
vector backbone, 1 unit of T4 DNA ligase and 1X ligation buffer in a 25ul reaction at 
16oC for 20 minutes and then 5ul of the ligation reaction was immediately 
transformed into 50ul of HB101 cells by heat shock at 42oC for 45 seconds and then 
recovered and cultivated on Luria Broth (LB) agar plates supplemented with 50mg/ml 
ampicillin (LB amp+) at 30oC. Ten colony-forming units were cultured in LB amp+ 
broth for 14 hours and plasmids were purified from HB101 cells using the QIAprep 
Spin Miniprep Kit (250) (QIAGEN®) according to the manufacturer’s instructions 
and purified plasmids were eluted in 50ul of EB buffer.  
To determine if PR-RT was successfully ligated into the p8MJ4-HSC backbone, each 
purified plasmid was double digested with Apa I and Hpa I, as previously described. 
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If the ligation was successful, a ~1.5kb DNA fragments was released from the 
recombinant Gag-PR expression vector. 
2.3 Phylogenetic and bioinformatics analyses 
2.3.1 Phylogenetic reconstruction of PR-RT sequences 
The phylogenies of intra-patient viral populations were estimated via a maximum 
likelihood (ML) approach with the program raxmlGUI version 1.3 [213]. Given a 
sequence alignment, the ML method determines the probability of observing a tree 
[214, 215]. The likelihood of all possible trees for a given sequence alignment, i.e the 
probability of observing a particular tree given the alignment and an explicit model of 
nucleotide substitution, is calculated and the tree that has the greatest likelihood is 
selected as the most probable one [216]. The statistical robustness of the trees was 
evaluated by bootstrap analysis with 1,000 rounds of replication. The phylogenetic 
trees were visualized and edited using FigTree software version 1.4 provided by 
http://tree.bio.ed.ac.uk/software/figtree/. 
2.3.1.1 Inter-patient viral evolution 
An MSA was generated for all single genomes derived PR-RT sequences from each 
sampling time point per patient and was used to reconstruct an ML phylogenetic tree 
under the GTR model of nucleotide substitution and 1,000 rounds of bootstrapping. 
The total ML-tree was visualized in FigTree 1.4 and rooted by midpoint rooting to 
determine if there was contamination between patient data or from external genetic 
sources such as HIV based plasmids used in the laboratory. 
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2.3.1.2 Intra-patient viral evolution  
For each patient, multiple sequence alignments were generated from single genome 
derived PR-RT sequences obtained at each available sample time point for that patient 
and subsequently imported into raxmlGUI version 1.3 to construct ML phylogenetic 
trees under the GTR model of nucleotide substitution and 1,000 rounds of 
bootstrapping. Each tree was rooted against an outgroup which was a HIV-1 subtype 
C PR-RT sequence from the test sample, TS5, used to troubleshoot the PCR and SGS 
protocols. The criteria I used to choose an appropriate outgroup to predict the 
direction of evolution within the ML trees were an HIV-subtype C PR-RT sequence 
from an ART naïve patient. This sequence was related enough to the patient 
sequences so that it was basal to the rest of the sequences in each tree, but not too 
closely related that it grouped with test sequences. 
2.3.1.3 Mean pairwise genetic distance to measure population diversity 
I used the Molecular Evolutionary Genetic Analysis (MEGA) software version 5.2 
[217] to calculate the mean pairwise genetic distances (MPDs) of PR-RT sequences 
within and between sampling time points in each child. In this case, I used the Tamura 
and Nei 1993 nucleotide substitution model, which was determined as the best fit 
model for this data by MEGA (lowest Bayesian Information Criterion, therefore 
highest posterior probability). Regression analysis was used to determine if the 
number of sequences obtained at each time point affected the estimation of genetic 
distances. I determined whether differences in the mean number of nucleotide 
substitutions per site in PR-RT MPDs between consecutive time points were 
significant using an unpaired two-tailed Student’s t-test. MPD was expressed as 
number of nucleotide substitutions per site of all PR-RT sequences. 
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2.3.2 Assessment of recombination in PR-RT 
Evidence of recombination between PR-RT sequences derived from single genomes 
over time was determined using the Single Breakpoint Analysis (SBP) and Genetic 
Algorithm Recombination Detection (GARD) from the online Datamonkey software 
package at http://www.datamonkey.org. Significant breakpoints were reported for P 
values <0.05. 
2.3.3 Intra-patient analysis of selection pressure on the HIV-1 PR and RT 
genes  
Intra-patient selective pressures on HIV-1 PR-RT and gag-PR-RT were determined 
with the Datamonkey software package. For positive selection analyses, the rate of 
non-synonymous substitutions per non-synonymous site (dN) over the rate of 
synonymous substitutions per synonymous site (dS), dN/dS or ω, was calculated 
using three different algorithms. If dN/dS = 1 then this suggested neutral selection, if 
dN/dS is <1 this suggested negative selection because there were more synonymous 
substitutions than non-synonymous ones (indicating that non-synonymous changes at 
that site are removed from the population) and if dN/dS is >1, positive selection is 
suspected because there were more non-synonymous substitutions than synonymous 
ones (Vandamme et al., 200λ). The three different algorithms used to determine ω 
within each patient viral population were FEL (Fixed Effects Likelihood), SLAC 
(Single Likelihood Ancestor Counting) and FUBAR (Fast Unbiased Bayesian 
AppRoximation).  
All three methods calculate dN/dS ratios for each codon in a given sequence 
alignment: FEL, which directly estimates nonsynonymous and synonymous 
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substitution rates at each site [218]; SLAC, which estimates the number of non-
synonymous and synonymous substitutions that occurred at each codon in an 
alignment, by reconstructing the most likely ancestral sequences and counting 
substitutions using a weighting scheme [219]; FUBAR, which detects selection under 
a model which allows substitution rate variations from site to site and calculates the 
mean posterior distribution of synonymous (α) and non-synonymous (β) substitution 
rates [220]. 
Multiple sequence alignments of PR-RT accompanied by corresponding ML-trees 
generated from raxmlGUI version 1.3 were uploaded to the online Datamonkey 
platform. Substitution models were determined using the automatic substitution model 
selection tool, which selected the HKY85 model for PR-RT sequence alignments. 
SLAC, FEL, and FUBAR algorithms were then run with the selected substitution 
model with confidence intervals of 1.0 and a significance level of <0.05 (SLAC and 
FEL) or a posterior probability of 0.95 (FUBAR). 
2.3.4 Co-evolution analysis 
I also used the algorithm Spidermonkey [221] at http://www.datamonkey.org to 
determine if positively selected sites by SLAC, FEL or FUBAR co-evolved, i.e. if the 
evolution of amino acids at any pair of positively selected were dependent on each 
other during the course of protein evolution 
2.3.5 Position Specific Scoring Matrix 
I used the perl-based script “aa_freq.pl” developed by Professor Simon Watson 
(unpublished) to produced a position specific scoring matrix (PSSM) from an MSA of 
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amino acids from the 891 HIV-1 Subtype C Gag sequences from treatment naïve 
children from Sub-Saharan African children that were available in the HIV Los 
Alamos sequence database on June 1st 2014. I used the PSSM to determine the natural 
variation of amino acids found at these key positions in Gag for patients from my 
study cohort using population sequence analysis. 
2.4 Tissue culture 
2.4.1 Pseudovirus production 
Pseudoviruses were generated from gag-pol expression vectors with successfully 
cloned patient PR-RT fragments (see section 2.2.10) from patient derived virions 
using the method developed by Parry et al in 2009 [203]. In brief, Human Embryonic 
Kidney 293T cells (293T cells) were co-transfected using FuGENE® 6 Transfection 
Reagent (Promega UK) with the gag-pol expression vectors p8MJ4-HSC, which 
expresses patient derived gag-pol fragments with the pCSFLW and pMDG vectors. 
The pseudoviruses produced contain the HIV-1 gag encoded structural elements, the 
HIV-1 pol encoded enzymatic elements surrounded by a VSV-G envelope from 
pMDG and a genome encoding the luciferase reporter gene from pCSFLW. 
2.4.2 FuGENE® 6 transfection for pseudovirus production 
Four millilitres Gibco® Dulbecco's Modified Eagle Medium supplemented with 10% 
foetal calf serum (DMEM) (Life Technologies Ltd) containing 5 X 105 293T cells 
were seeded into each well of a 6-well plates the day before transfection. The next 
day, 6ul of FuGENE® 6 was added drop-wise into 70 ȝL Opti-MEM® I Reduced 
Serum Media (Opti-MEM®) (Life Technologies) in a 1.5ml eppendorf which was 
mixed by flicking for each well. The mixture was left for 3-5 min and then a 10 ȝL 
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mixture containing 300ug of the gag-pol expression vector, 300ug of pMDG and 
500ug of pCSFLW was added drop-wise into the Opti-MEM®/ FuGENE® 6 mixture 
and mixed by flicking and left for 15 minutes, in which time the 2ml of DMEM in 
each well of seeded 293T cells was refreshed with 4ml of DMEM. The Opti-MEM®/ 
FuGENE® 6/DNA mixture was then added drop-wise on to the 293T cells, mixed by 
swirling and then incubated at 37°C with 10% CO2 for 48 hours. Pseudovirions were 
subsequently harvested from the supernatant using 0.45ȝm filters and either used 
immediately for further experiments or stored in at least two aliquots at -80°C. 
2.4.3 Single-replication cycle drug susceptibility assay 
HEK 293T cells were infected with the pseudovirions produced from the triple-
plasmid co-transfection of producer 293T cells as described in section 2.4.1 and 
luciferase mRNA is integrated into the host cell genome so that the expression of 
luciferase can be measured as an indicator of infection from transduced cells. This 
process is exploited for drug susceptibility assays by producing pseudovirions in the 
presence of antiretrovirals and the measure of luciferase expression served as an 
indicator of resistance to the drug where the concentration of the drug that induced 
50% infectivity compared to a baseline (IC50) can be calculated. 
This is a single-replication cycle assay that can be carried out in the Category 2 
laboratory because harvested pseudovirions do not harbor gag-pol mRNA after 
transfection, therefore no further virions were generated. 
  
95 
95 
2.4.4 Replication capacity 
The replication capacity (RC) of pseudoviruses produced by each chimeric vector was 
determined from titrations of serially diluted viruses on 293T cells for 48 hours. 
Infection was determined by measuring the luciferase expression of infected target 
cells. An enzyme linked immunosorbent assay (ELISA) (Reverse Transcriptase 
Assay, colorimetric®Roche; Catalogue number 11468120910) was used to measure 
the reverse transcriptase activity of each pseudovirus. RC was measured as RLU/ng of 
RT activity and expressed as % of the WT for each virus. 
2.4.5 Protease inhibitor susceptibility assay 
The protocol for pseudovirus production in the presence of serially diluted PIs is 
outlined in Figure 2.7. As indicated in Steps 2 to 3 of Figure 2.7, producer cells 
generated pseudovirus in the presence of PIs, where PIs were serially diluted 
horizontally across the 96-well plate with the highest concentration of antiretroviral 
(top drug) starting at the second well of the plate (A2-H2) (Step 2). The first well in 
the plate (A1-H1) was always designated as the 293T cell-free control and the final 
well in the series was always designated as the virus free control (A12-H12). One 
hundred microliters of producer cells that were transfected the day before were added 
to each well of the plate (Step 3). The pseudovirus produced in the presence of each 
concentration of drug were used to infect fresh 293T cells (steps 4 to 5) and luciferase 
activity in transduced cells was measured as relative light units (RLU) (step 6) 
(Steady-Glo® Luciferase Assay System by Promega). The HIV-1 C-type gag-pol 
expression vector p8MJ4-HSC was used as the baseline RLU from which the IC50 for 
each patient derived pseudovirus was calculated. The PIs used in this project were 
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LPV, SQV, NFV and DRV. The top drugs used for each antiretroviral are indicated 
in Table 8.
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Table 8. PIs concentrations used in drug susceptibility assays. 
Figure 2.7 PI susceptibility assay. (1) 293T cells were triple transfected as described in section 2.4.1 and 2.4.2. (2) PIs were titrated across a 96-well plate as described 
in Table 8 and section 2.4.5 (3) Transfected cells were re-aliquoted into the serially diluted PI from step 2. (4) Pseudovirus produced in the presence of PIs were harvested (5) 
and used to infect fresh 293T cells. (6) SteadyGlo (Promega) was added to each well to lyse transduced cells and measure their luciferase activity as RLU. 
4.
5.
6.
PI Top drug (nM) Dilution fold 
LPV 2000 3-fold 
SQV 600 3-fold 
NFV 600 3-fold 
DRV 100 3-fold 
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2.4.6 Reverse transcriptase inhibitor susceptibility assay 
The protocol for pseudovirus production in the presence of serially diluted RTIs is 
outlined in Figure 2.8. Prior to starting the RTI susceptibility assays, the harvested 
pseudovirus from step 2 of the protocol was used for a retroviral titration in the 
absence of antiretrovirals to determine the concentration at which 106 RLU were 
generated for each test sample (step 3). Harvested pseudovirus from a 2nd aliquot 
stored at -80oC was diluted to the concentration that yielded 106 RLU in the retroviral 
titration and used to continue with the RTI susceptibility assay (step 4). RTIs were 
serially diluted horizontally across the 96-well plate and included cell-free and virus-
free controls in the same plate format on the plate described for the PI susceptibility 
assay (step 4) and luciferase activity in transduced cells was measured as relative light 
units (RLU) (step 5). The HIV-1 C-type gag-pol expression vector p8MJ4-HSC was 
used as the baseline RLU from which the IC50 for each patient derived pseudovirus 
was calculated. The details of the top drug and fold-dilutions for the antiretrovirals 
used in this project are described in Table 9 for the NNRTIs: NVP and EFV and in 
Table 10 for the NRTIs: 3TC, AZT, ABC and ddI. 
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Figure 2.8 RTI susceptibility 
assay. (1) 293T cells were triple 
transfected as described in section 
2.4.1 and 2.4.2. (2) Pseudovirus from 
transfected cells were harvested. (3) 
RTIs were titrated across a 96-well 
plate as described in Tables 9 & 10 
and section 2.4.6 (4) Fresh 293 T-cells 
were added to the RTI from step 3 and 
infected with harvested pseudovirus 
from step 2. (5) SteadyGlo (Promega) 
was added to each well to lyse 
transduced cells and measure their 
luciferase activity as RLU. 
Table 9. Details of NRTIs used in drug susceptibility assays. 
 
Table 10. Details of NNRTIs used in drug susceptibility assays. 
gag-pol pCFSLW pMDG
293T cells
1. Triple vector co-transfection into 293T cells
2. Harvest 
pseudovirus
3. Titration of RTIs across
 96-well plate
 
4. Infection of fresh 293T cells 
with 106 RLUs of pseudovirus
in presence of serially diluted RTIs  
5.  Measure luciferase activity 
in transduced cells
Transduced cell                  
fresh 293T cells
NNRTI Top drug (nM) Dilution fold 
NVP 300 3-fold 
EFV 100 3-fold 
 
NRTI Top drug (nM) Dilution fold 
3TC 400 4-fold 
AZT 55 3-fold 
ABC 2000 3-fold 
ddI 400 3-fold 
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Chapter 3 Results 
3.1 Single genome analysis reveals linked, multi-class drug resistance in HIV-
1 infected children from the Children with HIV Early Antiretroviral (CHER) 
study 
In this chapter I characterised drug resistance in ten children from the CHER study 
who acquired HIV infection despite NVP prophylaxis and subsequently failed 
immediate PI-based therapy. I described the trends in viral load for each child in the 
context of ART status over time. I then compared bulk sequence analysis to SGS 
results and used the latter technique to reveal the presence of viral genomes with 
genetically linked drug resistance mutations that confer reduced susceptibility to 
multiple drug classes. 
After median follow-up of 4.8 years, 12% (27/230) from the immediate therapy 
groups had a viral load >1,000 copies/ml [111]. Children experiencing treatment 
failure at the first time point (40 weeks) were first identified. Then those with 
sufficient samples at subsequent time points of interest were selected and from these, 
ten were randomly selected. Plasma remaining after viral load testing was used for my 
analyses and therefore were subject to availability. Plasma was available for 10/10 
children before ART was started and at week 40 of ART. 2/10 children who were 
viraemic at week 72 of ART had plasma samples available at this time point and 3/10 
children had plasma samples available at week 96 of ART. I obtained plasma samples 
after week 96 of ART from 2 children who developed multiple linked multi-class 
drug resistance in the viral population by week 96 of ART (141806 and 134102) and 
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from another child (147636) for whom I did not detect such drug resistant variants by 
week 96 of ART. 
I validated the sensitivity and specificity of reverse transcription, cDNA dilution and 
PCR protocols required for bulk sequence analysis and SGS of PR-RT.I reconstructed 
the phylogeny of all bulk and SGS sequences generated for each child from all 
sampling time points available for each child to determine if sequences from each 
child clustered together. If sequences clustered together by the child from which they 
were derived, then I used this result was used as confirmation that there was no 
external genomic contamination or cross-contamination between patient samples. The 
PR-RT consensus sequences were submitted to the HIV Drug Resistance Database 
[102] for HIV-1 subtyping and DRM identification. I used a Fisher exact test (p<0.05 
for significance) to identify those codons for drug resistance mutations whose change 
in frequency between two sequential time points was significant [222]. 
3.1.1 Results 
3.1.1.1 Participants 
8/10 children received perinatal NVP for PMTCT. One child did not receive this 
prophylaxis (Study ID 134102) while this information was not recorded for a second 
child (Study ID 147636).  All mothers received a single dose of NVP at the onset of 
labour.  
Continuous ART was given to 3/10 children (Study IDs 143646, 130166 and 131326) 
until the end of the CHER trial and their viral loads were supressed to undetectable 
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levels (<400 copies/ml) at week 96 of early ART and continued to be suppressed until 
the end of the trial. Early ART was given to 3/10 children (Study IDs 153716, 138506 
and 146666) for 0-40 weeks, 0-44 weeks and 0-99 weeks respectively. These 
children’s viral load histories did not pass the last recorded viral load time point and 
they were also viraemic at the last recorded time point because Study IDs 153716 and 
146666 died of non-AIDS related causes and Study ID 138506 defaulted from the 
clinic. 4/10 children (Study IDs 141586, 147636, 141806 and 134102) received early 
ART for 0-96 weeks and only 1 child (Study ID 147636) had an undetectable viral 
load at week 96. At the end of an ART free period, (weeks 97-164), the viral load 
reached undetectable levels in only 1 child (Study ID 134102). ART was restarted in 
2 of these children, (Study IDs 141806 and 134102), from weeks 165-272 in Study 
IDs 141806 and weeks 165-298 in Study ID 134102. The viral load of Study ID 
141806 became undetectable during re-started ART at week 265 and remained 
supressed until the end of the CHER trial, while Study ID 134102 remained viraemic 
during re-started ART. The viral load histories of each child are shown in Table 10. 
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Study ID   Weeks Therapy status 
0 24 40 72 96 164 224 265 281 298 Early 
ART 
No 
ART 
Re-started 
ART 
Viral Load (copies RNA/ml blood) Duration (weeks) 
143646 >750,000 <50 58,200  <400 <400 <400    0-273   
141586 >750,000 <400 729,000 <400 11,040 6,050     0-96 97-164  
130166 >750,000 <400 4,890 640,000  <400 <400   <400 0-313   
131326 318,000 44,000 295,000 56,600 <400      0-316   
153716* >750,000 <400 4,100        0-44   
138506 617,000 >750,000 >750,000        0-40   
146666* >750,000 5,400 >750,000  66,300      0-99   
147636 >750,000 3,050 281,000 <400 <400 503,000     0-96 97-164  
141806 >750,000 7,000 96,400 852,000 152,200 181,000 194,000 <400 <400  0-96 97-164 165-272 
134102 535,000 3,570 >750,000 40,200 326,000 <400 88,400  402 7,440 0-96 97-164 165-298 
Table 11. Viral load histories of the ten children in this study. Plasma samples were taken at baseline and then every 4 weeks until week 24, 
then every 8 weeks until week 48, and then every 12 weeks until the end of the CHER trial.“*” Indicated those children who died by the end of 
the trial from non-AIDS related causes. Underlined viral loads indicated those samples that were used for sequence analysis in this study. See 
Table 12 for full details of the therapeutic history of each child. 
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3.1.1.2 Validation of cDNA synthesis and PR-RT amplification protocols 
3.1.1.2.1 Sensitivity of protocols 
The cDNA concentration that yielded 30% positive PCR reactions increased with 
increasing RNA inputs. The number of PR-RT sequences retrieved from HIV-1 
single genomes for each viral load tested were 18 sequences for an input of 350 RNA 
molecules, 16 sequences for an input of 1,000 RNA molecules and 16 sequences for 
an input of 10,000 RNA molecules. 15-20 sequences derived from single genomes 
have an ≥κ0% probability of detecting ≥10% of the viral population [138]. The 
overall average pairwise nucleotide difference among the single genome derived PR-
RT sequences was 0.0004 nucleotide substitutions per site with a standard deviation 
of 0.0001. 
3.1.1.2.2 Specificity of protocols 
All bulk amplicons derived from each patient sampling time point were determined 
to be HIV-1 PR-RT, from subtype C (Methodology in Section 2.2.7). A total of 
1,026 PR-RT sequences derived from HIV-1 single genomes were analysed by 
maximum likelihood (ML) phylogenetic inference. This was because the sequences 
clustered together based on the patient that they were derived from (Figure 3.1). The 
same result was seen when ML trees included these sequences as well as those from 
TS5 and PR-RT the original p8MJ4-HSC and p8.9NSX+ plasmids (data not shown). 
TS5 sequences and plasmids PR-RT sequence also formed individual clusters 
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together in the ML tree. This data verified that there was no contamination between 
patient samples or from plasmids used in this project. 
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Figure 3.1 ML tree of 1,026 PR-RT single genomes sampled 
from ten children from the CHER trial. Taxa in the tree coloour-coded by Study ID. The scale is for the number of nucleotide substitution per 
site. * represents bootstrap values of 100. 
141806 
146666 
138506 
147636 
153716 
134102 
131326 
138506 
143646 
130166 
Study ID 
0.02 
*	
*	
*	
*	
*	
*	*	
*
*	
*	
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3.1.1.3 PMTCT history of ten children in this study 
8/10 children in this study cohort received perinatal NVP for PMTCT and all mothers 
received the same regimen at the onset of labour (Table 12). 
Study ID PMTCT NVP Antiretroviral exposure  
 
 Mother Child  
143646 Yes Yes AZT, 3TC, LPV/r 
141586 Yes Yes AZT, 3TC, LPV/r 
130166 Yes Yes AZT, 3TC, LPV/r 
131326 Yes Yes AZT, 3TC, LPV/r 
153716* Yes Yes AZT, 3TC, LPV/r 
138506 Yes Yes AZT, 3TC, LPV/r 
146666* Yes Yes AZT, 3TC, LPV/r, RTV 
147636 Yes Unknown AZT, 3TC, LPV/r, RTV 
141806 Yes Yes AZT, 3TC, LPV/r 
134102 Yes No AZT, 3TC, LPV/r, RTV 
Table 12. CHER trial unique study identifications (Study IDs) allocated to the 
ten children in this study. The table also indicates their exposure to 
PMTCT/prophylactic NVP and antiretrovirals received during immediate therapy. * 
Indicates children who died of causes unrelated to AIDS before the end of the CHER 
trial. 
3.1.1.4 Detection of baseline drug resistance 
All PR-RT sequences analysed in this study were derived from HIV-1 subtype C. 
Bulk sequence analyses detected baseline NVP-selected resistance in 5/10 children: 
K103N (1/10), V106M (1/10), Y181C (2/10) and Y188C (1/10). However SGS 
detected NVP-selected resistance mutations in 7/10 (70%) of these children, and 
demonstrated a broader selection of mutations at higher frequency. The mutations 
detected by SGS were K103N (3/10), V106M (3/10) Y181C (3/10), Y188C (1/10), 
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A98G (1/10), K101E (2/10), V106A (2/10) and G190A (2/10). The results of 
baseline bulk sequencing and SGS for each child are shown in Table 13. All children 
had wildtype sequences present at a frequency >40%, however bulk sequencing was 
not able to detect these wildtype sequences in 3/10 children (Study IDs 130166, 
153716 and 147636). A mixture of tyrosine (Y) and cysteine (C) were detected at 
position 181 in RT in the baseline viral population of Study ID 134102. 
PI and NRTI DRMs were detected by SGS only and at baseline in two children, Study 
IDs 131326 and 153716. Study ID 153716 died before samples could be taken after 
40 weeks of ART, but the major PI DRM, I50V was detected at a frequency of 3% 
(n=30 sequences) at baseline, which was not detected at week 40 of ART. T215I, a 
reversion mutation of the thymidine analogue mutation (TAM) T215F/Y [223, 224], 
was detected at a frequency of 5% (n=21 sequences) in the baseline viral population 
of Study ID 131326. This mutation was not detected at subsequent sampling time 
points, but virological failure occurred at week 40 with M46I in the minority 
quasispecies (3%, n = 38 sequences), This child achieved a viral load <400 c/ml by 
week 96 of early ART that was maintained until the end of the CHER trial.  
Genetic linkage of RT DRM was detected in the viral population of two children. 
Y181C was linked with V106M (2%, n=49 sequences) and the TAM, K219N (2%) in 
the baseline viral population of Study ID 134102. Study ID 153716, also had a 
baseline minority variant with Y181C and K219N as genetically linked (3%, n=30 
sequences) as well as a Y181C + L74V variant at a frequency of 7%.. 
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Table 13. Frequencies of baseline antiretroviral drug resistance variants by SGS. Frequencies in bold represent variants detected by both 
SGS and bulk sequence analysis.
 Study ID  143646  141586 130166 131326 153716 138506 146666 147636 141806 134102 
No of variants analysed (n)  49 30 33 21 30 57 26 34 30 50 
Wildtype (%) 100 93 45 95 37 42 96 47 100 44 
NNRTI resistance (%) 
A98G       4    
K101E   3     12     
K103N   36  7     4 
V106A  7 3        
V106M      37  3  4 
Y181C     40 21    44 
Y188C   3     38     
G190A   9   3      
Y181C+V106M          2 
NNRTI+NRTI resistance 
Y181C + L74V     7      
NNRTI resistance + TAM 
Y181C+K219N     3     2 
TAM revertants 
T215I    5       
PI resistance 
I50V     3      
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3.1.1.5 Detection of low frequency NNRTI mutations during PI–based 
therapy 
Despite treatment regimens lacking NNRTIs, NVP-selected mutations detected at 
baseline were also detected after 40 weeks of ART in two children by SGS (Table 
14). In Study ID 147636, K101E was detected at week 40 of ART at a frequency of 
7% but was not detected by bulk sequencing at either time point. In Study ID 134102, 
Y181C was detected at a frequency of 5% at week 40 of ART with SGS but was not 
detected by bulk sequence analysis at this time point. V108I was first detected at 
week 96 of ART at a frequency of 3%, then it was not detected at week 224 during re-
started ART, and again detected at a frequency of 5% at week 298 during re-started 
ART. Emergence of V108I after ART initiation was not statistically supported 
(p=0.189) for test of proportions of genomes carrying V108I between baseline and 
week 298). 
3.1.1.6 Detection of genetically linked dual-class resistance to PI and NRTI 
Dual-class drug resistance was detected in the viral populations of 2 children (Study 
IDs 141806 and 134102) during ART by bulk sequence analysis. The same mutations 
were detected as linked on the same genome by SGS. M184V in RT and V82A in PR 
were detected on the same genome at weeks 40, 72 and 96 at frequencies of 68% (n = 
28 sequences), 91% (n = 44 sequences), 79% (n = 47 sequences) respectively for 
Study ID 141806 (Table 15). This combination of genetically linked DRMs was also 
detected in the viral population of Study ID 134102 at weeks 96, 224 and 298 at 
frequencies of 29% (n = 32 sequences), 100% (n = 34 sequences), 100% (n = 39 
sequences) respectively (Table 16). Two other dual-class drug resistant variants were 
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detected by SGS in the viral population of this child at week 96: M184V linked to 
M46I (31%) and M46L (3%) in PR (Table 16). Despite the high frequency of M46I, it 
was not detected by bulk sequence analysis. M46L could have been present at 
baseline given that only 1/32 sequences had this mutation at week 96 (p = 0.457, 
Fisher’s Exact test of the proportion of sequences with M46L at baseline versus week 
96). 
  
112 
112 
Therapy status Early ART No ART Re-started ART 
Week 0 40 96 164 224 298 
Number of variants analysed for Study ID H (n) 34 29  39   
Number of variants analysed for Study ID J (n) 31 38 32  34 39 
Study ID 147636 K101E (%) 12 7     
Study ID 134102 Y181C (%) 48 7     
Y188C (%)  3     
V108I (%)   3   5 
Table 14. Frequencies of Nevirapine-selected NNRTI resistance mutations detected by SGS in two children, Study IDs 147636 and 134103. 
The sampling time points for SGS are indicated. Frequencies in bold represent variants detected by both SGS and bulk sequence analysis.
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3.1.1.7 Detection of genetically-linked triple class resistance to PI, NRTI and 
NNRTI 
Genetically linked triple-class PI, NRTI and NNRTI DRMs were detected by SGS in 
Study ID 134102 during ART. Such variants were first detected at week 96 of early 
ART with additional RTV as a minority species (3%, n=32 sequences) The variant 
contained M184V, and V108I in RT and M46I in PR (Table 16). Variants with triple 
class DRMs were also detected at week 298 during re-started ART as a minority 
species (5%, n=39 sequences) and contained M184V, V108I and the PI DRMs: 
V82A, I54V, M46I, Q58E and L10F. 
3.1.1.8 Multi-class drug resistance during ART is associated with high viral loads 
M184V was the first DRM to be detected in the viral populations of Study IDs 
141806 and 134102 who had virological failure with DRMs known to confer 
resistance to components of ART (Table 15 and Table 16). Viral load rebounds 
>50,000 copies/ml during ART in these children frequently coincided with dual-class 
drug resistance in the majority species (Table 11).  
In Study ID 141806, 92% (n=37 sequences) of the viral population contained M184V 
only at week 12 of ART while the viral load fell from >750,000 copies/ml at baseline 
to 7,000 copies/ml at week 24 of ART. At week 40 of ART, there was a viral load 
rebound to 96,400 copies/ml. M184V single mutants were in the minority species 
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Therapy status Early ART No ART Re-started ART 
Week 0 12 40 72 96 164 224 
Number of variants analysed (n) 33 37 28 44 47 38 22 
Wildtype (%) 100 8    100 100 
M184V (%)  92 32 9 21   
V82A + M184V (%)   68 91 79   
Table 15. Dual-class resistance detected by SGS during 1st line PI-based therapy for Study ID 141806. Frequencies in bold indicated 
variants detected by both SGS and bulk sequence. “+” Indicated linkage on the same genome. Early ART was stopped at week 96 and re-started 
at week 165. 
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(33%, n=28 sequences) of the viral population and the majority species (67%) 
contained M184V and V82A. 
In Study ID 134102, the first viral load rebound was seen between week 24 and week 
40 of early ART when the viral load rebounded from 3,570 copes/ml at week 24 of 
early ART to >750,000 copies/ml at week 40 of ART without the detection of 
multiple linked multi-class drug resistance; the quasispecies contained wildtype virus 
(47%), M184V (45%) and NNRTI DRMs Y181C and Y188C at a combined 
frequency of 8% (n=38 sequences). The viral load decreased to 40,200 copies/ml at 
week 72 of ART before rebounding to 326,000 copies/ml at week 96 of ART when 
receiving additional RTV, with dual-class drug resistance (M184V genetically linked 
to V82A or M46I) detected in the majority species (68%, n=32 sequences). The viral 
load was erratic thereafter, and at the last sample (week 298 during re-started ART) 
was measured at 7,440 copies/ml with dual-class drug resistance in 95% of the viral 
population (n=39 sequences), where these variants contained M184V genetically 
linked to 3 major and 2 minor PI resistance mutations (Table 16). 
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Therapy status Early ART Re-started ART 
Week  0 40 96 224 298 
Number of variants analysed (n) 50 38 32 34 39 
Frequencies (%) 
Wildtype  44 47    
M184V   45 28   
M184V + V82A    34 71  
M184V + M46I   31   
M184V + M46L     3   
M184V + M46I + V108I   3   
M184V + V82A + L10F    29  
M184V + V82A + 154V + L10F     3 
M184V + V82A + I54V + M46I + Q58E + L10F     92 
M184V + V82A + I54V + M46I + Q58E + L10F +V108I     5 
Table 16. Dual- and triple-class resistance detected by SGS during 1st line PI-based therapy in Study ID 134102. Frequencies in bold 
indicate variants detected by both SGS and bulk sequence analysis. “+” Indicated linkage on the same genome. Early ART was stopped at week 
96 and re-started at week 165.
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3.1.2 Discussion 
This study is the first to use SGS to characterise antiretroviral resistance in children 
on early combination ART. The extent to which differences in sequencing approaches 
impact the interpretation of drug resistance has been highlighted in previous studies 
[113-115]. In the present study, SGS was advantageous because it allowed a 
longitudinal assessment of the evolution of population diversity in each child and 
allowed us to determine genetic linkages of DRMs between viral PR and RT. 
However SGS remains unsuitable for routine clinical use because of the complexity 
of the methodology and interpretation of the data. I used Superscript III for cDNA 
synthesis (error rate = 1/30,000 nucleotides [225]) and Phusion High-Fidelity DNA 
Polymerase for PCR because of their low error rates (2.2% of PCR products would 
have 1 nucleotide mis-incorporation for a ~1.4kb product and 35 PCR cycles 
http://www.thermoscientificbio.com/webtools/fidelity/). Thus the fidelity of the PCR 
products was well maintained. Nonetheless, it is possible that some single instances of 
drug resistance mutations could be PCR artefacts. 
SGS identified an additional 20% of children with NNRTI resistance as compared to 
bulk sequence analysis. SGS was also able to detect NNRTI resistance during PI-
based ART in 2 of the children, which was not evident by bulk sequencing. I did not 
rule out the possibility that the DRMs I observed could have been the result of natural 
viral nucleotide variation. 
At some of the time points in each child, bulk sequence analysis did not reveal any 
drug resistance, however SGS was able to detect DRMs in 25-35% of the sequences 
obtained. The limit of detection of bulk sequencing approaches to detect DRMs in pol 
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have been reported as 25%-35% [115] [226] [227] [228]. In my study, my SGS 
approach had a sensitivity that was comparable to that of Palmer et al [115], where 
any mutation detected at a frequency ≥35% by SGS was detected with bulk sequence 
analysis. Similarly I saw a variation in sensitivity at some nucleotide positions. There 
were some mutations or wildtype codons that were detected at a frequency between 
25% and 35% which were not detected by SGS. These were the wildtype amino acids 
in the baseline viral populations of Study IDs 130166, 138506 and 147636 and 82A 
and 46I, at frequencies of 31.2% and 29.4% respectively in the viral population at 
week 96 of ART for Study ID 134102. These discrepancies could be due to variations 
in primer sensitivities for their templates during cDNA synthesis and/or PCR 
amplification. 
M184V was the first mutation selected in the majority of the viral population of the 
two children failing ART with DRMs; the viral load rebounds coincided with the 
majority of the viral population being replaced with dual-class drug resistant variants 
and notably no AZT-selected mutations were detected during ART. Furthermore, 
despite failing AZT and LPV/r-containing therapy, 215I and 219N in RT and I50V in 
PR were not detected by SGS or bulk sequencing during ART for the two children 
(Study IDs 131326 and 153716) that harboured these mutations in their baseline viral 
populations. These observations are consistent with previous data on the ‘protective’ 
effect of PI on the development of NRTI resistance [196, 229, 230]. 
Recently Palumbo et al [89] found that children given sdNVP for PMTCT were less 
likely to have treatment failure on LPV/r based first line therapy compared to NVP-
based ART. This finding emphasizes the need for alternate PMTCT or ART strategies 
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in resource-limited settings. The WHO recommends first-line PI-based ART for 
such children and NNRTI-based therapy as second-line therapy, usually NVP or EFV. 
But very few studies have described the persistence of NNRTI resistance selected by 
prophylactic single dose NVP during PI-based ART in vertically infected children.  
Bulk sequence analysis did not reveal persistence of NNRTI resistance during PI-
based ART, but SGS revealed persistence of such mutations in more than one child as 
minority species. Prophylactic NVP was not given to 134102, but this child’s mother 
received it at the onset of labour, 7.9 weeks before the baseline sample was taken 
(Appendix A Table 21). I do not know exactly when maternal sdNVP was given 
relative to birth, but the current literature concludes that maternal NVP can remain at 
a dose representing 10 times the IC50 in neonates for 2.4 weeks or at suboptimal 
levels for 4 weeks after sdNVP is given to the mother at the onset of labour (30 to 480 
minutes prior to birth) [231]. Therefore, assuming that this child was not breast-fed, it 
is possible that maternal NVP was transferred via the placenta, which selected the 
variety of NNRTI resistant viruses detected at baseline in this child: K103N, V106M 
and Y181C. Alternatively, the presence of NNRTI resistance in this child without a 
history of sdNVP for PMTCT was most likely explained by vertical transmission of 
DRMs[119] or maternal NVP [231].  
The baseline PI DRM I50V, TAM revertant T215I and the TAM K219N of the 
double mutant Y181C + K219N, that were detected in Study IDs 131326, 153716 and 
134102 may have also been vertically transmitted. Vertical transmission of drug 
resistance has been previously determined by phylogenetic comparison of maternal 
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and neonatal sequences[232]. Unfortunately, maternal plasma samples were not 
available for my study.  
Age adjusted, full-dose RTV can select M46I, I54Vand V82A in children [233] , as 
well as L10F, M46L, Q58E in adults[234]. I detected genetic linkage of all these 
mutations in the viral population of 134102 after RTV super-boosted LPV/r, 
conferring greater PI resistance and reducing treatment options as compared to Study 
ID 141806 [102]. Currently there are no published data on the selection of resistance 
after RTV super-boosting of LPV/r, therefore my findings, although novel and 
important, require verification in a larger sample cohort. 
The current virological understanding of drug resistant reservoirs suggests that multi-
class drug resistant viruses can compromise ART in the future, although this requires 
formal testing in children where drug class options are limited. I consider the 
possibility that V108I was selected by NVP for PMTCT because it is not usually 
found in patients infected with subtype C who were not exposed to this drug [102]. 
my evidence also points to the triple class drug resistant variants detected in Study ID 
134102 to be a result of genetic ‘hitch hiking’ by V10κI. V10κI is known to confer 
modest reductions in NVP/EFV susceptibility in vitro [102] but its clinical 
significance is not known [102].  
Although multi-class drug resistance may be more common than previously thought, 
it should be emphasised that the CHER trial demonstrated excellent outcomes overall 
with 84.6% (280/331) of the children on ART achieving viral loads <400 c/ml at the 
end of the trial. These include 2/10 children from my study cohort (Study IDs 130166 
and 141806) who achieved and maintained viral loads <400 copies/ml at week 164 
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and week 265 respectively, until the end of the CHER trial. Further large-scale 
studies are needed to address long-term implications in these NVP exposed, vertically 
infected children with virological failure on LPV/r, and in particular the efficacy of 
the second-generation NNRTI etravirine and the PI darunavir warrant investigation. 
Finally these data reinforce the urgent requirement for appropriate paediatric 
formulations of a wider array of antiretroviral medications in the future. 
3.1.3 Conclusions 
Although the CHER trial demonstrated excellent outcomes overall with 84.6% 
(280/331) of the children on ART achieving viral loads <400 c/ml at the end of the 
follow up period, my results show the potential for early ART in vertically infected 
children to give rise to multi-class resistant viruses after NVP-based PMTCT and 
persistence of NNRTI resistance during ART. These findings continue to suggest a 
clinical role for highly sensitive assays like SGS to detect and quantify drug resistant 
viruses at low frequencies and to determine the inter- and intra-.host prevalence of 
multi-class drug resistance. 
I also reinforce previous conclusions that RTV super-boosting of LPV in infants and 
children poses a significant risk of development of multiple protease inhibitor 
resistance conferring mutations, not just within the viral population but within single 
virions as majority species. This further highlights the urgent need for appropriate 
paediatric formulations of a wider array of antiretroviral medications in the future. 
The current virological understanding of drug resistant reservoirs suggests that multi-
resistant HIV will compromise ART in the future, although this requires formal 
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testing in children. These data highlight future therapeutic challenges as a large 
cohort of vertically infected children on ART move into adolescence. 
In the following chapters I continue to address the evolution of drug resistance in 
these children using phylogenetic and phenotypic techniques.  
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3.2 Phylogenetic analysis of PR-RT to characterise the development of 
multiple linked multi-class drug resistance 
This chapter addresses the second objective of this thesis: to characterise the 
evolution of the viral populations using phylogenetic tools for the children from my 
study cohort. This was done particularly given of the development of multiple linked 
multi-class drug resistance. I also determined the evolutionary profile of NVP 
selected resistance that was detected at baseline and during early ART. Finally, I 
wished to determine if drug resistant and drug susceptible viruses, that were detected 
after and before early ART started persisting from previous time points or emerged 
from independent evolutionary events. Data for Study ID 153716 was not included in 
these analyses because I only obtained 1 sequence from one of the two sampling time 
points for this child. 
Genetically linked PI and RTI resistance mutations developed in the majority species 
of the viral populations of two children, Study IDs 141806 and 134102, and were 
detected as genetically linked by SGS. Previously, I saw that these variants were 
detected in the majority species during the first-round of ART and during re-started 
ART for Study ID 134102. For Study ID 141806, multi-class drug resistant variants 
were detected in the majority species during the first-round of ART, but were not 
detected during re-initiated ART. Instead, sequences without DRMs re-emerged 
during re-initiated ART and persisted as the majority species. 
Sequences with G-to-A mutations due to APOBEC3G/F cytidine deamination would 
have confounded the diversity calculations in the viral populations of the children 
from out study cohort. Therefore I submitted MSAs of PR-RT derived single genomes 
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obtained for each child at all sampling time points to the Los Alamos Hypermut 
2.2 algorithm: 
http://www.hiv.lanl.gov/content/sequence/HYPERMUT/hypermut.html. Results of 
this analysis can be viewed in Appendix B. 
Correlations between the genetic variation of PR-RT and viral load trends, or between 
genetic variation and development of viruses with multiple drug resistance conferring 
mutations linked on the same genome were determined. I used the Molecular 
Evolutionary Genetic Analysis (MEGA) software version 5.2 [217] to calculate the 
mean pairwise genetic distances (MPDs) of PR-RT sequences from each sampling 
time point per child (Appendix B Table 23). In this case, I used the Tamura and Nei 
1993 nucleotide substitution model, which was determined as the best fit model for 
this data by MEGA (lowest Bayesian Information Criterion, therefore highest 
posterior probability). Regression analysis was used to determine if the number of 
sequences obtained at each time point affected nucleotide variation. I determined 
whether differences in the mean number of nucleotide substitutions per site in PR-RT 
MPDs between consecutive time points were significant using an unpaired two-tailed 
Student’s t-test. MPD was expressed as number of nucleotide substitutions per site of 
all PR-RT sequences. For 4/9 children (Study IDs 138506, 141586, 143646 and 
130166), there were not enough data points to do this analysis. 
Next, I divided the children into 3 groups based on their ART experience: Group 1 
had early ART until week 40 or 96 and they did not re-start ART during the CHER 
trial (n = 4 children; Study IDs 141586, 138506 and 147636). Since the last sampling 
time point before death for Study ID 146666 was at week 99 of early ART, this child 
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was included in Group 1. Group 2 received early ART that was uninterrupted until 
the end of the CHER study (i.e. continuous ART; n = 3 children; Study IDs 143646, 
131326 and 130166). Group 3 received early ART which was interrupted from weeks 
97 to 164 and then the same ART regime was re-started from week 165 until the end 
of the CHER trial (i.e. interrupted ART; n = 2 children; Study IDs 141806 and 
134102). I plotted both viral load (copies/ml) and the mean pairwise genetic distances 
(nucleotide substitutions per site in PR-RT) against sampling time (weeks since start 
of early ART) for these children. 
The evolution of drug resistance was depicted from maximum likelihood inferences 
for each child. I re-constructed viral phylogenies for each child using the program 
RaxMLGUI [235], The parameters used for these analyses were the general time 
reversible nucleotide substitution model, rapid bootstrap heuristics to do 1000 
independent RaxML searches to choose a tree with optimal ML value and to assess 
branch support with rapid bootstrapping. An HIV-1 subtype C PR-RT single genome 
sequence derived from the test sample was used as an outgroup to root the trees to 
assume the direction of evolution. 
I implemented recombination analyses to determine if recombination was a 
mechanism by which multiple linked multi-class drug resistant variants emerged from 
the viral populations of Study IDs 134102. I looked for evidence of recombination 
using SBP [236] and GARD [237] provided online at http://www.datamonkey.org. 
Codon-based maximum likelihood inferences were used to identify positively selected 
residues in the viral populations of Study IDs 141806 and 134102. The three methods 
used were: (1) single ancestor counting (SLAC) analysis, (2) fixed effect likelihood 
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(FEL) analysis [218, 238] to estimate dN/dS ratios at every codon in the MSA for 
each child and (3) Fast Unconstrained Bayesian AppRoximation (FUBAR) [220]. 
Spidermonkey analysis was used to determine if positively selected sites co-evolved, 
i.e. if the evolution of amino acids at any pair of positively selected sites were 
dependent on each other during the course of protein evolution. MSAs were submitted 
to the SLAC, FEL, FUBAR and Spidermonkey algorithms at Datamonkey webserver 
[221] at http://www.datamonkey.org. 
3.2.1 Results 
3.2.1.1 Correlations between the number of single genome sequences obtained at 
each time point and nucleotide variation 
There was no correlation between the number of single genomes obtained at each 
sampling time point and the genetic variation of PR-RT (p > 0.05). This suggested 
that the amount of genetic variation seen in the viral populations over time reflects the 
real diversity of the population and is not influenced by sample size. Figure 3.2 
depicts the linear regression analyses for these children. 
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Figure 3.2 Regression analysis for 5/9 children. r2 and p-value of the F-test determine if the slope of the best-fit line is true. When p >0.05, 
the slope of the line was not true and there was no correlation between number of single genomes obtained and MPD.
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3.2.1.2 Effect of ART on PR-RT genetic diversity 
None of the children from Group 1 maintained a viral load that was below the limit of 
detection (<400 copies/ml) even though 2 children achieved this during therapy. All 
the members of Group 2 achieved undetectable viral loads during ART at time points 
later than week 40. They maintained undetectable viral loads until the last sampling 
time point during the CHER trial. The members of Group 3 achieved undetectable 
viral loads during the first round of ART and only Study ID 141806 achieved an 
undetectable viral load during the second round of ART, which was maintained until 
the end of the CHER trial. 
In Group 1, 1/4 children (Study ID 138506) received ART until week 40 and 3/4 
children (Study IDs 141586, 146666 and 147636) had ART until week 96. The 
diversity of the viral population at baseline and week 40 of ART remained similar for 
Study ID 141586 (p >0.05; Student’s t-test of the difference between MPDs at 
different sampling time points). For 2/4 children, (Study IDs 138506 and 147636) the 
diversity of viral populations at week 40 of ART was greater than at baseline. For the 
fourth child in this group (Study ID 146666), the diversity of the viral population 
showed no particular pattern. These longitudinal trends in viral load and diversity 
versus time are shown in Figure 3.3A. 
In Group 2, children received continuous ART and the diversity of the viral 
populations at week 40 of ART was less than at baseline for 2/3 children (Study IDs 
143646 and 130166), whereas this trend in population diversity was not seen for the 
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third child in this group (Study ID 131326). These longitudinal trends in viral load 
and diversity versus time are shown in Figure 3.3B. 
In Group 3, early ART was interrupted from weeks 97-164. For Study ID 141806, the 
diversity of the viral population was less than that of the previous time point until 
week 72 of ART and then was greater at each subsequent time point until week 224. 
The opposite trend in population diversity observed For Study ID 134102: the 
diversity of the viral population was greater than the last until week 96 of early ART 
and then was less diverse at each subsequent time point until week 298. These 
longitudinal trends in viral load and diversity versus time are shown in Figure 3.3C.
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(A)     
(B)    
(C)        
Figure 3.3 Longitudinal HIV-1 plasma viral load (copies/ml) and diversity (MPD/nucleotide changes per site in PR/RT) profiles for children 
from (A) Group 1, (B) Group 2 and (C) Group 3. Study IDs are above each graph. Grey bars represent time on ART. 
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Within each group, there was no difference between MPDs before early ART was 
started compared to when the first viral rebound was observed during early ART in all 
three groups (p >0.05; Student’s t-test). There was also no difference among the 
baseline MPDs of each group or among the MPDs of each group at week 40 of ART 
(p>0.05; One-Way ANOVA test) (Figure 3.4). 
 
Figure 3.4 PR-RT diversity calculated as MPD before early ART (Baseline) and 
at the time of the first viral rebound during ART (Week 40) for 9 children. Group 1 
contains children who received early ART until week 40 of 96. Group 2 contains 
children who received continuous ART and Group 3 contains children who received 
interrupted ART. The number of children (n) in each group is shown in parentheses 
above each bar couple. Error bars represent the standard deviation of mean MPDs. 
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3.2.1.3 Effect of ART on phylogenetic structures 
The ML trees reconstructed with the sequences obtained from each child reflected the 
longitudinal trends in diversity I saw in each patient. My data showed 6 children from 
Groups 1 and 2 that had clusters of intermingled, identical sequences from baseline 
and week 40 of ART (Group 1: Study IDs 138506, 146666 and 141586 – (Figures 3.5, 
3.6, 3.7 and 3.8; Group 2: Study IDs 143646, 131326 and 130166 – Figure 3.9, 3.10 
and 3.11). This observation was over-represented for one patient who received 
continuous ART (Study ID 143646, Figure 3.9); the majority (42/49) of sequences 
obtained from baseline and week 40 of ART were identical. 
I also observed clusters of identical sequences from different time points when a drug 
resistant population was selected by components of ART in one child (Study ID 
141806; Figure 3.12) from Group 3. Such a cluster of sequences existed in the major 
M184V single-mutated population and the major M184V+V82A double-mutated 
population. Both of these populations shared a common ancestor and sequences were 
very closely related when they were not identical. The major M184V single-mutated 
population shared a common ancestor with the major double-mutated M184V+V82A 
population and V82A single mutated sequences were never detected in the viral 
populations of this child. 
The other child in Group 3 (Study ID 134102; Figure 3.13) had identical sequences 
from the same time point and with the same drug resistance mutation profiles. M184V 
single mutated viruses were selected from multiple viral populations but only one 
population was the major contributor to drug resistant viraemia at week 40 of ART. 
At week 96 of ART, there were 2 main viral populations that were the major 
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contributors to the viraemia. One was an M184V single-mutated population, from 
which a double-mutated M184V+M46I viral population emerged. The other 
population was a M184V+V82A double-mutated population, which shared a common 
ancestor with the major M184V single-mutated viruses from week 40 and 96 of ART. 
When ART was re-started in this child, it was the M184V+V82A double mutated 
viral population from week 96 of ART that was ancestral to the multiple-linked 
multiclass drug resistant populations detected at weeks 224 and 298. At week 224 
during re-started ART, all viruses were double-mutated with M184V and V82A and 
with the accumulation of LPV-selected mutations in PR (L10F, M46I, I54V Q58E) by 
week 298 of ART, the viral population became more homogenous. 
For Study ID 134102, despite a viral load <400 copies/ml at the end of treatment 
interruption (week 164) the drug resistant population at week 224 was not 
independently selected by re-started ART, but instead evolved from the major 
M184V+V82A sub-population at week 96 of ART. Despite the suppression of viral 
replication to 402 copies/ml at week 265 of re-started ART, the multiple linked multi-
class drug resistant population at week 298 during re-started ART evolved from the 
population at week 224 instead of being independently selected. In contrast, after 
ART was interrupted and re-started for Study ID 141806, no drug resistance 
mutations were detected. When ART was re-started, the viral load rebounded from 
undetectable (<400 copies/ml at week 164) to detectable (88, 400 copies/ml at week 
224) in the absence of known drug resistance mutations in PR or RT. 
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Figure 3.5 (A) MPD and (B) Phylogenetic structure of sequences from Study ID 138506. Both contain PR-RT sequences from baseline and 
Week 40 of ART. Encircled is the most ancestral sequence. 
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Figure 3.6 (A) MPD and (B) Phylogenetic structure of sequences from Study ID 146666. Both contain PR-RT sequences from baseline, 
Week 40 and 96 of ART. Encircled is the most ancestral sequence. 
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Figure 3.7 (A) MPD and (B) Phylogenetic structure of sequences from Study ID 141586. Both contain PR-RT sequences from baseline and 
Week 40 of ART. Encircled is the most ancestral sequence. 
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Figure 3.8 (A) MPD and (B) Phylogenetic structure of sequences from Study ID 147636. Both contain PR-RT sequences from baseline, 
Week 40 of ART and Week 164 without ART. Encircled is the most ancestral sequence. 
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Figure 3.9 (A) MPD and (B) Phylogenetic structure of sequences from Study ID 143646. Both contain PR-RT sequences from baseline and 
Week 40 of ART. Encircled is the most ancestral sequence. 
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Figure 3.10 (A) MPD and (B) Phylogenetic structure of sequences from Study ID 131326. Both contain PR-RT sequences from baseline and 
Weeks 40, 72 and 164 of ART. Encircled is the most ancestral sequence. 
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Figure 3.11 (A) MPD and (B) Phylogenetic structure of sequences from Study ID 130166. Both contain PR-RT sequences from baseline and 
Week 40 of ART. Encircled is the most ancestral sequence. 
130166 
Ba
se
lin
e
We
ek 
40
0.000
0.005
0.010
0.015
0.020
M
ea
n
 
n
u
m
be
r 
o
f n
u
cle
o
tid
e 
su
bs
tit
u
tio
n
s 
pe
r 
sit
e 
in
 
PR
-
R
T
p = 0.0057
(A) (B) 
// 
Time point 
 baseline 
 week 40 of ART 
 
Variant 
 outgroup 
 Wildtype 
NNRTI resistance 
 K101E 
 K103N 
 V106A 
 Y188C 
 G190A 
PI resistance 
 M46L 
 
  
141 
141 
 
 
 
 
Figure 3.12  (A) MPD and (B) 
Phylogenetic structure of 
sequences from Study ID 141806. 
Both contain PR-RT sequences 
from baseline, Weeks12, 40, 72 
and 96 of ART, Week 164 during 
ART interruption and Week 224 
during re-started ART. Encircled is 
the most ancestral sequence. 
141806
Ba
se
lin
e
We
ek 
12
 
of 
AR
T
We
ek 
40
 
of 
AR
T
We
ek 
72
 
of 
AR
T
We
ek 
96
 
of 
AR
T
We
ek 
16
4 d
ur
ing
 
AR
T f
re
e 
ph
as
e
We
ek 
22
4 d
ur
ing
 
re
-
sta
rte
d A
RT
0.000
0.005
0.010
0.015
0.020
M
ea
n
 
n
u
m
be
r 
o
f n
u
cle
o
tid
e 
su
bs
tit
u
tio
n
s 
pe
r 
sit
e 
in
 
PR
-
R
T
p < 0.0001
p < 0.0001
p < 0.0001
p < 0.0001
p < 0.0001p < 0.0001
(A) (B) 
 
 outgroup 
 baseline 
 week 12 of ART 
 week 40 of ART 
 week 72 of ART 
 week 96 of ART 
 week 164 during ART-free period 
 week 224 during re-started ART 
 
Variants 
 Wildtype 
NNRTI resistance 
 M184V 
Dual-class, genetically linked 3TC and PI resistance 
 M184V+V82A 
  
142 
142 
  
Figure 3.13 (A) MDP and (B) Phylogenetic structure of sequences from Study ID 134102. Both contain PR-RT sequences from baseline and 
Weeks 40 and 96 of ART, Weeks 224 and 298 during re-started ART. Encircled is the most ancestral sequence. 
Ba
se
lin
e
40
 
w
ee
ks 
of 
AR
T
96
 
w
ee
ks 
of 
AR
T +
 
13
 
w
ee
ks 
RT
V
We
ek 
22
4 d
ur
ing
 
re
-
sta
rte
d A
RT
We
ek 
29
8 d
ur
ing
 
re
-
sta
rte
d A
RT
0.000
0.003
0.006
0.009
0.012
Weeks of ART
N
u
m
be
r 
o
f n
u
cle
o
tid
e 
su
bs
tit
u
tio
n
s 
pe
r 
sit
e 
in
 
PR
-
RT *
*
*
*(A) (B) 
// 
 
 Wildtype 
NNRTI resistance 
 K103N 
 V106M 
 Y181C 
 Y188C 
3TC-selected resistance 
 M184V 
Dual-class, genetically linked RTI resistance 
 Y181C+V106M 
 Y181C+K219N 
Dual-class, genetically linked 3TC and PI resistance 
 M184V+V82A 
 M184V+M46I 
 M184V+M46L 
 M184V+V82A+L10F 
 M184V+V82A+I54V+L10F 
 M184V+V82A+Q58E+I54V+M46I+L10F 
Triple-class, genetically linked 3TC, PI and NNRTI resistance 
 M184V+M46I+V108I 
 M184V+V82A+Q58E+I54V+M46I+L10F+V108I 
  
143 
143 
3.2.1.4 Ancestry of the viral population during early ART 
Since the rooted ML trees allowed the assumption of the direction of evolution, I was 
able to observe the most ancestral sequence of all the single genome derived PR-RT 
sequences as the sequence closest to the base of the tree. For 9/9 children, the most 
ancestral sequence did not contain a known DRM in PR or RT. For 2/9 children 
(Study IDs 138506 and 143646; Figures 3.5 and 3.9) the most ancestral sequence was 
from the earliest sampling time point (week 0 / at baseline). But for most of the 
children (4/9; Study IDs 141586, 131326, 130166, and 134102; Figures 3.7, 3.10, 
3.11 and 3.13), the most ancestral sequence was from week 40 of early ART. For 1/9 
child (Study ID 146666; Figure 3.6) this sequences was from week 96 of ART and for 
2/9 children (Study IDs 147636 and 141806; Figures 3.8 and 3.12), this sequence was 
from the ART-free period at week 164.  
3.2.1.5 NNRTI resistant viruses that replicate during PI-based ART 
The NVP-selected resistance mutations Y181C and K101E were the only mutations 
found between week 40 of ART and the ancestral baseline sequences. Y181C was 
detected at baseline and week 40 of ART for Study ID 134102. K101E was detected 
at these two time points for Study ID 147636. The ML trees for these two children 
show the NVP resistance sequences from baseline and week 40 of ART clustered on 
the same branch of their respective ML trees. Figure 3.14 is the ML tree for Study ID 
134102 and Figure 3.15 is the ML tree for Study ID 147636. 
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Time point 
 outgroup 
 baseline 
 week 40 of ART 
 week 96 of ART 
 week 224 during re-started ART 
 week 298 during re-started ART 
 
 
 Wildtype 
NNRTI resistance 
 K103N 
 V106M 
 Y181C 
 Y188C 
3TC-selected resistance 
 M184V 
Dual-class, genetically linked RTI resistance 
 Y181C+V106M 
 Y181C+K219N 
Dual-class, genetically linked 3TC and PI 
resistance 
 M184V+V82A 
 M184V+M46I 
 M184V+M46L 
 M184V+V82A+L10F 
 M184V+V82A+I54V+L10F 
 M184V+V82A+Q58E+I54V+M46I+L10F 
Triple-class, genetically linked 3TC, PI and NNRTI 
resistance 
 M184V+M46I+V108I 
M184V+V82A+Q58E+I54V+M46I+L10F+V108I 
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Figure 3.14 ML tree from viral sequences sampled from Study ID 134102. The 
scale bar represents the number of nucleotide substitutions per site along the branches 
of the tree. The tree was rooted against an outgroup: an HIV-1 subtype C single 
genome derived PR-RT sequence from the test sample used to troubleshoot the SGS 
protocol. * indicated bootstrap values >50. Encircled is the cluster of sequences with 
NNRTI resistance that persisted from baseline to week 40 of ART. Shaded in red is 
node at which and M184  was positively selected to give rise to major drug 
resistant populations.  
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Figure 3.15 ML tree from viral sequences sampled from Study ID 147636. The 
scale bar represents the number of nucleotide substitutions per site along the branches 
of the tree. The tree was rooted against an outgroup: an HIV-1 subtype C single 
genome derived PR-RT sequence from the test sample used to troubleshoot the SGS 
protocol. * indicated bootstrap values >50. Encircled is the cluster of sequences with 
NNRTI resistance that persisted from baseline to week 40 of ART. 
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Figure 3.16 ML tree from 
viral sequences sampled from 
Study ID 134102. The scale bar 
represents the number of 
nucleotide substitutions per site 
along the branches of the tree. The 
tree was rooted against an 
outgroup: an HIV-1 subtype C 
single genome derived PR-RT 
sequence from the test sample 
used to troubleshoot the SGS 
protocol. * indicated bootstrap 
values >50. Red highlights are the 
nodes at which V82A and 
M184V were positively 
selected to give rise to major drug 
resistant populations. 
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3.2.1.6 No evidence of recombination for Study ID 134102 
M184V, V82A, M46I and V108I were present in variants detected in the viral 
population of Study ID 134102 at week 96 of ART, but they were not all linked on the 
same genome. At week 298, M184V, V82A and M46I were genetically linked in 
100% of the viral population and V108I was genetically linked to these mutations in a 
minority species. However recombination analyses (SBP and GARD) did not reveal 
evidence of recombination among the sequences obtained from this child, (p < 0.05 
statistical level), suggesting that multiple linked multi-class drug resistance mutations 
were not acquired through the recombination of single-class resistant variants detected 
at week 298. I also did not find any evidence of recombination among sequences from 
Study ID 141806 with the same methods. 
3.2.1.7 Positive selection and co-evolution analyses 
FUBAR and FEL analyses for Study ID 141806 revealed 2 positively selected sites in 
PR-RT common to both analyses (Table 17A). This was the protease inhibitor 
resistance mutation V82A and R38K in RT in these directions of evolution 
(Table 17A). However these sites did not co-evolve according to Spidermonkey 
analyses of coevolution. SLAC and FEL analyses for Study ID 134102 did not reveal 
any positively selected sites but FUBAR analysis revealed 1 positively selected site: 
M184V in RT in this directions of evolution (Table 17B). These nodes are 
highlighted in Figure 3.14 for Study ID 134102 and Figure 3.16 for Study ID 141806. 
The mean dN/dS ratios determined by SLAC for both children were <1 (Table 17) 
indicating that PR-RT evolution in both children was mainly driven by negative 
selection. 
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(A) 
Algorithm Positively selected sites dN dS dN-dS Number of negatively selected sites Mean dN/dS ratio 
SLAC     28 0.184 
FEL V82A in PR 3.25 0 3.25 54  
R38K in RT 4.045 5.35e-15 4.04   
FUBAR R38K in RT 4.045 2.653e-15 4.05 56  
V82A in PR 1.255 0.191 1.06  
D35E in RT 1.292 0.213 1.08  
R38K in RT 2.007 0.231 1.78  
N248D in RT 1.8 0.243 1.56  
 
(B) 
Algorithm Positively selected sites dN dS dN-dS Number of negatively selected sites Mean dN/dS ratio 
SLAC     6 0.375 
FEL     15  
FUBAR M184V in RT 2.352 0.256 9.186 
 
14  
Table 17. Positive selection analysis results for (A) Study ID 141806 and (B) Study ID 134102. SLAC and FEL significance level p-value = 
0.05. FUBAR posterior probability = 0.95 
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3.2.2 Discussion 
The most ancestral PR-RT sequence in the ML tree that was re-constructed for most 
children was not from the baseline population but from a later time point. This is a 
novel observation to be made in HIV-1 infected children on ART and implies that 
early ART did not effectively target or eliminate the viral reservoirs. Kieffer et al 
[239] made a similar observation for the evolution of the pol gene in HIV-1 positive 
adult patients, except that their patients maintained low-level viraemia (viral load <50 
copies/ml) during ART and maintained viral loads below the limit of detection 
without the detection of DRMs for up to 15 months.  
I also saw intermingling of viruses from early and late time points despite the 
development of drug resistance during ART for the majority of these children. For the 
children who did not develop drug resistance conferring mutations during ART, this 
result suggests the inhibition of viral evolution in children who received ART. I 
cannot be conclusive about this statement without comparing these results to those of 
children who did not receive early ART, but such a group did not exist in the CHER 
study and early ART became the standard of care at a median follow-up time of 40 
weeks (IQR 24–58); 20 weeks (IQR 16–25) for the deferred therapy group, because 
early ART was found to reduce the risk of death by 75% during the trial.  
The strong selection pressure exerted by ART was responsible for the inhibition of 
viral evolution from weeks 12 to 96 of ART for Study ID 141806, which is why the 
majority of drug resistant sequences adhered to the backbone of the ML tree. In 
contrast there was continuous evolution of the drug resistant population of Study ID 
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134102 from baseline and until week 298 during re-started ART with the 
accumulation of drug resistance mutations on the viral genomes. However similar to 
the findings of Shankarappa et al [240], ART seemed to inhibit viral replication more 
efficiently during re-started ART when the sequences from weeks 224 and week 298 
were more similar than within the previous time points and were the most similar, i.e. 
adhered to the backbone of the tree, at week 298. MTCT-NVP seemed responsible for 
this inhibition in the baseline population since this child did not receive prophylactic 
NVP. 
Recently Kearney et al [222] proposed that “the presence of identical sequences from 
difference sampling time points before and during ART suggested that there was a 
proliferating infected cell population that was the main source of viraemia”. 
Intermingled identical sequences from baseline and week 40 of ART, suggested that 
such an infected cell population was the source of persisting viraemia in 4 children 
until week 40 (2 children who received ART until week 40 and 2 children who 
received continuous ART). Kearney et al [222] also suggest that the viral reservoir 
may “contract during prolonged therapy”. Particularly in the case of Study ID 143646, 
my data suggests that the combination of prophylaxis, early ART and continuous 
therapy may have the potential to restrict the viral reservoir in the first instance and 
then reduce it (e.g. Figure 3.9). It was very unlikely that there was cross-
contamination between the samples from these two time points because these samples 
were received and processed independently (~12 months apart). 
The phylogeny for Study ID 141806, shows M184V single-mutated sequences as 
selected independently on multiple occasions, but only one of these events gave rise 
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to the major contributor to drug resistance during ART. Since the major M184V 
single-mutated population shared a common ancestor with the major double-mutated 
M184V+V82A population and V82A single-mutated sequences were never detected. 
I made the same observation for single-mutated M184V populations and double-
mutated M184V+V82A populations based on the phylogeny for Study ID 134102. 
V82A single-mutants were also not detected at any of the sampling time points for 
this child.  
Similar to my findings, M184V is known to be detected within 12 weeks of a 3TC 
inclusive ART regime [241, 242] and in combination with my phylogenetic analyses, 
I propose that V82A was only selected in M184V-mutated viruses. This finding may 
speak to the action of combination therapy suggesting that only when the action of 
3TC is inhibited at the start of the viral replication cycle by the M184V mutation, 
does the action of LPV at the end of the replication cycle become relevant enough to 
cause selection and proliferation of V82A in the viral population. There is still 
disagreement about the effect of NRTIs on cell-to-cell spread of HIV-1 [243, 244], 
but based on the findings of Sigal et al [244], that NRTIs are not very effective at 
blocking cell-to-cell spread, I hypothesize that when 3TC is no longer inhibiting viral 
replication through chain termination, the second NRTI, AZT is even less likely to 
inhibit cell-to-cell spread of M184V mutated viruses. Consequentially, this would 
have allowed the PI (LPV) to exert an even stronger selection pressure, resulting in 
M184V and V82A double-mutated viruses. 
These findings also highlight the fact that drug resistance can persist despite efficient 
suppression of viral replication by ART and HIV-1 can escape treatment recycling 
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through the proliferation of multiple linked multi-class drug resistant viruses from 
such a reservoir. In contrast, drug resistance mutations were not detected during 
treatment interruption (week 164) or during re-started ART (week 224) and by week 
265 of re-started ART for Study ID 141806. Instead, viral replication was suppressed 
to undetectable levels (<400 copies/ml at weeks 265 and 281), possibly because 
rebounding viraemia after treatment interruption was a result of archived wildtype 
viruses that were susceptible to re-cycled ART.  
My data suggests that NVP-resistant viruses detected at week 40 of ART were 
proliferating from the NVP-resistant reservoir that was producing these viruses at 
baseline. Many studies have concluded that failed prophylactic NVP is associated 
with failure of NNRTI-based ART in HIV-1 infected adults and children and an 
obvious deduction from this is that an NNRTI-resistance viral reservoir can be 
established from NNRTI-resistant viruses that were selected by prophylactic NVP. To 
my knowledge, my study demonstrated the persistence of these viruses despite the 
lack of other published data showing that these viruses can persist in the viral 
population during PI-based ART. 
M184V in RT and V82A in PR did not co-evolve despite evidence that V82A was 
only selected on a background of M184V mutated sequences. Without this 
phylogenetic analysis, I might have assumed an evolutionary relationship between 
these two sites in PR and RT. But my phylogenetic data implied that the development 
of V82A in these variants was not dependent on the development of M184V in RT. 
Therefore I considered a lack of sensitivity of the methods used to detect co-evolution 
between M184V and V82A, but to my knowledge, Spidermonkey [221] is currently 
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the most rigorous co-evolution analysis platform because it considers evolutionary 
history of my data, the phylogenetic relationships of my intra-host sequences and 
utilizes coupled nucleotide substitution models in order to avoid predictions of false 
positives [245-247]. 
When Vif does not efficiently sequester APOBEC3G/F, it can cause guanine-to-
adenine transitions in the viral genome, which can lead to premature STOP codons in 
the viral genome and sometimes point mutations that can give rise to drug resistance 
mutations. These APOBEC-induced mutations usually exist at a low frequency in the 
viral population of adults and children, but since SGS is able to detect low-level 
variants in the viral population, these mutated sequences can confound analyses aimed 
at determining ART-selected drug resistance, population diversity and phylogenetic 
reconstructions [248] [180]. Since there is no known correlation between disease 
progression and frequency of APOBEC-induced mutations in the HIV-1 genome in 
infected children [249] I analysed the single genome sequences from all the sampling 
time points in each child (Study IDs 141806 and 134102) in a single MSA per child. 
There are very few studies on the prevalence or contribution of APOBEC3G/F-
induced guanine-to-adenine transitions contribute to the diversity of HIV-1 pol in 
infected children, and I found only one that addressed the contribution of this cytidine 
deamination of pol in children [250]. They determined that HIV-1 pol was one of the 
most affected genes in vertically infected children [250] but it did not surpass a 
prevalence of 13%. Therefore I did not expect or observe APOBEC3G/F cytidine 
deamination in pol to surpass 13% compared to the most ancestral sequence obtained 
per child. 
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3.2.3 Conclusions 
In my study, when M184V is detected with PI resistance and as genetically linked on 
the same viral genome, my evidence suggests that PI-resistance mutations are only 
selected in M184V mutated sequences selected by 3TC during PI-based ART. But the 
evolution of PI resistance mutations in PR and M184V in 3TC were not shown to be 
dependent on each other. NNRTI resistance detected by SGS at baseline and week 40 
of PI-based ART are examples of persistence of PMTCT-NVP selected resistance 
from a reservoir of NNRTI resistant virus. Further research, such as prospective 
studies with larger cohorts is needed to generalise these findings for children who 
receive PI-based ART. 
I also saw that early ART did not effectively eliminate the viral reservoir so that it 
continued to be a major contributor to the evolution of the viral populations during 
virological success and failure on ART; highlighting the importance of the viral 
reservoir. I also suggest that prophylaxis and early ART may not just be strategies to 
improve child mortality and disease progression, but may also be strategies to restrict 
the viral reservoir in the first instance and then reduce it. This aspect of early ART 
needs to be researched further. 
My findings do not give more clarity to the effectiveness of recycled PI-based ART 
regimes in children because I saw the re-emergence and susceptibility of viruses 
during re-cycled ART in one of the children who developed majority species drug 
resistance during the first round of ART, while multiple linked multi-class drug 
resistance persisted in the other child who continued to fail a recycled regime of re-
started ART. 
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3.3 Longitudinal trends in replication capacity and drug susceptibility 
associated with development of multiple linked multi-class drug resistance and 
characteristics of Gag during PI-based ART 
In this chapter I examine the drug susceptibility and replication capacity (RC) 
conferred by multi-class drug resistant PR-RT from two children who developed such 
resistance in their majority species during ART (Study ID 141806 and 134102). In 
previous chapters I described the genotypic development of variants in these two 
children and the persistence of drug resistance with time. 
PR-RT from selected single genome derived PR-RT sequences were cloned into the 
gag-pol expression vector p8MJ4-HSC to produce a chimeric gag-pol expression 
vector. I used an MSA of the cloned patient PR-RT amino acid sequences to 
characterize amino acids that were known to affect PI and RTI susceptibility and 
amino acids that changed over time. I used single replication cycle assays to 
determine replication capacity (RC) and drug susceptibility of pseudoviruses 
produced from these chimeric vectors.  
The RC of pseudoviruses produced from each chimeric vector was determined from 
titrations of serially diluted viruses on 293T cells for 48 hours. Infection was 
determined by measuring the luciferase expression of infected target cells. An enzyme 
linked immunosorbent assay was used to measure the reverse transcriptase activity of 
each pseudovirus. RC was measured as RLU/ng of RT activity and expressed as % of 
the WT for each child.  
I measured the drug susceptibility of the pseudoviruses as the concentration of the 
drug that inhibited pseudoviral replication by 50% (IC50) and susceptibilities were 
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expressed as fold change in IC50 relative to the baseline WT pseudovirus 
produced for each child. 
I tested the susceptibility of these viruses to the components of early ART (AZT, 3TC 
and LPV) as well as the components of the recommended second line therapy for 
these children (Abacavir (ABC), Didanosine (ddI), Efavirenz (EFV) and NVP). I also 
tested their susceptibilities to two other PIs that have been approved for use in 
children, namely Nelfinavir (NFV) and Saquinavir (SQV). 
I also tested DRV susceptibility of the pseudovirus that was singly mutated with 
M184V and the pseudovirus from week 298 of ART from Study ID 134102 which 
had multiple major and minor PI drug resistance mutations in PR (V82A, I54V, 
Q58E, M46I and L10F). The fold changes in IC50 of these two viruses were 
measured relative to the HIV-1 subtype C gag-pol expression vector p8MJ4-HSC. 
Each drug mentioned in this chapter, along with its abbreviation and drug class are 
listed in Appendix C Table 24. 
Finally I used population sequence analysis of HIV-1 Gag from the sampling time 
points of Study IDs 141806 and 134102 to determine the involvement of Gag that 
may have also affected PI susceptibility. I identified amino acids in Gag that have 
been associated with PI susceptibility in the literature and amino acid changes over 
time at positions associated with PI-exposure. A position specific scoring matrix 
(PSSM) was produced from an MSA of the 891 HIV-1 Subtype C Gag sequences 
from treatment naïve children from Sub-Saharan African children that were available 
in the HIV Los Alamos sequence database on June 1st 2014. I used the PSSM to 
determine the natural variation of amino acids found at these key positions in Gag for 
my study cohort using population sequence analysis. 
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3.3.1 Results 
3.3.1.1 Longitudinal amino acid changes in PR-RT  
I replaced PR-RT in the p8MJ4-HSC plasmid with PR-RT from select single genome 
sequences. Obtained were 4 chimeric vectors for Study ID 141806 and 6 chimeric 
vectors for Study 134102 that produced pseudovirus based on retroviral titrations. The 
amino acids in PR and RT associated with drug susceptibility or replication capacity 
of HIV-1 that defined each chimeric vector are listed in Table 17 for Study ID 141806 
and Table 18 for Study ID 134102. 
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Pseudovirus 1 2 3 4 Background amino acids 
associated with RC and PI-
exposures/resistance Viral element 
Amino acid 
position 
Amino acid 
changes 
pol TFP 50 V A A A 
Protease 
14 R K K K M36I, R41K, L63T, I93L 
20 K R R R 
35 E D D D 
82 V V A V 
94 G A A G 
Reverse 
transcriptase 
36 D E E D  
40 E D D E 
184 M V V M 
250 N D D N 
Table 18. Amino acids in PR-RT associated with RC or drug resistance for Study 
ID 141806. Longitudinal amino acid changes in pol for Study ID 141806 in columns 
3 to 6. Background amino acids present in all pseudoviral PR-RT sequences are listed 
in column 7. Identifying elements of pseudoviruses are: (1) WT from baseline (2) 
184V single-mutated sequence from week 12 of early ART (3) 184V and 82A double-
mutated sequence representing the majority consensus from weeks 40, 72 and 96 of 
early ART (4) Sequence from week 164 without known DRMs and during ART 
interruption 
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Variant 1 2 3 4 5 6 Background amino acids 
associated with RC and PI-
exposures/resistance Viral element 
Amino 
acid 
position 
Amino acid 
pol TFP 9 P P P P L L 
Protease 
10 L L L L F F K20R, R41K, L63P, V77I, 
L89M and I93L 46 M M M M I I 
54 I I I I V V 
58 Q Q Q Q E E 
82 V V V A A A 
98 N N S N N N 
Reverse 
transcriptase 
108 V V V V V I  
162 C C C S S S 
174 Q Q Q Q R R 
181 Y C C Y Y Y 
184 M M V V V V 
277 R R R R K K 
292 V V I I I V 
296 N N T T T N 
312 E E Q Q Q E 
Table 19. Amino acids in PR-RT associated with RC or drug resistance for Study 
ID 134102. Longitudinal amino acid changes in pol for Study ID 134102 in columns 
3 to 8. Background amino acids present in all pseudoviral PR-RT sequences are listed 
in column 7. TFP is the transframe protein. Identifying elements of pseudoviruses are: 
(1) WT from baseline (2) 181C single-mutated sequence from week 40 of early ART 
(3) 181C single-mutated sequence from week 96 of ART (4) 184V and 82A double-
mutated sequence from week 224 during re-started ART (5) 184V and 82A, 54V, 
58E, 46I and 10F multiple-mutated sequence from week 298 during re-started ART 
(6) 108I, 184V, 82A, 54V, 58E, 46I and 10F multiple-mutated sequence from week 
298 during re-started ART. 
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3.3.1.2 Single round infectivity of pseudoviruses 
To determine the phenotypic impact of DRMs that accumulate in PR-RT. I used the 
TCID50 and RT-activity (ng of cDNA produced) of each pseudovirus to measure RC 
as RLU/ng of RT-activity as a % of WT (Appendix C Figure 5.2A and 5.2B). 
When M184V in RT was the only DRM present, the single round infectivity (as a 
surrogate for) replication capacity of these pseudoviruses was less than the WT (RC 
was 2% of the WT for Pseudovirus 2 from Study ID 141806 and 50% of the WT for 
Pseudovirus 3 from Study ID 134102). 
For Study ID 134102, the RC of the Y181C mutated pseudovirus (Pseudovirus 2) was 
80% less than the WT. The variance of RC for Pseudovirus 3 did not conclusively 
determine if the RC recovered with the PR mutation N98S and the RT mutations: 
M1κ4V, V2λ2I, N2λ6T and E312Q. However Pseudovirus’ 4, 5 and 6 had 
comparable RCs to WT with the mutations seen in Pseudovirus 3 as well as additional 
mutations in PR and RT: Pseudovirus 4 had the same mutation profile as Pseudovirus 
3 plus V82A in PR and M184V, C162S in RT. Pseudovirus 5 also had the same 
mutations profile as Pseudovirus 4 as well as L10F, M36I, I54V, Q58E in PR and 
Q174R in RT. Pseudovirus 6 had the same mutation profile as Pseudovirus 5 plus 
V108I in RT. K20R in PR is associated with increased fitness of HIV-1 when 
detected with V82A in PR [102] and is present as a background mutation in all of 
these pseudoviruses. 
For Study ID 141806, Pseudovirus 2 had the mutations R14K, K20R, E35D in PR 
and D36E, E40D, M184V, N250D in RT and had an RC that was 80% less than the 
WT. Pseudoviruses 3 and 4 ha RCs that were comparable to WT with additional 
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mutations. Pseudovirus 3 had the mutation profile of Pseudovirus 2 plus V82A in 
PR. In Pseudovirus 4, G94A, V82A in PR and D36E, E40D, M184V and N250D 
reverted to the WT amino acids at these positions. K20R was not present in the WT 
pseudovirus, but was present in the other 3 pseudoviruses (Pseudoviruses 2, 3 and 4).
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(A) 
  
(B) 
  
Figure 3.17 Replication capacity expressed as relative light units (RLU) per ng of 
RT-activity as % of the RC of WT pseudovirus. Therefore when the mean RC = 1, 
this means equal RC compared to the WT. * above the bar of the RC indicated that 
the mean RC of 2 independent experiments was significantly different from that of 
Pseudovirus 1 (Student’s t-test; p < 0.05). (A) Relative RC for the pseudovirus panel 
of Study ID 141806 (B) Relative RC for the pseudoviral panel of Study ID 134102. 
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3.3.1.3 Drug susceptibility 
The phenotypic susceptibility of viruses from the 2 study patients was assessed as 
detailed above. The mean IC50 and standard error of the mean IC50 (SEM) were 
plotted for each child and for each drug class. The baseline WT virus was assigned 
“Pseudovirus 1” for both children and its IC50 for all the drugs tested in my study 
was comparable to the original gag-pol expression vector p8MJ4-HSC (Appendix C 
Figure 5.1A and 5.1B).  
2.1.1.1 Study ID 134102 
2.1.1.1.1 PI resistance 
As expected, pseudoviruses that did not have known PI resistance conferring 
mutations in PR (Pseudoviruses 2 and 3) had comparable IC50 to WT. Pseudovirus 4 
had a 5-fold increase in SQV IC50 (p = 0.0133; IC50 = 2.22nM ± 0.0805) and 8-fold 
increase in NFV IC50 (p = 0.0027; IC50 = 13.91nM ± 1.36) with V82A and K20R in 
PR, whereas its LPV IC50 was comparable to WT (2-fold change in IC50, p = 0.33; 
IC50 = 0.3986nM ± 0.1602). Pseudoviruses 5 and 6 had >200-fold changes in LPV 
IC50 compared to WT (p = 0.0419; IC50 = 69.5nM ± 14.66 and p = 0.0059; IC50 = 
54.71nM ± 4.19), >20-fold changes in NFV IC50 (p = 0.0002; IC50 = 105.9nM ± 
1.25 and p = 0.0113; IC50 = 40.53nM ± 14.26) and >10-fold change in SQV IC50 (p 
= 0.0007; IC50 = 5.504nM ± 0.1295 and p = 0.0003; IC50 = 4.801nM ± 0.0545). 
High-level PI-resistance, especially for LPV, was expected of these two 
pseudoviruses because they had the major PI-DRMs M46I, I54V and V82A [102] as 
well as the minor PI-DRMs L10F and Q58E, which further enhance LPV resistance 
and cross-resistance to the other PIs. (L10F is an minor PI mutation that is associated 
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with reduced susceptibility to all the PIs except SQV, tipranavir (TPV) and 
atazanavir (ATV) and Q58E is associated with reduced susceptibility to all but TPV 
[102]. Pseudoviruses 3 and 5 were susceptible to DRV. These results are shown in 
Figure 3.18. 
2.1.1.1.2 RTI resistance 
Only pseudoviruses with known NNRTI resistance conferring mutations in RT had 
higher fold-changes in EFV and NVP IC50s compared to WT. Pseudovirus 2 was 
Y181C-mutated from week 40 of ART and it had a 209-fold increase in NVP IC50 (p 
= 0.01626; IC50 = 29.04nM ± 13.4) and 18-fold increase in EFV IC50 (p = 0.0111; 
IC50 = 11.81nM ± 1.222) compared to WT, which is in-keeping with the literature 
[102].  
Pseudovirus 6 was V108I mutated and also had a 35-fold increase in NVP IC50 (p = 
0.0161; IC50 = 69.4nM ± 8.665) but had comparable susceptibility for EFV as WT.  
All pseudoviruses with M184V in RT (Pseudoviruses 3-6) had >400-fold increase in 
3TC IC50 (p = 0.0370; IC50 = 29.62nM ± 5.789, p = 0.0009; IC50 = 33.02nM ± 
0.957, p = 0.0055; IC50 = 87.5nM ± 6.48 and p = 0.0011; IC50 = 34.44 ± 1.109, 
respectively). None of the viruses had a significantly different mean AZT IC50, ABC 
IC50 or ddI IC50 compared to WT. This was expected, given that no known TAMs 
were present in RT of these pseudoviruses and M184V has only been shown to confer 
low-level resistance to ABC and potential low-level resistance to ddI [102]. These 
results are shown in Figure 3.19.
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Figure 3.18 PI IC50s of Pseudoviruses 1-6 for Study ID 134102. * above the bar of the PI IC50 indicated that the mean IC50 of 2 independent 
experiments was significantly different from that of Pseudovirus 1 (Student’s t-test; p < 0.05). In parentheses is the fold change in PI IC50 
compared to Pseudovirus 1.  Each PI tested is indicated on the y-axis
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Figure 3.19 RTI IC50s of Pseudoviruses 1-6 for Study ID 134102. * above the bar of the RTI IC50 indicated that the mean IC50 of 2 
independent experiments was significantly different from that of Pseudovirus 1 (Student’s t-test; p < 0.05). In parentheses is the fold change in 
RTI IC50 compared to Pseudovirus 1 when the two means were different.  Each RTI tested is indicated on the y-axis 
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2.1.1.2 Study ID 141806 
2.1.1.2.1 PI resistance 
As expected, Pseudovirus 3 had V82A in PR and had an 11-fold increase in SQV 
IC50 and 27-fold increase in NFV IC50 compared to WT (p = 0.0053; IC50 = 
0.9962nM ±0.05385 and p = 0.0052; IC50 = 13.65nM ± 0.85). However Pseudovirus 
4, which had no known major PI-resistance conferring mutations in PR, had a 14-fold 
increase in SQV IC50 and a 25-fold increase in NFV IC50 compared to WT (p = 
0.0052; IC50 = 2.255nM ± 0.148 and p = 0.0297; IC50 = 13.73nM ± 2.26). 
Pseudovirus 4 differed from Pseudovirus 1 in PR with the mutations R14K, K20R and 
E35D. These results are shown in Figure 3.20. 
2.1.1.2.2 RTI resistance 
None of the pseudoviruses had significantly higher NVP IC50s or EFV IC50s 
compared to WT, and they did not harbour any known NVP or EFV resistance 
conferring mutations in RT. Pseudoviruses 2 and 3, both had M184V in RT and 148-
and 158-fold increase in 3TC IC50 (p = 0.0388; IC50 = 16.77nM ± 3.38 and p = 
0.0416; IC50 = 19.33nM ± 4.046). All but Pseudovirus 3 were susceptible to AZT, 
ddI and ABC. Pseudovirus 3 had 84-fold increase in ABC IC50 (p = 0.027; IC50 = 
6.692nM ±1.108) and 25.5-fold increase in ddI IC50 (p = 0.0399; IC50 = 0.4871nM 
±0.0635). These results are shown in Figure 3.21. 
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Figure 3.20 PI IC50s of Pseudoviruses 1-4 for Study ID 141806. * above the bar of the PI IC50 indicated that the mean IC50 of 2 independent 
experiments was significantly different from that of Pseudovirus 1 (Student’s t-test; p < 0.05). In parentheses is the fold change in PI IC50 
compared to Pseudovirus 1 when the two means were statistically different.  Each PI tested is indicated on the y-axis. 
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Figure 3.21 RTI IC50s of Pseudoviruses 1-4 for Study ID 141806. * above the bar of the RTI IC50 indicated that the mean IC50 of 2 
independent experiments was significantly different from that of Pseudovirus 1 (Student’s t-test; p < 0.05). In parentheses is the fold change in 
RTI IC50 compared to Pseudovirus 1 when the two means were different.  Each RTI tested is indicated on the y-axis. 
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3.3.1.4 Variation of Gag 
I analysed the population sequence of gag-PR-RT at baseline for the 10 children in 
my study cohort and at week 40 of ART for 8 children. To determine changes in Gag 
with the development of PI-resistance mutations in PR, I also analysed the population 
sequence of Gag at weeks 0, 12, 40, 72, 96 and 164 for Study ID 141806 and at weeks 
0, 40, 96, 224 and 298 for Study ID 134102 (Tables 20 and 21). 
3.3.1.4.1 Variation of Gag cleavage sites 
PSSM analysis of 891 HIV-1 subtype C gag sequences derived from treatment naïve 
children from Sub-Saharan Africa (HIV Los Alamos Sequence database) revealed 
high conservation (≥90%) of the amino acid sequence of the p17/p24 and p24/p2 
cleavage sites of HIV-1 subtype C sequences in children compared to HXB2 and 
subtype B sequences [251]. The amino acid sequences of these two cleavage sites 
from children within my study cohort were also identical to subtype B and C 
consensus sequences (Table 20).  
The amino acid sequence of the p2/p7 cleavage site remained identical between week 
0 (baseline) and 40 of ART of the study cohort (n=10) and at each sampling time 
point for Study ID 141806. Asparagine (N) has a frequency of 70% and serine (S) has 
a frequency of 22% at position 375 in the p2/p7 cleavage site of paediatric treatment 
naïve sequences. For Study ID 134102, (N) was replaced with (S) at position 375 at 
week 40 of ART, but reversion to N was detected at week 96 and subsequent 
sampling time points. However at week 96 of ART, methionine (M) was replaced 
with lysine (L) at position 378 and M378L was maintained at the subsequent 
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sampling time points for this child. This coincided with glutamic acid (E) being 
replaced by aspartic acid (D) at position 428 in the p7/p1 cleavage site, which was 
also maintained at subsequent sampling time points for this child. 378M and 428E are 
highly conserved in treatment naïve paediatric subtype C sequences (both have 
frequency of 97%), whereas 378L and 428D are rare at these positions (0.6% and 
0.1% respectively). The p7/p1 cleavage site was conserved between time points for 
Study ID 141806 and between week 0 and week 40 of ART for the study cohort.  
The p1/p6 cleavage site was conserved between sampling time points for Study IDs 
141806 but for Study ID 134102, proline (P) was replaced with lysine (L) at position 
453 at week 298 during re-started ART, where L is rarely seen at this position 
(frequency = 7% in subtype C infected treatment naïve children) and P is the most 
frequently observed residue (frequency = 86%). N451S was detected in the p1/p6 
cleavage site between week 0 and week 40 of ART in the study cohort and both 
residues have comparable frequencies within this cleavage site of treatment naïve 
subtype C infected children (N = 54.7% and S = 42.4%). 
3.3.1.4.2 Variation of structural elements of Gag, p2 and p6 
In addition to the cleavage site mutations described in the previous section, I also 
detected mutations in structural elements of Gag, p2 and p6 (Table 21) that were 
associated with PI exposure as detailed in the literature [154]. All sequences from the 
consensus study cohort sequences from baseline and week 40 of ART as well as 
Study IDs 141806 and 134102 had an amino acid deletion at position 371 in p2. This 
was not a surprise given that my PSSM of subtype C sequences revealed a 98% 
frequency of a deletion at this position in Gag. All sequences obtained from Study ID 
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141806 had Y79F in p17 where the frequency of phenylalanine (F) at this position 
was 48.5% and the frequency of tryptophan (Y) was 43% based in my PSSM result. 
T487I in p6 was detected at week 12 of ART (the sampling time point before V82A 
was first detected in PR, i.e. week 40) and continued to be detected at all subsequent 
time points. Isoleucine (I) (22%) was not as common as threonine (T) (77%) at 
position 487 of Gag based on the PSSM. Their detection also coincided with the 
emergence of the minor PI-resistance mutation, K20R in PR. 
For Study ID 134102, V82A in PR was first detected in this child at week 96 of ART. 
In Gag, I401L in p7 and E428D in the p7/p1 cleavage site were also first detected at 
this time point and at all subsequent time points. I (82%) was the most common 
amino acid at position 401 and E (97%) was the most common amino acid at position 
428 based on the PSSM).  
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     Gag cleavage sites 
 
 
Protease p17/p24 p24/p2 p2/p7 p7/p1 p1/p6 
 
Amino acid 
position 10 14 20 35 46 54 58 82 94 98 128-137 359-368 373-382 428-437 444-453 
HXB2 L R K E M I Q V G N VSQNY/PIVQN KARVL/AEAMS SATIM/MQRGN ERQAN/FLGKI RPGNF/LQSRP 
134102 
Baseline L R R E M I Q V G N VSQNY/PIVQN KARVL/AEAMS NINIM/MQKSN ERQAN/FLGKI RPGNF/LQNRP 
Week 40 L R R E M I Q V G N VSQNY/PIVQN KARVL/AEAMS NISIM/MQKSN ERQAN/FLGKI RPGNF/LQNRP 
Week 96 L R R E M I Q A G S VSQNY/PIVQN KARVL/AEAMS NINIM/LQKSN DRQAN/FLGKI RPGNF/LQNRP 
Week 224 L R R E M I Q A G N VSQNY/PIVQN KARVL/AEAMS NINIM/LQKSN DRQAN/FLGKI RPGNF/LQNRP 
Week 298 F R R E I V E A G N VSQNY/PIVQN KARVL/AEAMS NINIM/LQKSN DRQAN/FLGKI RPGNF/LQNRL 
141806 
Baseline L R K E M I Q V G N VSQNY/PIVQN KARVL/AEAMS NANIM/MQRGN ERQAN/FLGKI RPGNF/LQNRP 
Week 12 L K R E M I Q V G N VSQNY/PIVQN KARVL/AEAMS NANIM/MQRGN ERQAN/FLGKI RPGNF/LQNRP 
Week 40 L K R D M I Q A G N VSQNY/PIVQN KARVL/AEAMS NANIM/MQRGN ERQAN/FLGKI RPGNF/LQNRP 
Week 72 L K R D M I Q A G N VSQNY/PIVQN KARVL/AEAMS NANIM/MQRGN ERQAN/FLGKI RPGNF/LQNRP 
Week 96 L K R D M I Q A G N VSQNY/PIVQN KARVL/AEAMS NANIM/MQRGN ERQAN/FLGKI RPGNF/LQNRP 
Week 164 L K R D M I Q V A N VSQNY/PIVQN KARVL/AEAMS NANIM/MQRGN ERQAN/FLGKI RPGNF/LQNRP 
Study cohort 
(n=10) 
Baseline (n=10) L R K E M I Q V G N VSQNY/PIVQN KARVL/AEAMS NTNIM/MQRSN ERQAN/FLGKI RPGNF/LQNRP 
Week 40 (n=8) L R K E M I Q V G N VSQNY/PIVQN KARVL/AEAMS NTNIM/MQRSN ERQAN/FLGKI RPGNF/LQSRP 
 
Table 20. Variation of Gag cleavage sites. Cleavage site sequences were compared to HXB2 amino acid positioning (Genbank accession 
number K035). In red are amino acids at positions that are known to confer reduced susceptibility to PI.
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3.3.1.4.3 Variation of sites in Gag - p17, p24, p7 and p6 
  
       Gag (non-cleavage site elements) 
 
 
Protease p17 (MA) p24 (CA) p2 p7 (NC) p6 
 
Amino acid 
position 10 14 20 35 46 54 58 82 94 98 76 79 81 200 219 370 371 389 390 401 409 468 474 487 497 
HXB2 L R K E M I Q V G N R Y T M H V T I V I R E Q T P 
134102 
Baseline L R R E M I Q V G N R Y T M H V - T V I R E Q T P 
Week 40 L R R E M I Q V G N R Y T M H V - T V I R E Q T P 
Week 96 L R R E M I Q A G S R Y T M H V - T V L R E Q T P 
Week 224 L R R E M I Q A G N R Y T M H V - T V L R E Q T P 
Week 298 F R R E I V E A G N R Y T M H V - T V L R E Q T S 
141806 
Baseline L R K E M I Q V G N R F T M Q V - I V I R E Q T P 
Week 12 L K R E M I Q V G N R F T M Q A - I V I R E Q I P 
Week 40 L K R D M I Q A G N R F T M Q A - I V I R E Q I P 
Week 72 L K R D M I Q A G N R F T M Q A - I V I R E Q I P 
Week 96 L K R D M I Q A G N R F T M Q A - I V I R E Q I P 
Week 164 L K R D M I Q V A N R F T M Q A - I V I R E Q I P 
Study 
cohort 
(n=10) 
Baseline (n=10) L R K E M I Q V G N R F T M Q A - I V I R E Q I/T P 
Week 40 (n=8) L R K E M I Q V G N R F T M Q A - I V I R E Q I P 
 
Table 21. Variation of Gag p17, p24, p7 and p6. Sites were compared to HXB2 amino acid positioning (Genbank accession number K035). 
In red are amino acids at positions that are known to confer reduced susceptibility to PI. Keyμ ‘–‘ is an amino acid deletion. 
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3.3.2 Discussion 
In this chapter a comprehensive phenotypic assessment of viruses from two patients 
was undertaken. In published drug assays, comparable fitness in a single cycle 
replication assay have been reported between WT and Y181C mutated viruses, [252-
254], in keeping with the data presented here. M184V is known to incur significant 
fitness cost to the virus compared to WT in the absence of 3TC [255, 256], which was 
also reflected in my RC data for single-mutated M184V pseudovirus from both 
children. 
My PI-susceptibility results for V82A mutated pseudoviruses reflect what is already 
known about this mutation: V82A is known to confer between 2.8 and 16.2-fold 
change in IC50 compared to a reference strain without this mutation [205, 257, 258]. 
In combination with minor PI-resistance mutations in PR, the effect of V82A is 
enhanced to confer higher levels of resistance and cross-resistance to NFV and SQV 
[102]. Pseudovirus 4 from Study ID 141806 did not have any known major PI-
resistance mutations in PR. M36I, R41K, L63T, I93L, K20R and E35D have all been 
described as common polymorphisms found in HIV-1 subtype C protease [188, 259, 
260], so it was not a surprise to find them in the PR sequences of these children. 
Several studies have tried to assess the effect of these polymorphisms on the PI-
susceptibility of HIV-1 subtype C viruses [188, 260-263]. My findings may implicate 
a R14K, K20R and E35D in PR to confer PI-resistance because these mutations 
emerged during PI-based therapy and they may also confer resistance in combination 
with one or more subtype C polymorphisms (M36I, R41K, L63P and I93L in PR). 
Future studies using site-directed mutagenesis to sequentially add or revert these 
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amino acids to the subtype-B amino acid should shed more light on the effect of 
these polymorphisms on the PI-susceptibility of subtype C viruses in these children. 
Based on my results, the recommended second-line regime (ABC, ddI and EFV) for 
participants in the CHER trial [78, 111] would be expected to successfully inhibit 
viral replication in the two children who developed multi-class drug resistance during 
ART. DRV would also be an option for children with a DRM profile like study ID 
134102 at week 298 because this virus was resistant to all PIs available in paediatric 
formulations. The DRV:RTV ratio for paediatric formulations per age group also 
remains unclear but it is a priority formulation according to current WHO 
documentation [28]. 
The correlation coefficient as determined by Liu and Shafer [102], between M184V 
and reduced ddI susceptibility supports the theory that this mutation may confer low-
level ddI resistance, however the impact of this mutation on ddI susceptibility remains 
conflicting. For example the loss of M184V has also been reported when 3TC is 
replaced by ddI in ART regimes [264] or this mutation has not been maintained in the 
presence of ddI [265]. My results reflect this conflict since I did not always observe 
reduced susceptibility to ddI with M184V mutated pseudovirus.  
None of the amino acid changes observed in RT for this child have been described in 
the literature as associated with high-level ABC or ddI susceptibility. However, there 
were multiple background amino acids in RT that were different from the reference 
sequence provided by Stanford University HIV drug resistance database [102] that 
may be associated with high-level ABC and ddI resistance shown by Pseudovirus 3 
from this child. These mutations in RT were V35T, E36D, T39R, S48T, T165I, 
K173A, D177E, T200A, Q207D, R211K, V245Q, E248N, D250N, A272P, K277R, 
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E291D, I293V, T296N and one or several of these mutations may be associated 
with high-level ABC and ddI resistance in combination with M184V. This requires 
further testing. 
My results also confirm that persisting Y181C mutated virus at week 40 of PI-based 
ART (Pseudovirus 2 for Study ID 134102) continued to confer reduced susceptibility 
to NVP. I also expected this virus to have reduced susceptibility to EFV since Y181C 
is known to confer intermediate EFV resistance [102]. The variance of the mean EFV 
IC50 from the two independent experiments for this drug with pseudovirus 2 was 
significantly different (p=0.0075), which explains this result. 
P453L in the p1/p6 cleavage site of Gag is known to enhance PI resistance when in 
combination with I50V, I84V and L90M in PR [208, 266, 267] and the current 
literature has only described P453L selection by IDV [154]. Given the treatment 
history of this child is IDV-free and the lack of results from my literature review, this 
may be the first time that P453L in the p1/p6 cleavage site of Gag has been selected 
by LPV. On its own, P453L has not been shown to confer PI-resistance; instead it 
enhances resistance to all the PIs approved for clinical use if present in combination 
with I50V, I84V, N88D and L90M in PR (10 - 15 fold change in PI IC50) [267], 
which can compromise the use of PIs in Study ID 134102. The effect of P453L in 
Gag on DRV susceptibility has not yet been determined. 
The mechanism of action of the P453L mutation in the p1/p6 cleavage site of Gag in 
combination with the mentioned amino acid changes in protease is likely to be similar 
to that of the A431V mutation in the same cleavage site [268]: it can fill gaps between 
the substrate and the mutated protease enzyme, compensating for the loss of contact 
between the two when only the enzyme has mutated. 
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In the viral population of Study ID 141806, T487I in the p6 region of Gag 
emerged before V82A and simultaneously with K20R in PR at week 12 of ART. 
Therefore one could argue that this mutation may facilitate the emergence of the 
Major PI mutation, V82A, in PR. And/or T487I in the p6 of Gag could be a 
compensatory mutation to the minor PI mutation K20R in PR. 
Usually mutations in Gag that are associated with PI-exposure and PI-resistance and 
the frequency of these amino acids have been determined for HIV-1 subtype B [154, 
206] and determined in HIV-1 infected adults. Based on my review of the literature, 
this may be the first study that examines Gag variability in children vertically infected 
with HIV-1 subtype C. My PSSM analysis showed high conservation of amino acid 
sequence except in the p2/p7 cleavage site and a deletion at position 371 in p2 as most 
frequent in subtype C treatment naïve children from Sub-Saharan Africa, which was 
reflected in the sequences from the children in my study. I also found the deletion at 
position 371 to be the most frequent occurrence, which was also reflected in 100% of 
the sequences from my study. Future work on the phenotypic effect of these Gag 
polymorphisms and changes seen in the Gag in my patients would give insight into 
their effect on PI-susceptibility. This would be especially important for the children 
who were failing PI-based therapy in the absence of known PI- resistance conferring 
mutations in the viral protease, as well as to highlight the importance of HIV-1 
subtype C Gag polymorphisms in children, akin to adult studies [154, 269, 270]. 
Introductory section 1.4.3.2 discussed what is known and thought about 
polymorphisms in the Gag cleavage sites and matrix that have been associated with 
PI-susceptibility may be more prevalent in non-subtype B viruses and my PSSM 
results suggest such a relationship for subtype C. It is also likely that the mutations 
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observed in Gag known to be associated with PI-exposure were linked on the 
same genome with known major mutations observed in protease, though I could not 
formally prove this. Therefore I also identify the need for my drug susceptibility and 
replication capacity assays to be repeated with pseudoviruses that contained patient 
gag-PR-RT from single genomes to determine the contribution of co-evolved sites in 
Gag to PI resistance and the relevance of subtype C polymorphisms in Gag.
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3.3.3 Conclusions 
The results of this chapter confirm and extend to children infected with subtype C 
HIV-1 what is known about the effect of known drug resistance mutations in PR and 
RT on susceptibilities and replication capacities. However the PI susceptibility of 
Pseudovirus 4 from Study ID 141806 adds to the discussion on the outcomes of 
polymorphisms in PR to PI-susceptibility. My results were in support of the 
possibility of R14K, K20R, E35D M36I, R41K, L63P and I93L in PR contributing to 
reduced PI-susceptibility and further work needs to be done to determine this. More 
work needs to be done on the effect of polymorphisms in Gag on PI-resistance, 
especially in treatment naïve children and the phenotypic contributions of genetic 
linkage of Gag mutations and polymorphisms to mutations in PR. Finally, I highlight 
the importance of the development of appropriate paediatric DRV co-formulations 
and dosages.
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Chapter 4 Final Discussion, Project Limitations and Future 
Work 
Sub-Saharan Africa continues to have the highest burden of new paediatric HIV 
infections, but the availability and uptake of ART by HIV infected children has been 
increasing since 2005 [25]. An implication of the increased access ART is that more 
children eventually fail first-line treatment and the demand for second-line therapy 
drug regimens increases especially in more rural areas where patients are poorly 
monitored [91, 271]. In addition, access to second-line paediatric ART in resource-
poor settings is very challenging and ARV options are limited [272]. 
Since 2008, WHO guidelines [81] stipulated that children who are confirmed as HIV 
positive start LPV/r-based therapy regardless of their immune or clinical status. This 
is because of previous exposure to NVP for PMTCT and the superiority of LPV/r-
based first line therapy. One such superiority is LPV/r’s relatively high genetic barrier 
to resistance compared to RTI-based treatment, that is more forgiving of suboptimal 
adherence to therapy (adherence <95%) [273]. However the effectiveness of this drug 
regime in children is confounded by metabolic complications [274], poor-palatability 
[274] and drug-drug interactions [275]. 
The South African CHER trial demonstrated a 76% (95% CI: 49%–89%) reduction in 
mortality associated with early ART compared to deferred ART in children <12 
weeks of age [78, 93, 111]. The effects of early ART in older children are less clear 
[276-278] and evidence from randomized controlled trials regarding the optimal 
timing of ART initiation in children between 2 and 5 years of age [276, 277] is still 
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too deficient to influence treatment policy guidelines. While early ART may 
reduce mortality in infants, it could also increase the risk of toxicity and earlier 
development of drug resistance. South Africa also has a high burden of tuberculosis 
for which rifampicin is used for treatment in HIV infected children [279], but LPV/r - 
rifampicin interactions can lead to sub-therapeutic levels of LPV and virological 
failure due to the development of DRMs [275, 280-282]. 
HIV resistance testing is not generally available in resource-poor settings because of 
the lack of expertise required for data analysis and the expense of high-quality 
implementation and maintenance of this service [283]. Even though South Africa has 
a low prevalence rate of transmitted PI and NRTI resistance in children (<5%) [233, 
284], transmitted NNRTI resistance is between 5% and 15% because of sdNVP for 
PMTCT [88, 284]. Therefore failure of first-line PI-based regimes because of the 
development of PI and/or NRTI resistance can severely limit ARV options for 
children in South Africa or similar resource-poor settings.  
My aim was to describe the longitudinal development of drug resistance in the viral 
population of HIV-1 infected children who failed early ART in the CHER trial and 
explore the contribution of variants in the viral population to drug resistance and 
treatment failure. In particular, I theorized (1) the development of drug resistance 
mutations in PR and RT that were linked on the same genome, (2) the persistence of 
NNRTI resistance during PI-based ART and (3) drug resistant minority species 
contributing to future ART outcomes by eventually becoming the dominant species 
under the correct conditions. 
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I was able to use SGS to show multiple drug resistance mutations in PR and RT 
that were genetically linked. Viruses that harboured these genomes were shown to 
confer reduced susceptibility to 2 or 3 drug classes in my drug susceptibility assay. 
During early ART, two children developed the 3TC-selected resistance conferring 
mutation M184V, which conferred high-level resistance to 3TC (part of the first line 
ART regime) in two children as well as high-level cross-resistance to ABC, (a 
component of second line ART), in one of these children. V82A in PR was always 
selected in M184V mutated viruses, however my phylogenetic analyses did not 
determine the emergence of these mutations to be dependent on each other.  
After treatment interruption and during a second round of recycled PI-based ART, 
dual-class drug resistant viruses persisted in the majority species of the viral 
population of one child and triple class drug resistant viruses were present in the 
minority species. This child received rifampicin for the treatment of tuberculosis and 
also had additional RTV to achieve a 1:1 ratio of LPV:RTV for ART in accordance 
with local HIV treatment guidelines [275]. This child developed multiple PI-
resistance mutations that were genetically linked in PR as well as P453L in Gag at the 
population level. Therefore it is possible that additional RTV may not have been 
sufficient to prevent sub-therapeutic levels of LPV during rifampicin treatment, which 
caused the selection of multiple PI-resistance mutations in PR and Gag. Unfortunately 
I did not have sufficient sample volumes to determine the concentration of LPV 
circulating in this child at each sampling time point. I also did not have enough 
sample volumes to compare circulating LPV concentration in the other children from 
my study cohort.  
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Multiple studies have shown the correlation between virological failure during 
NNRTI-based ART and pre-existing minority NNRTI resistance [117, 123, 126-128, 
285]. Several studies have also shown the correlation between virological failure 
during NNRTI-based ART and prior exposure to NVP for PMTCT in mothers [286] 
and children [89, 287]. These NNRTI resistant viruses are also likely to be archived in 
resting CD4+ T-cells [288, 289] that implies a permanent risk of the re-emergence of 
these viruses that can compromise future ART outcomes. The recommended second-
line based ART regime in the CHER trial was EFV-based ART for children <3 years 
old or NVP-based ART for children >3 years old [78, 111]. I detected NNRTI 
resistance selected by NVP for PMTCT at baseline and to my knowledge I am the 
first to show that these viruses (K101E and Y181C mutated viruses) can persist in the 
viral population of children as minority species until week 40 of LPV/r-based ART. 
They are also likely to be present in the latent viral reservoir and have the potential to 
compromise EFV- or NVP-based second line ART. In one child, V108I was detected 
at week 96 of early ART and week 298 of recycled ART after treatment interruption. 
This child was >3 years old with virological failure on recycled LPV/r based ART 
and the V108I mutated virus detected at this time point conferred high-level 
resistance to NVP (35-fold decreased susceptibility to NVP compared the WT). 
Therefore this virus presents a risk to second-line ART failure for this child because 
of possible selection of circulating V108I-mutated viruses and V108I-mutated viruses 
assumed to be in the viral reservoir. 
In my study, there were several instances of DRMs in the minority species of the viral 
populations of some children before first-line ART began and these viruses had the 
potential to be selected by components of early ART. These mutations were L74V, 
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T215C and K219N in RT and I50V in PR. Despite the first-line ART regime these 
mutations were not detected by SGS in the viral populations of these children during 
ART. The literature is divided on the contribution of pre-existing DRMs to the 
outcomes of first-line ART but my results are in in-line with the body of evidence that 
does not correlate pre-existing DRMs in the minority species with virological failure 
during first-line ART [99, 290, 291]. 
To my knowledge, this project is also the first to identify multi-class drug resistance 
mutations in PR and RT that were linked on the same genome as well as characterise 
their development during early PI-based ART in children. All multi-class drug 
resistant viruses had M184V in RT and one or more PI-resistance mutations in PR.. 
The triple class drug resistant viruses detected in the minority species of the viral 
population of Study ID 134102 demonstrated significant levels of resistance to LPV, 
SQV, NFV, 3TC and NVP. 
I also saw that early ART did not effectively eliminate the viral reservoir so that it 
continued to be a major contributor to the evolution of the viral populations during 
virological success and failure on ART; highlighting the importance of the viral 
reservoir. 
This project was limited in several ways. First, There were a relatively low number of 
children who failed first-line PI-based early ART (27/377) from the CHER trial and 
the project used a convenience sample that of an even lower number of children (n = 
10), which severely limited the power of the study. It was also unfortunate that my 
study did not include longitudinal samples from a control group, i.e. children who did 
not fail early ART form the CHER study. Insufficient volumes of plasma from each 
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child limited some prospects for my research: I was reliant on leftover plasma 
samples after viral load testing during the CHER trial, therefore I could not determine 
drug concentrations or obtain gag-PR-RT single genomes to determine genetic 
linkage of DRMs between these genes. I was also unable to reliably assess treatment 
adherence, I did not have access to plasma samples or treatment history of mothers. 
All of these limitations restricts the generalizability of this study so that I cannot infer 
outcomes for children receiving early ART or for children in other resource-limited 
settings. Notwithstanding these limitations, the study results suggests that prophylaxis 
and early ART may not just be strategies to improve child mortality and disease 
progression, but may also be strategies to restrict the viral reservoir as suggested 
recently by Kearney et al [222]. However it can also lead to multi-class rug resistance 
viruses that have the potential to severely limit ARV options, especially in resource-
limited settings.  
More research needs to be undertaken before the association between early initiation 
of ART and the risks of toxicity and development of drug resistance is more clearly 
understood in children. My findings support calls [292] to evaluate the effect of 
rifampicin concentrations on therapeutic levels of LPV/r with additional RTV and the 
development of drug resistance in children is needed. More prospective studies or a 
follow-up study from the CHER trial is needed to effectively evaluate the contribution 
of minority species detected during early ART to second-line treatment outcomes, 
including the contribution of genetic linkage of mutations in Gag, PR and RT and the 
evolution of DRMs in the latent viral reservoirs.
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Chapter 5 Appendices 
5.1 Appendix A 
Patient 
ID 
Time between DOB and 
baseline sample (weeks) 
Time between start of early ART and 
baseline sample (weeks) 
143646 5.1 1.0 
141586 8.6 1.0 
130166 6.4 0.4 
138506 5.0 1.1 
141806 5.6 1.0 
131326 6.1 1.0 
147636 5.4 1.0 
134102 7.9 1.0 
153716 7.6 1.0 
146666 8.7 1.0 
Table 22. Date of birth (DOB) and start of early ART relative to the time the baseline samples 
were taken for 10 children from the CHER study. 
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5.2 Appendix B 
APOBEC3G/F cytidine deamination of PR-RT 
I determined the contribution of cytidine deamination by APOBEC3G/F to the 
diversity of HIV-1 pol and the development of drug resistance in the viral populations 
of 9 children from my study cohort. I analysed the single genome sequences from all 
the sampling time points in each from a single MSA per child. Based on the ML trees 
of the viral population infecting each child, I used the most ancestral sequence 
obtained from each child as the reference sequence for these analyses and a built-in 
Fisher exact test detected any increases in APOBEC3G/F-mediated G-to-A mutations 
in the test sequences of the MSA compared to the reference sequence. Only one child 
had evidence of this type of mutation and it was a single sequence at week 164 of 
ART for Study ID 131326. This sequence had 10/197 (5%) sites that were 
APOBEC3G/F-mediated G-to-A mutations (Fisher exact test p-value = 0.00573719). 
I removed this sequence from the MSA for this child before continuing with further 
analyses. 
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 Study ID Time point 
(Week) 
MPD Standard Deviation 
of MPD 
Number of PR-RT single 
genome sequences obtained 
Length of PR-RT 
(nucleotides) 
Ntd changes in PR-
RT based on MPD 
Group 1 141586 0 0.0012 0.00101 30 1489 1 
24  -  - -   
40 0.0012 0.00099 39  1 
138506 0 0.0012 0.00123 57 1509 1 
24  -  - -   
40 0.0045 0.00177 40  6 
146666 0 0.001 0.00079 26 1477 1 
24  -  - -   
40 0.0018 0.00129 39  2 
72  -  - -   
96 0.003 0.00117 14  4 
147636 0 0.0014 0.00103 34 1507 1 
24  -  -     
40 0.0008 0.00056 29  1 
72  -  - -   
96  -  - -   
164 0.005 0.00168 39  7 
Group 2 143646 0 0.0002 0.00034 49 1498 <1 
24  -  - -   
40 0.0001 0.00020 22  <1 
130166 0 0.0024 0.00332 49 1477 3 
24  -  - -   
40 0.0013 0.00066 25  1 
131326 0 0.0012 0.00117 21 1483 1 
24  -  -     
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40 0.0019 0.00083 38  2 
72 0.0039 0.00138 12  5 
96  -  - -   
164 0.0031 0.00198 39  4 
Group 3 141806 0 0.0069 0.00477 33 1495 10 
12 0.0057 0.00515 37  8 
24  -  -  -   
40 0.0046 0.00394 28  6 
72 0.002 0.00202 44  2 
96 0.0034 0.00215 30  5 
164 0.0075 0.00286 38  11 
224 0.0108 0.00011 22  16 
134102 0 0.0016 0.00093 31 1498 2 
24  -  - -   
40 0.003 0.00148 38  4 
72  -  - -   
96 0.0038 0.00208 32  5 
164  -  - -   
224 0.0028 0.00230 34  4 
298 0.0014 0.00119 39  2 
Table 23. Mean pairwise genetic distance (nucleotide substitutions per site in PR-RT) for 9 children. Also shown are the Standard 
Deviations of the MPDs, the number of single genome sequences obtained at each time point and the absolute number of nucleotide changes in 
PR-RT at each time point based on the MPD and the consensus nucleotide length of PR-RT obtained form each child.
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5.3 Appendix C 
Drug / drug class Abbreviation 
Nucleoside reverse transcriptase inhibitors 
Lamivudine 3TC 
Zidovudine AZT 
Didanosine ddI 
Abacavir ABC 
Non-nucleoside reverse transcriptase inhibitors 
Efavirenz EFV 
Nevirapine NVP 
Protease inhibitors 
Ritonavir RTV 
Lopinavir LPV 
Lopinavir boosted with RTV LPV/r 
Darunavir DRV 
Tipranavir TPV 
Atazanavir ATV 
Table 24. List of antiretrovirals, their abbreviations and drug class. 
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(A) 
 
(B) 
 
Figure 5.1 IC50 of p8MJ4-HSC compared to the IC50 of Pseudovirus 1 of Study 
ID 141806 and 134102. (A) PI (B) RTI. Student’s t-determined that the mean IC50 of 
2 independent experiments for the patient pseudoviruses were not significantly 
different from p8MJ4-HSC for each drug (p > 0.05). 
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(A) 
 
(B) 
Study ID Pseudovirus HIV-1 RT concentration (ng/ul)  
141806 WT 0.014 
184V 0.015 
184V+82A 0.015 
E4 0.014 
134102 WT 0.014 
184V 0.014 
184V+82A 0.015 
184V+82A+54V+58E+46I+10F 0.015 
108I+184V+82A+54V+58E+46I+10F 0.016 
 p8MJ4-HSC 0.014 
 
Figure 5.2 Standardization of pseudoviral titres. (A) HIV-1 RT ELISA calibration 
curve. (B) HIV-1 RT concentrations from pseudovirus produced from recombinant 
gag-pol/patient PR-RT expression vectors. p8MJ4-HSC was the original expression 
vector.
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